## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 1 3 2006

In re Applicant

PECKER Iris et al

10/676,079

Filed:

October 2, 2003

For:

HEPARANASE SPECIFIC MOLECULAR

PROBES AND THEIR USE IN RESEARCH

AND MEDICAL APPLICATIONS

Examiner:

DIBRINO, MARIANNE NMN

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1644

Attorney

Docket: 26871

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached please find copies of IDS PTO Form1449 submissions made in the above identified applications. It is requested that they be made of record in the instant application.

Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This is a divisional of U.S. Patent Application No. 09/704,772, filed November 3, 2000, which is a divisional of U.S. Patent Application No. 09/322,977, filed June 1, 1999, now U.S. Patent No. 6,531,129, issued March 11, 2003, which is a, divisional of U.S. Pat. application No. 09/071,739, filed May 1, 1998, now U.S. Patent No. 6,177,545, issued January 23, 2001, which is a continuation-in-part of U.S. Pat. application No. 08/922,170, filed September 2, 1997, now U.S. Patent No. 5,968,822, issued October 19, 1999.

This Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

06/15/2006 HALI11 00000012 501407 10076079 180.00 DA

01 FC:1806

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin a Mozinha

Martin D. Moynihan

Registration No. 40,338

Dated: June 11, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 and persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

JUN 1 3 2006

(use as many sheets as necessary)

Complete if Known				
Application Number	11/154,805			
Filing Date	October 17, 2001			
First Named Inventor	Oron JACOBY-ZEEVI			
Art Unit	1636			
Examiner Name	unknown			

Sheet 1 of 19 Attorney Docket Number 29714 U.S. PATENT DOCUMENTS Examiner Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where Initials\* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code<sup>2 (if known)</sup> US-6,177,545 1 01-13-2001 Pecker et al. 2 US-6,348,344 02-19-2002 Ayal-Hershkovitz et al. 3 US-4,946,778 08-8-1990 Ladner et al. 4 US-5,997,863 07-7-1999 Zimmermann et al. 5 US-6,242,238 05-5-2001 Freeman et al. 6 US-5,688,679 11-18-1997 Powell 7 US-6,387,643 05-14-2002 Heinrikson et al. US-6,423,312 8 07-23-2002 Yacoby-Zeevi 9 US-6,531,129 03-11-2003 Pecker et al. 10 US-4,455,296 06-19-1984 Hansen et al. 11 US-5,571,506 05-5-1996 Regan et al. 12 US-5,917,830 06-29-1999 Chen et al. 13 US-5,859,660 01-12-1999 Perkins et al. 14 US-5,600,366 04-4-1997 Schulman 15 US-6,020,931 01-1-2000 Bilbrey et al. 16 US-5,968,822 10-19-1999 Pecker et al. 17 US-6,153,187 11-28-2000 Yacoby-Zeevi 18 US-6,664,105 12-16-2003 Pecker et al. US-5,145,679 19 08-8-1992 Hinson 20 US-5,736,137 07-7-1998 Anderson et al. 21 US-5,194,596 03-16-1993 Tischer et al. 22 US-5,350,836 09-27-1994 Kopchick et al. 23 US-6,562,950 05-13-2003 Peretz et al. 24 US-6,699,672 02-2-2004 Pecker et al. 25 US-5,580.862 03-3-1996 Rosen et al. 26 US-5,474,983 12-12-1995 Kuna et al. 27 US-2002/0102560 01-1-2002 Pecker et al. 28 US-6,790,658 09-14-2004 Pecker et al. 29 US-6,798,658 09-28-2004 Takedomi et al. 30 US-5,618,709 08-8-1997 Gewirtz et al. 31 US-5,656,595 08-12-1997 Schweighoffer et al. 32 US-4,683,195 07-28-1987 Mullis et al. 33 US-5,602,095 02-11-1997 Pastan et al. 34 US-2004/0142427 07-22-2004 Pecker et al. 35 US-4,117,841 03-3-1978 Perrotta et al. 36 US-2003/0161823 08-28-2003 Ilan et al. 37 US-5,962,321 05-5-1999 Gough et al. 38 US-5,830,759 03-3-1998 Chang et al. 39 US-4,859,581 08-22-1989 Nicholson et al. 40 US-4,882,318 11-21-1989 Vlodavsky et al. 41 US-5,129,877 07-14-1992 Gallo et al. 42 US-5,206,223 04-27-1993 Vlodavsky et al 43 US-5,332,812 07-26-1994 Nicolson et al. 44 US-5,362,641 08-8-1994 Fuks et al.

45	US-5,399,351	03-21-1995	Leshchiner et al	
46	US-5,550,116	08-27-1996	Lormeau et al.	
 47	US-5,667,501	09-16-1997	Fowler et al.	· · · · · · · · · · · · · · · · · · ·
 48	US-5,739,115	04-14-1998	Fugedi et al	
 i				

		FOREIGN	PATENT DOC	UMENTS		· · · · · · · · · · · · · · · · · · ·	_
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY		e of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	49*	PCT WO 99/57244	11-11-1999	Ben-Artz	i et al.		╁╴
	50*	PCT WO 99/57153	11-11-1999	Pecker et	al.		$\dagger \lnot$
	51*	PCT WO 99/11798	03-11-1999	Pecker et	al.		Ħ
	52*	PCT WO 88/01280	02-25-1988	Nicolson	et al.		1
	53*	PCT WO 95/04158	09-9-1995	Hoogewe			$\vdash$
	54*	PCT WO 99/21975	06-6-1999	Freeman		<u> </u>	$\dagger \exists$
	55*	PCT WO 91/19197	12-12-1991	Nicolson	et al.		$\vdash$
	56*	PCT WO 95/04518	02-16-1995	Midha et	al.		1
	57*	PCT WO 03/006645 A2	01-23-2003	Bohlen et	al.	-	$\Box$
	58*	PCT WO 97/11684	03-3-1997	Bennett e	t al.		tt
	59*	PCT WO 91/02977	07-7-1991	Fuks et al			$\sqcap$
	60*	PCT WO 97/27327	07-31-1997	Van Ness	et al.		$\dagger \exists$
	61*	PCT WO 00/52149	08-8-2000	Yacobi-Z	eevi		$\sqcap$
	62*	PCT WO 00/52178	08-8-2000	Pecker et	al.		$\dagger \exists$
	63*	PCT WO 00/52178	08-8-2000	Pecker et	al.		
	64*	PCT WO 99/40207	08-12-1999	Nakjima e	et al.		$\Box$
	65*	PCT WO 98/46258	10-22-1998	Bhaskar e			$\Box$
	66*	EP 0254067	01-27-1988	Cohen et	al.		П
	67*	PCT WO 98/03638	01-29-1998	Freeman	et al.		H
	68*	PCT WO 01/00643	04-4-2001	Pecker et	al.		П
	69*	DE 2819129	11-15-1979	Köhler et	al.		$\Box$
	70*	PCT WO 99/48478	09-30-1999	Yacoby-Z	Zeevi		П
Examine	• 1		<u> </u>	1	Date	<u> </u>	Ш
Signature	<u> </u>				Considered	1	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Su	bstitute for form 1449A/PTO	Application Number	if Known 11/154,8	805 .
	INE	ORMATION DISCLOSURE	Filing Date		17, 2001
			First Named Inventor	Oron JA	
	STA	TEMENT BY APPLICANT		ZEEVI	
		(use as many sheets as necessary)	Group Art Unit	1636	
01			Examiner Name	unknow	<u>n</u>
Sheet	3	Of 19	Attorney Docket Number	29714	
F		OTHER PRIOR ART – NON PATENT LITER Include name of the author (in CAPITAL LETTERS), title of the			
Examiner Initials	Cite No. <sup>1</sup>	item (book, magazine, journal, serial symposium, catalog, etc.) da publisher, city and/or country where p	ite, page(s), volume-issue num		T <sup>2</sup>
	71	Wight et al. "The Role of Proteoglycans in Cell Adhes Proliferation", Curr. Opin. Cell. Biology, 4: 793-801, 1			
•	72	Jackson et al. "Glycosaminoglycans: Molecular Proper Role in Physiological Processes", Physiological Revie			
	73	Schoepe et al. "Neutralization of Hemolytic and Mous			
		Perfringens Alpha-Toxin Need Simultaneous Blockage			
		Monoclonal Antibodies", Microbiol. Pathogenesis, 23:			
	74	Chiba et al. "Generation of Neutralizing Antibody to the		of	
		Human Immunodeficiency Virus Type 1 by Immunizing	ng of Mice With An Infe		
		Vaccinia Virus Recombinant", J. Immunological Meth	ods, 207:53-60, 1997.		
	75	Wong "Monoclonal Antibodies: Therapeutic Applicati	ons Grow in Promise an	d	
		Number", Genetic Engineering News, P.23-49, 1998.			
	76	Sherman-Gold "Monoclonal Antibodies: The Evolutio	n From '80s Magic Bulle	ets to	
	ŀ	Mature, Mainstream Applications as Clinical Therapeu	itics", Genetic Engineeri	ng	
		News, P.4, 35, 1997.	-		
	77	Danheiser "Rituxin Leads Line of Hopeful Mab Thera	pies, Yet FDA Still Has	Bulk	
	1	Manufacture Concerns", Genetic Engineering News, P			
	78	Rader et al. "A Phage Display Approach for Rapid An	tibody Humanization:		
		Designed Combinatorial V Gene Libraries", Proc. Nat		910-	
		8915, 1998.	ŕ		
	79	Mateo et al. "Humanization of A Mouse Monoclonal A	Antibody That Blocks the	e	
		Epidermal Growth Factor Receptor: Recovery Antago			
	i	Immunotechnology, 3: 71-81, 1997.	• •		
	80	Nakajima et al. "Heparanases and Tumor Metastasis",	Journal of Cellular		
		Biochemistry, 36(2): 157-167, 1988.			
	81	Ngo et al. "Computational Complexity, Protein Structu	re Prediction, and the		······
		Levinthal Paradox", The Protein Folding Problem and		ction,	
		Birkhauser, Boston, P.433, 492-495, 1994.	•	,	
	82	Colman "Effects of Amino Acid Sequence Changes or	Antibody-Antigen		
		Interactions", Research in Immunology, 145(1): 33-36			
	83	Abaza et al. "Effects of Amino Acid Substitutions Out		n	
		Protein Binding to Monoclonal Antibodies of Predeter			
		Peptide Immunization: Demonstration With Region 94			
		Myoglobin", Journal of Protein Chemistry, 11(5): 433		1	
	84	Lederman et al. "A Single Amino Acid Substitution in		ele of	
		the CD4 Molecule Ablates Binding of the Monoclonal			
		Immunology, 28: 1171-1181, 1991.	• .		
	85	Li et al. "β-Endorphin Omission Analogs: Dissociation	n of Immunoreactivity F	rom	
		Other Biological Activities", PNAS, 77: 3211-3214, 1		1	
	86	Marchetti et al. "Neurotrophin Stimulation of Human		:	
		Selected Enhancement of Heparanase Activity and He			
		Specific Heparan Sulfate Subpopulations", Cancer Res			
		Also in: Advances in Enzyme Regulation, 37: 111-134		ļ	
	87	Kosir et al. "Human Prostate Carcinoma Cells Produce	e Extracellular Heparana	se",	
		Journal of Surgical Research, 67: 98-105, 1997.	•		
	88	Köhler et al. "Continuous Cultures of Fused Cells Sec	reting Antibody of Prede	fined	
		Specificity", Nature, 256: 495-497, 1975.	_ ,	}	

	89	Hulett et al. "Claving of Manuschien Honomogo, An Jamestont Common in Tumor	
	89	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999.	
	90	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. Biolog. Chemistry, 274(34): 24153-24160, 1999.	
	91	Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene", Biochemical and Biophysical Research Communication, 261(1): 183-187, 1999.	
-	92	Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrotrophin	
		Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.	
	93	Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar	
		Enzymes", Biochem J., 342: 361-368, 1999.	
	94	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Biochemistry and Molecular Biology, 30(5): 387-444, 1995.	
	95	Zhou et al. "A 182 Bp Fragment of the Mouse Proal(11) Collagen Gene Is Sufficient	
		to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108: 3677-3684, 1995.	
	96	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First	
		Intron in Expression of the α1 (I) Collagen Gene.", Mol Cell Biol., 18(6): 3368-3375, 1998. Abstract.	-
	97	Chow et al. "Development of An Epithelium-Specific Expression Cassette With	
		Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.	
	98	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P.431-437, 1998.	
	99	Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.	
	100	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Biophysica Acta, 1172: 37-42, 1993.	
	101	Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase	
•		in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.	
	102	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood, 92(3): 712-736, 1998.	
	103	Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181: 163-179, 1998.	
	104	Carpentier et al. "DNA Vaccinaiton With HuD Inhibits Growth of A Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824. 1998.	
	105	Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.	
	106	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene",	
	105	Journal of Biological Chemistry, 270(10): 5276-5281, 1995.	
	107	Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14: 27-37, 1994/5.	
	108	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features	
		of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.	
· · · · · ·	109	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory	
		Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research, 21(25): 5901-5908, 1993.	
	110	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that	
		the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 29587-29590, 1999.	
	111	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12: 135-176, 1986.	
	112	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions",	
	112	TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.	
	113	Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	····
	114	Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and Production of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3): 337-350, 1998.	

. .....

 115	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection	
 	Studies", Ann. NY Acad. Sci., 738: 104-115, 1994.	
116	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene Regulatory Sequences", Biochem. Cell Biol., 80(6): 777-788, 2002.	
117	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19: 396-399, 2002.	
118	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk", Mol. Immunol., 38(8): 619-625, 2002.	
 119	Clark et al. "Pharmaceuticals From Transgenic Livestock", TIBTECH, 5: 20-24, 1987.	
120	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and Alpha-Lactalbumin cDNA Clones", J. Biol. Chem., 256(1): 526-32, 1981.	
121	Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.	
122	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β-Casein Gene", Gene, 66: 87-96, 1988.	
123	Alexander et al. "Complete Sequence of the Bovine β-Lactoglobulin cDNA", Nucleic Acids Research, 17(16): 6739-6744, 1989.	·
124	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase", Exptl. Cell. Res., 201: 208-215, 1992.	
125	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P. 471-510, 1988.	
126	Murray et al. "The Extracellular Matrix", Harper's Biochemistry, McGraw-Hill Professional, 24th Ed., Chap.57, P.667-685, 1998.	
127	Selvan et al. "Heparan Sulfate in Immune Responses", Ann. NY Acad. Sci., 797: 127-139, 1996.	
 128	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", Science, 276: 71-74, 1997.	
129	Krivit et al. "Microglia: The Effector Cell for Reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases", Cell Transplant, 4(4): 385-392, 1995. Abstract.	
130	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Internatl. Conf. on Molec. Biol. and Pathology of Matrix, Session IV.	
131	Lazarus et al. "Ex Vivi Expansion and Subsequent Infusion of Human Bone Marrow- Derived Stromal Pregenitor Cells (Mesenchymal Progenitor Cells): Implications for Therapeutic Use", Bone Marrow Transplantation, 16: 557-564, 1995.	
132	Pomahac et al. "Tissue Engineering of Skin", Crit. Rev. Oral Biol. Med., 9(3): 333-344, 1998. Abstract.	
133	Benathan et al. "Living Epidermal and Dermal Substitutes for Treatment of Severely Burned Patients", Rev. Med. Suisse Romande, 118(2): 149-153, 1998. Abstract-Art. in French.	
134	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation:  Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	
 135	Duffy et al. "Maximizing Flap Survival in A Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 176-179, 1996.  Abstract.	
136	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg., 102(1):135-139, 1998. Abstract.	
 137	Raghunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into Matrix Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	
 138	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds", American J. Surg., 170(1): 75-83, 1995. Abstract.	
139	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for Grafting Into the Central Nervous System", Genet. Eng. NY, 13: 205-220, 1991.  Abstract.	
 140	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-1030, 1998.	
 141	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", Acta Orthop. Scand. Suppl., 269: 1-33, 1996. Abstract.	

.

-

	142	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone	
1		Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop. Scand., 67(3):	
1		229-236, 1996. Abstract.	
	143	Inui et al. "Local Application of Basic Fibroblast Growth Factor Minipellet Induces	
		the Healing of Segmental Bony Defects in Rabbits".	
	144	Tabata et al. "Bone Regeneration by Basic Fibroblast Growth Factor Complexed	
		With Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	
	145	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta	
	1	Orthop. Scand., 60(4): 473-476, 1989. Abstract.	
	146	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic	
	140	Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991.	
·		Abstract.	
}	147	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ulcer	
	177	Therapy: Findings in A Rat Model", J. Gastroenterol., 31(6): 777-784, 1996.	
		Abstract.	
	148	Chleboun et al. "The Development and Enhancement of the Collateral Circulation in	
	140	An Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(3): 202-207, 1994.	
		All Allina Model of Lower Ellib Ischaeffia , Aust. NZ Suig., 64(3). 202-207, 1994.  Abstract.	
	140	Aplin "Adhesion Molecules in Implantation", Reviews of Reproduction, 2(2): 84-93,	
	149		
		1997.	
	150	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the	
		Establishement of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116,	
		1998. Abstract.	
1	151	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum.	
		Reprod. Update, 2(4): 307-321, 1996.	
	152	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases	
		During Blastocyst Implantation", Contracept Fertil Sex, 22(1): 48-51, 1994. Abstract.	
		Article in French.	
	153	Smith et al. "Expression of Heparan Sulfate Protoglycan (Perlecan) in the Mouse	
		Blastocyst Is Regulated During Normal and Delayed Implantation", Dev. Biol.,	
		184(1): 38-47, 1997. Abstract.	<u> </u>
	154	Abrahamsohn et al. "Implantation and Decidualization in Rodents", J. Exp. Zool.,	
		266(6): 603-628, 1993. Abstract.	
	155	Goshen et al. "Purification and Characterization of Placental Heparanase and Its	
		Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9):	
		679-684, 1996.	
	156	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse	•
		Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176,	
		1996. Abstract.	
	157	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation	
		Development", Biol. Reprod., 50(4): 725-733, 1994. Abstract.	
	158	Carlone et al. "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat	
		Uterus", Biology of Reproduction, 49(4): 653-665, 1993.	
	159	Wordinger et al. "The Immunolocalzation of Basic Fibroblast Growth Factor in the	
		Mouse Uterus During the Initial Stages of Embryo Implantation", Growth Factors,	•
		11(3): 175-186, 1994. Abstract.	
	160	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxford	
		Review of Reproduction in Biology, 15: 43-81, 1993. Abstract.	
	161	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and	
		Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.	· <u>····</u>
	162	Esko et al. "Tumor Formation Dependent on Proeoglycans Biosynthesis", Science,	
	1	241(4869): 1092-1096, 1988. Abstract.	
	163	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and	
		Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19):	
		13534-13540, 1990.	
	164	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic	•
		Shock", American Journal of Physiology, 275: H23-H30, 1998.	
	165	Sasisekharan et al. "Heparinase Inhibits Neovascularization", Proc. Natl. Acad.Sci.	
	1 .55	USA, 91: 1524-1528, 1994.	
	166	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and	
	100	Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase,	
		Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17): 10079-10086,	
ь		1	

•			
		1996.	
	167	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and	
		Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular	
<u> </u>	160	Matrix", Cell Regulation, 1: 833-842, 1990.  Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of	
	168	Cellular Physiology, 148: 274-280, 1991.	1
	169	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain	
	100	From An Inhibitor to A Potent Activator of FGF-2", Nature Medicine, 4(6): 691-697,	
i		1998.	
	170	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human	
		Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.	
l	171	Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and	
		Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes",	
	172	J. Biol. Chem., 270(7): 3268-3277, 1995.  Oldberg et al. "Characterization of A Platelet Endoglycosidase Degrading Heparin-	
	172	Like Polysaccharides", Biochemistry, 19: 5755-5762, 1980.	
	173	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine	
	173	Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10	İ
		Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.	
	174	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine	
		β-Casein Gene", Mol. Cells, 8(3): 259-265, 1998. Abstract.	
	175	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective",	
		Arzneimittelforschung, 48(11): 1111-1120, 1998. Abstract.	
	176	Guriec et al. "CD44 Isoforms With Exon V6 and Mestastasis of Primary N0M0	
		Breast Carcinomas", Breast Cancer Res. Treat., 44(3):261-268, 1997. Abstract.	
	177	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by	·
		Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132, 1997. Abstract.	
	178	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function	
	1,3	in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999.	
	179	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain	
		Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin.	
		Invest., 97(1): 162-171, 1996.	
	180	Zheng et al. "Increment of hFIX Expression With Endogenous Intron 1 In Vitro",	1
· · · · · · · · · · · · · · · · · · ·		Cell Res., 7(1):21-29, 1997 Abstract.	
	181	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target	
	100	RNA Levels", Curr. Opin. Biotechnol., 9(5): 486-496, 1998. Abstract.	
	182	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise", Proc. Natl. Acad. Sci. USA, 93: 3161-3163, 1996.	Ì
	183	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the	<del></del> .
	105	Modulation of Gene Expression in Human Disease", Journal of American Cell	_
		Surgery, 191(1): 93-105, 2000.	
	184	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", TIBTech, 14: 376-	
		387, 1996.	
	185	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of	·
		Antisense Molecules", Bioconjugate Chem., 8: 935-940, 1997.	
	186	Luft "Making Sense Out of Antisense Oligodeoxynucleotide Delivery: Getting There	ļ
	187	Is Half the Fun". J. Mol. Med, P.75-76. 1998.  Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human	
	187	Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the	
		Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.	
	188	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense	
		Oligodeoxynucleotides", Molecular and Cellular Biochemistry, 172: 213-225, 1997.	
	189	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the	
		Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research	
		Communications, 231: 540-545, 1997.	
	190	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense	
ļ		Oligonucleotides", Biochimica et Biophysica Acta, 1520: 105-114, 2001.	
	191	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A	
İ		Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999.	

192	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21):	
	7855-7860, 2001.	
193	Clancy "Handbook of Microbiology", 1: 239-242, 1974.	
194	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving Biotechnology", American Society for Microbiology, Chap.2-3, 1990.	
195	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived From Cystic Fibrosis Patients", Mol. Microbiol., 22(5): 1005-1012, 1996. Abstract.	
196	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)", Clin. Exp. Immunol., 106(2): 374-399, 1996. Abstract.	
197	Davies et al. "Regulation of the Alginate Biosynthesis Gene AlgC in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture", Appl. Environ. Microbiol., 61(3): 860-867, 1995. Abstract.	
198	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudomonas Aeruginosa to Human Lung Epithelial Cells", Glycobiology, 5(1): 39-44, 1995. Abstract.	
. 199	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, NY, P.114-118, 148-153, 418-423, 420-423, 1994.	
200	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A Bacterial Biofilm", Science, 280: 295-298, 1998.	
201	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", Can. J. Microbiol., 43(11): 999-1004, 1997. Abstract.	
202	Stickler et al. "An Assessment of the Ability of A Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", British J. Urology, 78: 579-588, 1996.	
203	Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News, 64(6): 321-322.	
204	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", J. Catatact Refract. Surg., 24: 124-129, 1998.	
205	Pier "Rationale for Development of Immunotherapies That Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt., 98: 350-360, 1997. Abstract.	-
206	Goldberg et al. "Biologic Activities of Antobodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide Are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun., 63(1): 21-26. Abstract.	
207	Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in A Biofilm In Vitro Are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule But Not by Antibodies Produced During Chtonic Lung Infection in Cystic Fibrosis Patients", J. Immun., 155(4): 2029-2038, 1995. Abstract.	
208	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett., 130(1): 51-57, 1995. Abstract.	
209	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 154(4): S175-S182, 1996. Abstract.	
210	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl. Acad. Sci. USA, 94(22): 12088-12093, 1997.	
211	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in A Mouse Model of Respiratory Infection", Infect. Immun., 65(9): 3838-3846, 1997. Abstract.	
212	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J. Bacteriol., 178(2): 511-523, 1996. Abstract.	
213	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoid Pseudomonas Aeruginosa and Inflammation in A Mouse Model of Repeated Respiratory Challenge", Infection and Immunity, 66(1): 280-288, 1998.	

•

	014	L. L. L. L. HE. L. L. G. Bonnero of Custic Fibracia Mice to	
	214	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to	
	Į	Bronchopulmonary Infection With Pseudomonas Aeruginosa", J. Clin. Invest.,	
	215	100(11): 2810-2815, 1997.  Mrsny et al. "Addition of A Bacterial Alginate Lyase to Purulent CF Sputum In Vitro	
	215	Can Result in the Disruption of Alginate and Modification of Sputum	
	i	Viscoelasticity", Pul. Pharmacol., 7(6): 357-366, 1994. Abstract.	
	216	Wills et al. "Short-Term Recombinant Human DNase in Bronchiectasis. Effect on	
	216	Clinical State and In Vitro Sputum Transportability". Abstract.	
<u> </u>	217	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediatr.	
	217		
	210	Pulmonol., 22(6): 402-407, 1996. Abstract.  Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Sputum:	
	218	Implications to Pulminary Targeting Strategies", J. Drug. Therapy, 4(4): 233-243,	
		1996.	
	219	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the	
	219	Extracellular Polysaccharide of Mucoid Pseudomonas Aeruginosa", Antimicrob.	
•		Agents. Chemother., 42(4): 974-977, 1998. Abstract.	
<u></u>		Speert et al. "Modulation of Macrophage Function for Defense of the Lung Against	
	220	Pseudomonas Aeruginosa", Behring Inst. Mitt., 98: 274-282, 1997. Abstract.	
	221	Ying et al. "Alginate, the Slime Exopolysaccharide of Pseudomonas Aeruginosa,	
	221	Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-Proteinase	
		Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am. J.	
-		Cell. Moll. Biol., 15(2): 283-291, 1996. Abstract.	
 	222	Johansen et al. "Chronic Pseudomonas Aeruginosa Pneumonia: A New Prophylactic	
Ì	222	Principle", Behring Inst. Mitt., 90: 269-273, 1997. Abstract.	
	222	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and	
	223	Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol., 35(2): 103-	
	224	108, 1997. Abstract.  Spencer "Invasive Streptococci", Eur. J. Clin. Microbiol. Infest. Dis., 14(Suppl.1):	~
	224		
	226	S26-S32, 1995. Abstract.  Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular	
1	225	Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol., 76(5): 424-430,	
		1994. Abstract.	
	226	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated With Rapidly	
	220	Fatal Outcome in Taiwan", J. Formos Med. Assoc., 95(5): 364-371, 1996. Abstract.	ļ
<del></del>	227	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to	
	221	Virulence in A Mucoid Strain of the Group A Streptococcus", Infect. Immun., 65(1):	
		64-71, 1997. Abstract.	
	228	Scott et al. "Visualization of An Extracellular Mucoid Layer of Treponema Denticola	
	220	ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral	
		Microbiol. Immunol., 12(2): 121-125, 1997. Abstract.	
	229	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression	
	229	in Septricemia and Septic Arthritis", Infect. Immun., 65(10): 4216-21, 1997.	
l .		Abstract.	
	230	Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for	
İ		Hyaluronic Acid Capsule Expression in Group A Streptococci", Infect. Immun.,	
		62(2): 433-441, 1994. Abstract.	
<u> </u>	231	Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated	
	:	Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research, 9: 247-248,	
1		1982.	
	232	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in	
		Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS	
		Microbiol. Lett., 147(2): 195-202, 1997. Abstract.	
	233	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the	
		Expolysaccharide From Mucoid and Non-Mucoid Pseudomonas Aeruginosa", FEMS	
		Microbiol. Letters, 77(1-3): 35-44, 1992. Abstract.	
	234	Jorba et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned	
		by Aminosugars", Rev. Esp. Fisiol., 36(2): 155-161, 1980. Abstract.	
	235	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis	
		in Lactococcus Lactis", Appl. Environ. Microbiol., 67(1): 33-41, 2001. Abstract.	ı
-	236	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic Biliary	-
		Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane	ł
		Conductance Regulator", Hepatology, 27(1): 7-14, 1998. Abstract.	<u></u>
L			

237	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) Maintained in A Low Concentration of Serum", Biochem. J., 207(3): 369-379. Abstract.	
238	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med.,	
239	62(1): 113-122, 1997. Abstract.  Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.	
240	Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.	
241	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol., 6(5): 591-593, 1987. Abstract.	
242	Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic. Microbiol., 34(1): 3-10, 1994. Abstract.	
243	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients With Cystic Fibrosis", J. Clin. Microbiol., 26(12): 2505-2509, 1988. Abstract.	
244	Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis", The New England Journal of Medicine, 304(24): 1445-1449, 1981. Abstract.	
245	Tatnell et al. "Characterisation of Alginates From Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions, 24: 404S, 1996.	
246	Tatnell et al. "Chemical Analysis of Alginates From Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions, 22: 310S, 1994.	
247	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate From Mucoid Variants", Biochemical Society Transactions, 24: 406S, 1996.	
248	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology, 162(2): 504-509, 1985. Abstract.	
249	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides", Biotech. Adv., 12: 393-448, 1994.	
250	Anatolii "Hyaluronic Capsule as One of the Factors of Hemolytic Streptococcus Pathogenicity", Chem. Abstracts 86(17): 339, 1977. Abstr.118714 in Zh. Mikrobiol. Epidemiol. Immunobiol., 2: 22-27, 1977.	
251	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem. & Molecular Biol., 13: 1-32, 1984.	
252	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V., P.1-33, 1984.	
253	Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.	
254	Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.	
255	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int., 39(3): 563-571, 1996.	
256	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.	
257	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981.	
258	Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.	
259	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6086, 1990. Abstract.	
260	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease",	
261	<ul> <li>J. Nat. Cancer Inst., 85: 1725-1732, 1993.</li> <li>Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983.</li> </ul>	
262	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Biochemistry, Proceedings of the American Association for Cancer Research, 37: 495, 1996.	

		The state of the s	
	263	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-	
		Lymphocytes", International Journal of Cancer, 47(1): 92-98, 1991.	
	264	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal	
		Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.	
	265	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on	
		STN, US National Library of Medicine (Bethesda MD), 1996.	
	266	Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse GenBank on	
		STN, US National Library of Medicine (Bethesda MD), 1996.	
	267	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	
		Interscience, New York: 2.1.1-2.1.2, 1991.	
	268	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic	
	200	Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.	
	269	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro	
	209		
		Using Combined Treatment With Nacystelyn and RhDNase", Pediatric Pulmonology,	
		22: 161-166, 1996.	
	270	Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92	•
		(Suppl.64): 6A-44S - 6A-52S, 1992.	
	271	Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4,	
		1970.	
	272	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-	
		3074, 1980. Abstract.	
	273	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate	
	-	Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway	
		Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.	
	274	Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial	
	2/4	Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989.	
		Abstract.	
	275	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways	
		Disease", Acta Paediatr. Scand. Suppl., 363: 25-29, 1989.	
	276	Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower	
		Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997. Abstract.	
	277	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis:	
	į	Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	
	}	the Disease", Clinica Chimica Acta, 132: 143-155, 1983.	
	278	Allen "Opportunities for the Use Aerosolized al - Antitrypsin for the Treatment of	
	1 - 7 0	Cystic Fibrosis", Chest, 110: 256S-260S, 1996.	
	279	Schwab et al. "Increased Adherence of Staphylococcus Aures From Cystic Fibrosis	
	2/9	Lungs to Airway Epithelial Cells", Am. Rev. Respir., 148(2): 365-369, 1993.	
	-		
	200	Abstract.	·
	280	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires	
		Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-	
		3428, 1995. Abstract.	
	281	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in	
		Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice",	
		APMIS, 105(11): 838-842, 1997. Abstract.	
	282	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected	
		With Pseudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 1997. Abstract.	
	283	Zahm et al. "Early Alterations in Airway Mucociliary Clearance and Inflamation of	
		the Lamina Propria in CF Mice", Am. J. Physiol., 272(3 Pt 1): C853-C859, 1997.	
		Abstract.	
	201	Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast	
	284	Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.	
	1005		
	285	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-	
		Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997.	
		Abstract.	
	286	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	
		Lipoprotein Lipase to Cultured Bovine Endothelial Cells", J. Clinical Invest., 68(4):	
I		995-1002, 1981. Abstract.	
		Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in	
	287		
	287		
_	287	Feline Myocardial Ischemia-Reperfusion Injury", J. Pharm. Exp. Ther., 283(3): 1032-1038, 1997. Abstract.	

288	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattactant Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-	
289	560, 1997. Abstract.  Matgolies et al. "Identification of A Major Heparin-Precitable Protein in Human	
289	Serum and Its Relationship to Cystic Fibrosis", Pediatr. Res., 16(3): 181-186, 1982.  Abstract.	
290	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun., 66(3): 994-999, 1998. Abstract.	
291	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J. Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.	
292	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
293	Alvarez-Dominguez et al. "Host Cell Heparian Sulfate Proteoglycans Mediate Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein ActA Is Involved in Heparan Sulfate Receptor Recognition", Infection & Immun., 65(1): 78-88, 1997. Abstract.	
294	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract.	
295	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	
296	Inaba et al. "Effect of Heparinon Infection of Cells by Porcine Reproductive and Respiratoy Syndrome Virus", Am. J. Vet. Res., 58(5): 488-491, 1997. Abstract.	
297	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997. Abstract.	
298	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin Is Mediated by Its Glycosminoglycan-Binding Region and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	
299	Robert et al. "Chondroitin-4-Sulphate (Proeoglycan), A Receptor for Plasmodium Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial Cells", Res. Immunol., 146(6): 383-393, 1995. Abstract.	
300	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes", Mol. & Biochem. Parasit., 65: 73-83, 1994.	
301	Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.	
302	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies", Pediatr. Pulmonol, 28(4): 248-54, 1999. Abstract.	
303	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	
304	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol., 28(3): 159-166, 1999. Abstract.	
305	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England Journal of Medicine, 340(1): 23-30, 1999. Abstract.	, , , , , , , , , , , , , , , , , , , ,
306	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in A Neonatal Mouse Model of Infection", Infect. Immun., 64(1): 37-43, 1996. Abstract.	
307	Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 153(6 Pt.1): 1796-1801, 1996. Abstract.	
308	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children With Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 156(4 Pt.1): 1197-1204, 1997. Abstract.	
309	Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984. Abstract.	
310	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", Pediatric Pulmonology, 24: 143-146, 1997.	

٠

•

	311	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest, 115: 1120-	-
	311	1126, 1999.	
	312	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast Under Central Surveillance",	
		Science, 289: 1501-1504, 2000.	
	313	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and	
	<u> </u>	Regeneration", Nature Biotechnology, 16: 247-252, 1998.	
	314	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	
		Journal, 15: 1661-1663, 2001.	
	315	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	
	<del> </del>	Journal, Published Online, 2001.	
	316	Finkel "Potential Target Found for Antimetastasis Drugs", Science, 285: 33-34, 1999.	<del> </del>
	317	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of A Good Thing", TIG, 13(5): 178-182, 1997.	
	318	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During Endochondral Ossification", Exp. Cell. Res., 229(1): 126-136, 1996. Abstract.	
	319	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as Osseous Cicatrizing Agents", Ann. Endocrinol., 55(2): 121-123, 1994. Abstract.	
<del></del>	320	Blanquaert et al. "Heparan-Like Molecules Induce the Repair of Skull Defects",	1
	320	Bone, 17(6): 499-506, 1995. Abstract.	
	321	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on	
		Trabecular Bone In Vivo", Blood, 88(4): 1314-1320, 1996. Abstract.	
	322	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains A Heparin-Binding	
		Site Which Modifies Its Biological Activity", Eur. J. Biochem., 237(1): 295-302, 1996. Abstract.	
	323	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	
		Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell.	
		Biol. 143(4): 1113-1128, 1998. [Abstract]	
	324	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone	
		Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res.,	
	325	57(4): 554-559, 1996.  Kiberstis et al. "Bone Health in the Balance", Science, 289: 1497, 2000.	
		Service "Tissue Engineers Build New Bone", Science, 289: 1497, 2000.	
	326	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase",	<u> </u>
	327	Advan. Enzyme Regul., 37: 135-144, 1997. Introduction.	
	328	Bost et al. "Antibodies Against A Peptide Sequence Within the HIV Envelope	
		Protein Crossreacts With Human Interleukin-2", Immunol. Invest., 17: 577-586, 1988.	
	329	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	
		of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J.	
		Histochem. Cytochem. 43: 881-886, 1995.	
	330	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
		Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2):	
		551-557, 1987.	
	331	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated	
		Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene	
	222	Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.  Ross "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", Nature,	
	332	Ross "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s, Nature, 362: 801-809, 1993.	
	333	Putnak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine,	
	333	3(8): 828-829, 1997.	
	1224	Chick at al IICall Confees Describes for Homes Cimpley Vince And Homes College	
	334	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281, 1992.	
	335	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed From	
	1	the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA,	
		92: 5037-5041, 1995.	<u> </u>
	336	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	
1		Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation",	
L		Cell, 79: 1015-1024, 1994.	
	337	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor:	
	1	Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl.	
1	1	Acad. Sci. USA, 84: 2292-2296, 1987.	1

 338	Vlodavsky et al. "Involvement of the ExtraCellular Matrix, Heparin Sulfate	
336	Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and	
	Metastis", Tumor Angeogenesis, P.125-140, 1997.	
 339	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	
1339	Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry,	
	28: 1737-1743, 1989.	
 240	Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion,	
340	Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met.	
l l		
 <del> </del>	Rev., 7: 143-188, 1988.	
341	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996.	
 	Claims: 9, 10.	
342	Adams et al. "Initial Assesment of Human Gene Diversity and Expression Patterns	
	Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174,	
	1995. GenBank Entry AA304653, 1997. Claims: 30.	
343	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share In Vitro	
	Invasive Properties of Malignant Cells", J. Cellular Physiology, 136: 455-462, 1988.	-
 344	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta,	
	24: 424-430, 2003.	
 345	Dempsey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular	
	Damage", Glycobiology, 10(5): 467-475, 2000. Abstract, P.470, Col.1 - P.471, Col.1,	
	P.472, Col.1, § 4 - Col.2, § 2.	
 346	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	
3.0	Human Placenta", Molecular Human Reproduction, 8(6): 566-573, 2002.	
 347	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During	
1 347	Gestation", Reproduction, 121: 573-580, 2001.	
 249	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
348		
 	Biochem. Journal, 200: 1-10, 1981.	
349	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary	
 	Hemochromatosis", PNAS, 95(5): 2492-2497, 1998.	
350	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive	
	BioMedicine Online 2002, 4(2): 170-175, 2002. Abstract.	
351	Bean et al. "Fertilization In Vitro Increases Non-Disjunction During Early Cleavage	
	Divisions in A Mouse Model System", Human Reproduction, 17(9): 2362-2367,	
	2002. Abstract.	
352	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires	
ĺ	Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003.	
	Abstract.	
 353	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes From Cryopreserved	
	Primordial Mouse Follicles After Sequential In Vivo Transplantation and In Vitro	
	Maturation", Biology of Reproduction, 64: 171-178, 2001. Abstract.	
 354	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-	
1 55 '	Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse	
Ī	Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell	
	Stage", Biology of Reproduction, 66: 3810385, 2002. Abstract.	
 355	Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane	
333	Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies,	
1	and the Development of Improved Cryopreservation Methods", Biology of	
 125	Reproduction, 63: 1294-1302, 2000. Abstract.	
356	Yesildaglar et al. "The Mouse as A Model to Study Adhesion Formation Following	
ľ	Endoscopic Surgery: A Preliminary Report", Human Reproduction, 14(1): 55-59,	
 	1999. Abstract.	
357	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to	
	Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of	
	Reproduction, 62: 178-185, 2000. Abstract.	
358	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the	
	Neonatal Mouse Model", Biology of Reproduction, 38: 935-943, 1988. Abstract.	
 359	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters	
	the Ovary and Oviduct", Biology of Reproduction, 28: 735-744, 1983. Abstract.	
 360	1 ??? "Mouse Models for Reproductive Biology Research" - www.lax.org/laxmice: 1-	
 360	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-2, Summer 2002.	

•

•

.

	1261	LY 1 1941 1 1 Clarica and Duranceion of Human Hanaranaca cDNA"	
	361	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", Proceedings American Association for Cancer Research Annual Meeting, 1992, 33:	
		57, 1992. Abstract.  Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical	
	362	I huong et al. "Sequence-Specific Recognition and Modification of Double-Helical	
	1000	DNA by Oligonucleotides", Angew.Chem. Int. Ed. Engl. 32: 666-690, 1993.	
	363	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992.  Abstract.	
	264	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL	
	364	Antisense Oligodeoxynucleotides", Science, 253: 562-565, 1991. Abstract.	
	265	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential	
	365	Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An In	
		Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, 88:	
	- 200	2351-2355, 1991.  Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRN	
	366	Burch et al. "Oligodeoxynucleoudes Antisense to the Interiously 1 Receptor inking and Human Fibroblasts and in	
		Block the Effects of Interleukin I in Cultured Murine and Human Fibroblasts and in	
		Mice", J. Clin. Invest., 88: 1190, 1991. Abstract.	<del></del>
	367	Agrawal "Antisense Oligonucleotides As Antiviral Agents", Trends Biotechnol.,	
		10(5): 152-158, 1992. Abstract.	
	368	Ngo et al. "The Protein Folding Problem and Tertiary Structure", Ed Birkhauser,	
	0.00	Boston, P.491-495, 1994.	
	369	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of	
	İ	Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia",	
		Nature Medicine, 6(5): 568-572, 2000.	
	370	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling Is Defined by	
		Pericyte Coverage of the Preformed Endothelial Network and Is Regulated by PDGF-	
		B and VEGF", Development, 125: 1591-1598, 1998.	
	371	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1	
		(Bone Morphogenetic Protein 7)", Proc. Natl. Acad. Sci. USA, 93: 9021-9026, 1996.	
	372	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49:	
		437-438, 1987.	
	373	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human	
		Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption	
		and Formation in Organ Culture", Bone, 14: 717-720,1993.	
	374	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of	
		Computational Approaches in the Genomic Era", Trends in Biotechnology, 18: 34-	
		39, 2000.	
	375	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome	
		Research, 10:398-400, 2000.	
	376	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends	
		in Genetics, 14(6): 248-250, 1998.	
	377	Smith et al. "The Challenges of Genome Sequence Annotation or 'The Devil Is in the	
		Details", Nature Biotechnology, 15: 1222-1223, 1997.	
	378	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.	
	379	Bork "Go Hunting in Sequence Databases But Watch Out for the Traps", Trends in	
		Genetics, 12(10): 425-427, 1996.	
	380	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino	
		Acid Substitutions", Science, 247: 1306-1310, 1990.	
	381	??? A Genesq, Accession No. AA17083, 1999.	
	382	Bendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Grafting",	
		Methods in Enzymology, 8: 83-93, 1995.	
	383	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Protein	
		Expression and Purification, 26: 425-431, 2002.	
	384	Coligan et al. "Current Protocols in Immunology", Immunology - Laboratory	1
		Manuals, 1991.	
	385	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene From	
		Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90: 3660-3664, 1993.	
<del></del>	386	Gordon-Cardo et al. "Expression of Basic Fibroplast Growth Factor in Normal	
		Human Tissues", Laboratory Investigation, 63: 832-840, 1990.	
	387	Harper "Harper's Biochemistry", 24th Ed., P. 660-685.	
		Boat et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia	
	388	Boat et al. Increased Sulfation of Olycoconjugates it i Cultured Planting	l .
	388	Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-	

389	Nossuli et al. "Heparinas III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical	
200	Experimental Therapy, 283(3): 1032-1038, 1997. Abstract.  Nakajima et al. "Immunochemical Localization of Heparanase in Mouse and Human	
390	Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.	
391	Wands Federal Circular, 1988,	
392	Fisher CCPA, 1970.	
393	Carson et al. Mucin and Proteoglucan Functions in Embryo Implantation", BioEssays, 20(7): 577-583, 1998. Abstract, P.580, Col.2, § 2, P.582, Col 1, Fig.1.	
394	Clonotech Laboratories "RT-PCR Methods and Applications Book 1", Clonotech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.	
395	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.	
396	Ennis et al. "Rapid Cloning of HLA-A,B cDNA by Using the Polymerase Chain	
	Reaction: Frequency and Nature of Errors Produced in Amplification", PNAS USA, 87: 2833-2837, 1990.	
397	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions as An Extracellular Matrix-Degrading Enzyme or as A T-Cell Adhesion Molecule,	
	Depending on the Local PH", Journal of Experimental Medicine, 181: 1929-1934, 1995.	
398	Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.	
399	Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.	
400	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.	
401	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.	
402	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
403	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.	
404	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged	
	Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.	
405	Sambrook et al. "Molecular Cloning, A Laboratory Manual", CSH Laboratory Press, 2: 7.37-7.52, 1989.	
406	Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression", Curr. Opin. Biotech., 6: 527-533, 1995.	
407	Freshney "Animal Cell Culture", P.48-49.	
408	Chang et al. "Differential Ability of Heparan Sulfate Protecoglycans to Assemble the Fibroblast Growth Factor Receptor Complex In Situ", FASEB Journal, 14: 137-144, 2000.	
409	Hillier et al. "The WashU-Merck EST Project", Database EMBL Accession No. N45367, XP 002198420, 1996. Abstract.	
410	Marra et al. ""The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. Al122034, XP 002198426, 1998. Abstract.	
411	Marra et al. "The WashU-HHMI Mouse Est Project", Database EMBL, Accession No. AA047943, XP002198424, 1996.	
412	Evans et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.	
413	Maniatis et al. "Extraction, Purification and Analysis of mRNA From Eukaryotic Cells", Moleular Cloning Manual, chapt. 6: 188-246, 1982.	
414	Suggs et al. "Use of SyntheticNucleotides as Hybridiztion Probes: Isolation of Cloned DNA Sequences for Human β2-Microglobulin", PNAS, 78(11): 6613-6617, 1981. P.13.	
415	Alberts et al. "Molecular Biology of the Cell", Arland Publishing, 2nd Ed., P. 195-196, 598, 1989.	
416	Sigma Catalog, P. 275, 1992. Collagenase Listing.	
417	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation, 1(2): 97-110, 1990.	
418	Hidde et al. "Construction and Characterization of A Fusion Protein of Single-Chain Anti-Carcinoma Antibody 323/A3 and Human Beta-Glucuronidase", Cancer Immunology Immunotherapy, 45(5): 266-272, 1998.	

•

419 420 421 422	Takayama et al. "Neutrophil-Dependent Goblet Cell Degranulation: Role of Membrane-Bound Elastase and Adhesion Molecules", American Journal of Physiology, 275(2/Part 1): L294-L302, 1998.  Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	
421	Physiology, 275(2/Part 1): L294-L302, 1998.  Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	
421	Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	
421	and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	
	, , , , , , , , , , , , , , , , , , , ,	
	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by	
422	Primary Human Fibroblasts", Journal of Cell Science, 115(10): 2179-2187, 2002.	
	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase Markedly	
	Promote Tumor Angiogenesis and Metastasis", Proc. Natl. Acad. Sci. USA, 99(15):	
	10031-10036, 2002.	
423	Guo et al. "Protein Tolerance to Random Amino Acid Change", PNAS, 101(25):	
	9205-9210, 2004.	
424	Dibrino "RT-PCR Method & Applications", Clonotech Laboratories, 1st Ed., 1: 11,	
425	1 0	
10.5	1989.	
426		
427	1	
400		
428		
/20*	Vladaysky et al. "Expression of Henaranase by Platelets and Circulating Cells of the	
727	Immune System: Possible Involvement in Dianedesis and Extra Vasation". Invasion	
430*	Vlodaysky et al. "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species	
750	of Hengrin". Invasion & Metastasis, 14(1-6): 290-302, 1994/95.	
431	Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory	
432	Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans	
	in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis",	
	Cancer Research, 43: 2704-2711, 1983.	
433	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and	
	Angiogenesis", Isr. J. Med. Sci., 24(9-10): 464-470, 1988.	
434	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by	
	Blocking Tumor-Cell-Derived Heparanases", Int. J. Cancer, 40: 511-517, 1987.	
435	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
436		
407	Factor: A Regulatory Mechanism?, Trends Biochem. Sci., 10: 206-271, 1991.	
437	Allowed Committed by Treetment of Animala With Law Doses of Henrin' The	
438	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in	· · · · · · · · · · · · · · · · · · ·
430		•
439	Sudhalter et al. "Importance of Size. Sulfation and Anticoagulant Activity in the	
137	Potentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem.,	
440	Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of	
	Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular	
	Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract.	
441	Inoue et al. "Selective N-Desulfation of Heparin With Dimethyl Sulfoxide	
	Containing Water or Methanol", Carbohydrate Research, 46: 67-95, 1976.	
442	Nagasawa et al. "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates With	
	Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 58: 47-	
	55, 1977.	
443	Matia Bar-New et al. Inhibition of Heparanase-Mediated Degradation of	
	70(2): 551-557, 1987.	
	434 435 436 437 438 439 440 441 442	426 Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991.  427 Ruoslahti et al. "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991.  428 Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", in: Basic Membranes: Cellular and Molecular Aspects, Academic Press, Orlando, Fla., P. 327-343, 1993.  429* Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasation", Invasion & Metastasis, 12(2): 112-127, 1992. Abstract.  430* Vlodavsky et al. "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14(1-6): 290-302, 1994/95.  431 Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.  432 Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.  433 Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Isr. J. Med. Sci., 24(9-10): 464-470, 1988.  434 Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor-Cell-Derived Heparanases", Int. J. Cancer, 40: 511-517, 1987.  435 Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.  436 Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.  437 Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", The Journal of Clinical Investigation, 83: 752-756, 1989.  438 Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin"

	444	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.	
	445	Haimovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-	
		Derived Factors", Blood, 78: 789-796, 1991.	
	446	Vlodavsky et al. "Extracellular Matrix-Resident Growth Factors and Enzymes:	
		Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis	
		Rev., 9: 203-226, 1990.	
	447	Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic	
		Compounds", J. Bioactive and Compatible Polymers, 8: 317-337, 1993.	
	448	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and	
		Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds",	
		Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	449	Katz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor	
		Binding of A Heparain-Mimicking Polyaromatic Anionic Compound", J. Amer. Soc.	•
		Nephrology, P.1688-1697, 1997.	
	450	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding	
		Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparain-	
		Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-1575, 1997.	
	451	Benezra et al. "Reversal of Fibroblast Growth Factor-Mediated Autocrine Cell	
	İ	Transformation by Aromatic Anionic Compounds", Cancer Research, 52: 5656-5662,	
		1992.	
	452	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate	
		Specific Endo-β-Glucuronidase (Heparanase) of Metastatic Melanoma Cells",	
		Biochemistry, 25: 5322-5328, 1986.	
	453	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated	
		Polysaccharides", Int. J. Cancer, 39: 82-88, 1987	
	454	Ornitz et al. "Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth	
		Factor to A Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	
		Cellular Biology, 12: 240-247, 1992.	
	455	Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required for Binding of	
		Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64: 841-848,	
		1991.	
	456	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate	
		Proteoglycans That Promote Binding of Basic Fibroblast Growth Factor to Its	
		Receptor", J. Biol. Chem., 269(1): 114-121, 1994.	
	457	Bartlett et al. " Comparative Analysis of the Ability of Leucocytes, Endothelial Cells,	
		and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for	
	l	Cytokine Dependence and Detection of A Novel Sulfatase", Immunology and Cell	
_		Biol., 73: 113-124, 1995.	
	458	Nakajima et al. " A Solid-Phase Substrate of Heparanase: Its Application to Assay of	
		Human Melanoma for Heparan Sulfate Degradative Activity", Analytical	
		Biochemistry, 157: 162-171, 1986.	
	459	Oosta et al. "Purification and Properties of Human Platalets Heparitanase", J. Biol.	
		Chem., 257(19): 11249-11255, 1982.	
	460	Sewell et al. "Human Mononuclear Cells Contain An Endoglycosidase Specific for	
		Heparan Sulfate Glycosaminoglycan Demonstrable With the Use of A Specific	
		Solid-Phase Metabolically Radiolabelled Substrate", Biochem J., 264: 777-783, 1989	
	461	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian	
	1	Heparanase Activity", Biochemical Journal, 325: 229-237, 1997.	
	462	Mullings et al. "New Reducing Sugar Assay for the Study of Cellulases", Enzyme	
		Microb. Technol., 6: 491-496, 1984.	
	463	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and A	
	ļ	Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.	
	464	Linhardt "Capillary Electrophoresis of Oligosaccharides", Methods in Enzymology,	
		230: 265-280, 1994.	
	465	Basu et al. " Analysis of Glycospingolipids by Fluorophore-Assisted Carbohydrate	
		Electrophoresis Using Ceramide Glycanase From Mercenaria Mercenaria",	
	-	Analytical Biochemistry, 222: 270-274, 1994.	
	466	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-Resolution of	
		Separation of Reducing Saccharides Labelled With the Fluorophore 8-	
		Aminonaphtalene-1, 3, 6-Trisulphonic Acid", Biochem J., 270: 705-713, 1990.	
	1		

	467	Coquet et al. "Applications of A Post-Column Fluorigenic Reaction in Liquid	
		Chromotagraphy for the Determination of Glucose and Fructose in Biological	
		Matrices", Analytica Chemica Acta, 252: 173-179, 1991.	
	468	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell-	
		Specific \(\lambda\)gt11 Library Using Antibodies Directed Against A Putative Heparanase	
		Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994.	
	469	Zsolnai et al. "Directional Immobilization of Heparin Onto Nonporous Surface of	
		Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	470	Bellott et al. "Closing the Loop in Combinatorial Chemistry", European Pharmaceutical Contractor, 1997.	
	471	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.	
	472	Yen et al. "Potentialities of A New Class of Anticlotting and Antihemorrhagic	
		Polymers", J. Macromol. Sci. Chem., 4(3): 693-714, in Chem. Abst. AN, 1970 418456 In: Chem. Abst. AN, 1970 418456.	
	473	Mes et al. "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of	
		Sugars and Sugar Derivatives Reported in Glycoproteins", J. Chromatogr., 43(\$): 480-486, 1969.	
	474	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and	
		Differentiation of Sugars and Sugar Derivatives in Glycoproteins", J. Chromatrogr., 38(1): 120-125, 1968.	
	475	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
		Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.	
	476	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", Annu. Rev. Biochem., 58:.575-606, 1989.	
	477	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.	
	478	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan	
		Sulfate on Cell Surface and Extracellular Matrix", J. Clin. Invest., 90: 2013-2021, 1992.	
	479	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - Is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 1988.	
	480	Folkman et al. "Angiogenic Factors", Science, 235: 442-447, 1987.	
	481	Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules",	
	400	Journal of Biological Chemistry, 267(9): 6093-6098, 1992.  Matzner et al. "Degradation of Heparan Sulfate in the Subendothelial Extracellular	<del></del>
	482	Matrix by A Readily Released Heparanase From Human Neutrophils", Journal of	
		Clinical Investigation, 76(4): 1306-1313, 1985.	
	483	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative	
	463	Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem. J., 327: 917-923, 1997.	
	484	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimer's β-	
	.5.	Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate	
		Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.	
	485	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-	
		Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.	
	486	Rapraeger et al. "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252: 1705-1709, 1991.	
	487	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and	
		Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J. Biol. Chem., 268(14): 10160-10167, 1993.	
	488	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998.	
	1.00		
Signature	_	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ 

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		cci of 1993, no persons are required to respond to a collection of infor		Complete					
	Sui	ostitute for form 1449A/PTO	Application Number	10/851,135					
-	INF	ORMATION DISCLOSURE		Filing Date	05/24/2004				
		TEMENT BY APPLICANT	First Named Inventor	Pecker					
	SIA	TEMENT DI ATTEKANI		Group Art Unit	1623				
		(use as many sheets as necessary)		Examiner Name					
Sheet	Ī	Of I	_	Attorney Docket Number	27970				
		OTHER PRIOR ART – NON PATENT	LITER	ATURE DOCUMENTS					
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), to item (book, magazine, journal, serial symposium, catalogublisher, city and/or count Fairbanks et al, "Processing of the Human He the Active Enzyme is a Heterodimer", J. Biol. 29590, 15 Oct. 1999.	og, etc.) dat ry where pu paranase	e, page(s), volume-issue numl ablished. Precursor and Evidence	thai				
4		Hulett et al, "Cloning of Mammalian Heparana Invasion and Metastasis", Nature Medicine, 5(	7):803-8	09, 1999					
		Toyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", <i>J. of Biolog. Chemistry</i> , vol. 274. No. 34, pp. 24153-24160, 20 Aug. 1999.							
		Miao et al, "Cloning, Expression, and Purification of Mouse Heparanase", <i>Protein Expression and Purification</i> , 26:425-431, 2002							
		Freeman et al, "Human Platelet Heparanase: P Catalytic Activity", <i>Biochem J.</i> , 330(3): 1341-							
<del></del>									
	1								
<del></del>	-								
Examiner Signature		1.		Date Considered					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

Under the P	aperwork	Reduction Act of 1995, no persons	are required t	o respond to a co	llection of information unless it contains a	valid OMB control number.	
		Substitute for form 1449A/	РТО	•			
]	INFC	RMATION DISC	LOSUI	RE	Filing Date	February 25, 2004	
;	STATEMENT BY APPLICANT First Named Inventor PECKER Iris et al						
	(1	use as many sheets as nec	1652				
	•	·			Examiner Name		
Sheet			of		Attorney Docket Number	27674	
	1		71.6	PATENTI	DOCUMENTS	<u> </u>	
Examiner	Cite	Document Number		ation Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.			D-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	1	Number-Kind Code <sup>2 (if brown)</sup> US-5,362,641	08-8-19	04	Fuks et al.		
					Leshchiner et al		
	2	US-5,399,351	03-21-1				
	3	US-5,550,116	08-27-1		Lormeau et al.	-	
	4	US-5,667,501	09-16-1		Fowler et al.		
	5	US-5,739,115	04-14-1		Fugedi et al		
	6	US-6,177,545	01-13-2		Pecker et al.		
	7	US-6,348,344			Ayal-Hershkovitz et al.		
	8	US-4,946,778	08-8-19		Ladner et al.  Zimmermann et al.		
		US-5,997,863	07-7-19				
	10	US-6,242,238	05-5-20		Freeman et al.		
	11	US-5,688,679	11-18-1		Powell Heinrikson et al.		
	12	US-6,387,643	05-14-2				
	13	US-6,423,312	07-23-2		Yacoby-Zeevi Pecker et al.		
	14	US-6,531,129	01-1-20				
	15	US-4,455,296	06-19-1		Hansen et al.		
	16 17	US-5,571,506	05-5-19		Regan et al. Chen et al.		
	18	US-5,917,830 US-5,859,660	06-29-1 01-12-1		Perkins et al.		
	19	US-5,600,366	04-4-19		Schulman		
	20	US-6,020,931	01-1-20		Bilbrey et al.		
	21	US-5,968,822	10-19-1		Pecker et al.		
	22	US-6,153,187	11-28-2		Yacoby-Zeevi		
	23	US-6,664,105	12-16-2		Pecker et al.		
	24	US-5,145,679	08-8-19		Hinson		
	25	US-5,736,137	07-7-19		Anderson et al.		
	26	US-5,194,596	03-16-1		Tischer et al.		
	27	US-5,350,836	09-27-1		Kopchick et al.		
	28	US-6,562,950	05-13-2		Peretz et al.		
	29	US-6,699,672	02-2-20		Pecker et al.		
	30	US-5,580.862	03-3-19		Rosen et al.		
	31	US-5,474,983	12-12-1		Kuna et al.		
	32	US-2002/0102560	01-1-20		Pecker et al.		
	33	US-6,790,658	09-14-2		Pecker et al.		
	34	US-6,798,658	09-28-2		Takedomi et al.		
	35	US-5,618,709	08-8-19		Gewirtz et al.		
	36	US-5,656,595	08-12-1		Schweighoffer et al.		
	37	US-4,683,195	07-28-1		Mullis et al.	·	
	38	US-5,602,095	02-11-1		Pastan et al.		
	39 .	US-4,859,581	08-22-1		Nicholson et al.		
	40	US-4,882,318	11-21-1		Vlodavsky et al.		
	41	US-5,129,877	07-14-1		Gallo et al.		
	42	US-5,206,223	04-27-1		Vlodavsky et al		
	43	US-5,332,812	07-26-1		Nicolson et al.		

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Olider the Paper		Act of 1995, no persons are required to respond to a cour	<u></u>	Complete i				
	Sul	ostitute for form 1449A/PTO		Application Number	10/785,116			
	INE	ORMATION DISCLOSURE		Filing Date	February 25, 2004			
			First Named Inventor	PECKER Iris et al				
	STA	TEMENT BY APPLICANT		Group Art Unit	1652			
	ı	(use as many sheets as necessary)		Examiner Name				
Sheet	T	Of		Attorney Docket Number	27674			
		OTHER PRIOR ART – NON F	ATENT LITER	ATURE DOCUMENTS				
Examiner Initials	Cite No.1		um, catalog, etc.) dat l/or country where pu	e, page(s), volume-issue numb iblished.	er(s), T <sup>2</sup>			
	44	Hulett et al. "Cloning of Mammalian I Invasion and Metastasis", Nature Med	icine, 5(7): 803-8	309, 1999				
	45	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, 274(34): 24153-24160, 1999.						
	46	Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene", Biochemical and Biophysical Research Communication 261(1): 183-187, 1999.						
	47	Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem J. 342: 361-368, 1999.						
	48	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.						
	49	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9): 679-684, 1996.						
	50	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.						
	51	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, XP 002139970, 1999.						
	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21): 7855-7860, 2001.							

Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through clause in not in combinative and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ant/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature

クプイスト

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nut ther. Complete i 'Known Substitute for form 1449A/PTO Application Number 10/781,758 Filing Date January 14, 2003 INFORMATION DISCLOSURE First Named Inventor ILAN, Neta et al. STATEMENT BY APPLICANT Group Art Unit 1652 (use as many sheets as necessary) Examiner Name Attorney Docket Number Of 2 Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines, Where Kind Code<sup>1</sup> Relevant Cite Date of Publication of Examiners Number Name of Patentee or Applicant (if known) Passages or Relevant Figures Initials No. Cited Document MM-DDof Cited Document Appear YYYY FOREIGN PATENT DOCUMENTS Foreign Patent Documents Date of Publication of Name of Patentee or Pages, columns, lines, Examiners Cite Kind Code5 Cited Document MM-DD-Where Relevant 7-6 Office<sup>1</sup> Number<sup>4</sup> Applicant of Cited Document Initials No. 1 Passages or Relevant (if known) Figures Appear

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the tw >-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → 🗵 Approved for use through 10/31/99 OMB 0651-0031 PTO/SB/08A (10-96)

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE:
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control in inher.

•	Sut	ostitute for form 1449A/PTO		Complete	f Known
	Jul	State to form 1449AF 10		Application Number	
	INF	ORMATION DISCLOSURE		Filing Date	
	STA	TEMENT BY APPLICANT		First Named Inventor	
	SIA	TEMENT BY ATTECAN		Group Art Unit	
	(	(use as many sheets as necessary)		Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	
		OTHER PRIOR ART – NON I			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LE item (book, magazine, journal, serial sympos publisher, city an		e, page(s), volume-issue numl	
		Vlodavsky et al. "Mammalian Hepara Tumor Progression and Metastasis", N	nase: Gene Clonir	ng, Expression and Func	tion in
		Chang et al. "Differential Ability Of F The Fibroblast Growth Factor Recepted 144, 2000.	Ieparan Sulfate Pr	rotecoglycans To Assem	
		Ishai-Michaeli et al. "Importance of S Fibroblast Growth Factor From the Va Biochemistry, 31(7): 2080-2088, 1992	ascular Endothelit 2. Abstract	um and ExtraCellular Ma	
		Gitay-Goren et al. "The Binding of Va Receptors Is Dependent on Cell Surfa Journal of Biological Chemistry, 2670	ce-Associated He (9): 6093-6098, 1	parin-Like Molecules", 992.	
		Hulett et al. "Cloning of Mammalian I Invasion and Metastasis", Nature Med	licine: 5(7): 803-8	309, 1999.	
		Toyoshima et al. "Human Heparanase Expression", J. of Biolog. Chemistry,			end
					-
Examiner Signature		1		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

37

US-5,739,115

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction

## Complete if Known Substitute for form 1449A/PTO Application Number 10/781.758 INFORMATION DISCLOSURE Filing Date January 14, 2003 STATEMENT BY APPLICANT First Named Inventor ILAN Neta et al (use as many sheets as necessary) Art Unit Examiner Name Attorney Docket Number Sheet of 18 27525 U.S. PATENT DOCUMENTS Cite No. Examiner Document Number Publication Date MM-DD-YYYY Pages, Columns, Lines, Where Initials' Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code? (if known) 1 US-6,177,545 01-13-2001 Pecker et al. 2 US-6,348,344 02-19-2002 Ayal-Hershkovitz et al 3 US-4,946,778 08-8-1990 Ladner et al. 4 US-5,997,863 07-7-1999 Zimmermann et al. 5 US-6,242,238 05-5-2001 Freeman et al 6 US-5,688,679 11-18-1997 Powell 7 US-6,387,643 05-14-2002 Heinrikson et al. 8 US-6,423,312 07-23-2002 Yacoby-Zeevi 9 US-6,531,129 01-1-2003 Pecker et al. 10 US-4,455,296 06-19-1984 Hansen et al. 11 US-5,571,506 01-1-1996 Regan et al. 12 US-5,917,830 06-29-1999 Chen et al. 13 US-5,859,660 01-12-1999 Perkins et al. 14 US-5,600,366 04-4-1997 Schulman 15 US-6,020,931 01-1-2000 Bilbrey et al. 16 US-5,968,822 10-19-1999 Pecker et al. 17 US-6,153,187 11-28-2000 Yacoby-Zeevi 18 US-6,664,105 12-16-2003 Pecker et al. 19 US-5,145,679 08-8-1992 Hinson 20 US-5,736,137 07-7-1998 Anderson et al. 21 US-5,194,596 03-16-1993 Tischer et al. 22 US-5,350,836 09-27-1994 Kopchick et al. 23 US-6,562,950 05-13-2003 Peretz et al. 24 US-6,699,672 02-2-2004 Pecker et al. 25 US-5,580.862 03-3-1996 Rosen et al. 26 US-5,474,983 12-12-1995 Kuna et al. 27 US-2002/0102560 01-1-2002 Pecker et al. 28 US-4,859,581 01-1-1989 Nicholson et al. 29 US-4,882,318 01-1-1989 Vlodavsky et al. 30 US-5,129,877 01-1-1992 Gallo et al. 31 US-5,206,223 04-27-1993 Vlodavsky et al US-5,332,812 Nicolson et al. 32 07-26-1994 33 US-5,362,641 08-8-1994 Fuks et al. 34 US-5,399,351 Leshchiner et al 01-1-1995 35 US-5,550,116 01-1-1996 Lormeau et al. 36 US-5,667,501 01-1-1997 Fowler et al

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Documents  Country Code <sup>3</sup> : Number <sup>4</sup> : Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T			
	38	PCT WO 99/57244	11-11-1999	Ben-Artzi et al.		$\Box$			

Fugedi et al

01-1-1998

40	PCT WO 99/11798	03-11-1999	Pecker et al.	
41	PCT WO 88/01280	01-1-1988	Nicolson et al.	
42	PCT WO 95/04158	09-9-1995	Hoogewerf et al.	
43	PCT WO 99/21975	06-6-1999	Freeman et al.	
44	PCT WO 91/19197	12-12-1991	Nicolson et al.	
45	PCT WO 95/04518	02-16-1995	Midha et al.	
46	PCT WO 03/006645 A2	01-23-2003	Bohlen et al.	
47	PCT WO 97/11684	04-4-1997	Bennett et al.	
48	PCT WO 91/02977	07-7-1991	Fuks et al.	
49	PCT WO 97/27327	07-31-1997	Van Ness et al.	
50	PCT WO OO/52149	08-8-2000	Yacobi-Zeevi	
51	PCT WO 00/52178	08-8-2000	Pecker et al.	
Examiner		L	Date	
Signature			Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's artique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE aformation unless it contains a valid OMB control number.

Older the Paperw	отк кеаистю	Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Kno	 WD
	Sut		81,758
	INF		ary 14, 2003
			N Neta et al
	SIA	Group Art Unit	
		(use as many sheets as necessary) Examiner Name	
Sheet	heet 2 Of 18 Attorney Docket Number 27525		
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
-	52	Wight et al. "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", Curr. Opin. Cell. Biology, 4: 793-801, 1992.	~
	53	Jackson et al. "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Review, 71(2): 481-539, 1991.	~
	54	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis", Glycobiology 7(2): 277-284, 1997.	~
	55	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research 21(25): 5901-5908, 1993.	V
	56	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", Journal of Biol. Chem., 274, (42): 29587-29590, 1999.	V
	57	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986.	
	58	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8):349-351, 2000. P. 350, Col.1, § 1; P.350, Col.3, § 1; Claims: 1-24.	v
	59	Niwa et al. "Efficient Selection for High-Expression Transfectants With a Novel Eukaryotic Vector", Gene, 108(2):193-199, 1991.	V
	60	Clark "The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):337-350, 1998.	V
	61	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection Studies", Ann NY Acad Sci, 738:104-115, 1994.	1 1
	62	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene Regulatory Sequences", Biochem Cell Biol., 80(6):777-788, 2002.	v'
	63	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002.	1
	64	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk", Mol Immunol., 38(8): 619-625, 2002.	V
-	65	Clark et al. "Pharmaceuticals from Transgenic Livestock", TIBTECH, 5: 20-24, 1987.	V
	66	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and Alpha-Lactalbumin Cdna Clones", J. Biol. Chem., 256(1): 526-32, 1981.	V
	67	Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.	V
	68	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β-Casein Gene", Gene, 66: 87-96, 1988.	V
	69	Alexander et al. "Complete Sequence of the Bovine β-Lactoglobulin cDNA', Nucleic Acids Research, 17(16): 6739-6744, 1989.	1
	70	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase." Exptl. Cell. Res. (1992) vol. 201:208-215	~
	71 -	Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-510.	V
	72	Murray et al. "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed., McGraw-Hill Professional, Chap. 57, pp 667-685, 1998.	V
	73	Selvan et al. "Heparan Sulfate in Immune Responses", An. NY Acad. Sci., 797: 127-	

	. 1			
	· .1			
[			139, 1996.	
		74	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", Science 276: 71-74, 1997.	v
		75	Krivit et al. "Microglia: The Effector cell for reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage diseases", Cell Transplant, 4(4): 385-392, 1995.(Abstract)	<b>V</b>
		76	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Int'l. conf. On Molec. Biol. And Pathology of Matrix, Session IV.	<i>\</i>
		77	Lazarus et al. "Ex Vivi Expansion and subsequent Infusion of Human Bone Marrow- Derived Stromal Pregenitor Cells (Mesenchymal Progenitor cells): Implications for therapeutic Use", Bone Marrow Transplantation, 16:557-564, 1995.	V
Ī		78	Pomahac et al. "Tissue Engineering of Skin" Crit Rev Oral Biol Med, 9(3):333-344, 1998. (abstract)	V
		79	Benathan et al. "Living epidermal and Dermal Substitutes for Treatment of Severely burned Patients", Rev Med Suisse Romande, 118(2): 149-153, 1998. (Abstract-art in French)	J
ĺ		80	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	<b>y</b>
		81	Duffy et al. "Maximizing Flap Survival in a Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 176-179, 1996.  Abstract.	V
Ī		82	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg., 102(1):135-139, 1998. Abstract.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
		83	Raghunath et al. "Cultured Epithelial Autografts: Diving from Surgery into Matrix Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	٧
		84	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds", American J. Surg., 170(1):75-83, 1995. Abstract.	V,
		85	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for Grafting into the Central Nervous System", Genet Eng (NY), 13: 205-220, 1991.  Abstract.	>
		86	Maillard et al. "Pre-Treatment with Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-1030, 1998.	V
		87	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", Acta Orthop Scand Suppl, 269: 1-33, 1006 (abstract)	٧
		88	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop Scand, 67(3): 229-236, 1996. Abstract.	<b>✓</b>
		89	Inui et al. "Loca Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits".	<b>✓</b>
		90	Tabata et al. "Bone Regeneration by Basic Fibroblast Growth Factor Complexed with Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	V
		91	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta Orthop. Scand., 60(4): 473-476, 1989. Abstract.	V
		92	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991. Abstract.	V
		93	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ulcer Therapy: Findings in a Rat Model", J. Gastroenterol, 31(6): 777-784, 1996. Abstract.	V
		94	Chleboun et al. "The Development and Enhancement of the Collateral Circulation in an Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(3): 202-207, 1994. Abstract.	j
		95	Aplin "Adhesion Molecules in Implantation", Rev Reprod, 2(2): 84-93, 1997.	V
		96	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the Establishement of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116, 1998. Abstract.	٧
		97	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum. Reprod. Update, 2(4): 307-321, 1996.	V
		98	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", Contracept Fertil Sex, (art in French) 22(1): 48-51, 1994. Abstract.	V

99	Smith et al "Evaporación of Unasana Culfata Destachusas (antinas) : 44 35	
	Smith et al. "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse Blastocyst is Regulated during Normal and Delayed Implantation", Dev. Biol., 184(1): 38-47, 1997. Abstract.	Ņ
100	Abrahamsohn et al. "Implantation and Decidualization in Rodents", J. Exp. Zool., 266(6): 603-628, 1993 Abstract.	J
101	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9): 679-684, 1996.	V
102	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176, 1996. Abstract.	J
103	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation Development", Biol. Reprod., 50(4): 725-733, 1994. Abstract.	U
104	Carlone et al. "Embryonic Modulaiton of Basic Fibroblast Growth Factor in the Rat Uterus", Biol. Reprod. 49(4): 653-665, 1993. Abstract.	V
105	Wordinger et al. "The Immunolocalzation of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation" Growth Factors, 11(3): 175-186, 1994. Abstract.	V
106	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxf. Rev. Reprod. Biol., 15:43-81, 1993. Abstract.	J
107	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998. Claims: P,X: 1-47, 51-58 / Y,P: 48-50.	·/
108	Esko et al. "Tumor Formation Dependent on Procoglycans Biosynthesis", Science, 241(4869): 1092-1096, 1988. Abstract.	J
109	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19): 13534-13540, 1990.	J
110	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", American Journal of Physiology 275:H23-H30, 1998.	V
111	Sasisekharan et al. "Heparinase Inhibits Neovascularization", Proc. Natl. Acad.Sci., 91:1524-1528, 1994.	V
112	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17):10079-10086, 1996.	V
113	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix", Cell Regulation, 1: 833-842, 1990.	ν
114	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of Cellular Physiology, 148: 274-280,1991.	V
115	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain from an Inhibitor to a Potent Activator of FGF-2", Nature Medicine, 4(6):691-697, 1998.	v
116	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer. 45: 1088-1095, 1990.	ν
117	Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes", J. Biol. Chem., 270(7):3268-3277, 1995.	V
118	Oldberg et al. "Characterization of a Platelet Endoglycosidase Degrading Heparin- Like Polysaccharides", Biochemistry 19: 5755-5762, 1980.	V
119	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.	V
120	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine β-Casein Gene", Mol Cells, 8(3):259-265,1998. Abstract.	V
121	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective", Arzneimittelforschung, 48(11):1111-1120, 1998. Abstract.	V
122	Guriec et al. "CD44 Isoforms with Exon v6 and Mestastasis of Primary N0M0 Breast Carcinaomas", Breast Cancer Res. Treat., 44(3):261-268, 1997. Abstract.	V
123	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132,	<b>V</b>

		1007 Abstract	
	105	1997. Abstract.	
	125	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain	
1		Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin.	~
		Invest., 97(1):162-171, 1996.	
'	126	Zheng et al. "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell	v
		Res, 7(1):21-29, 1997 (abstract)	
	127	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target	,
		RNA Levels", Cur.r Opin. Biotechnol., 9(5):486-496, 1998. Abstract.	$\checkmark$
	128	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on	
1 1		its Promise", Proc. Natl. Acad. Sci. USA, vol. 93: 3161-3163, April 1996.	V
	129	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the	
	127	Modulation of Gene Expression in Human Disease", Journal of American Cell	V
		Surgery, 191(1): 93-105, 2000.	
	130	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", Reviews: 376-387.	ν
<u> </u>			
]	131	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Elfficient Delivery of	✓
<u></u>		Antisense Molecules". Bioconjugate Chem., 8, 935-940, 1997.	,
	132	Luft " Making sense out of Antisense OligodeoxynucleotideDelivery: Getting there is	ν
		Half the Fun". J. Mol. Med, 75-76. 1998.	
	133	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human	
		Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the	V
		Hematopoietic Cell Subset". Blood, 91(3): 852-862, 1998.	
	134	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense	√
		Oligodeoxynucleotides". Molecular and Cellular Biochemistry, 172: 213-225, 1997.	\ \ \
	135	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides into the	
		Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research	$ _{\mathbf{v}}$
		Communications 231: 540-545, 1997.	<b>"</b>
}	136	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense	
	130	Oligonucleotides", Biochimica et Biophysica Acta 1520: 105-114, 2001.	V
	127		<del> </del>
	137	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to a	ν
		Structured RNA Target". Biotechnology and Bioengineering, 65(1): 1-9, 1999.	
	138	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression	
		Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research 61(21),	V
		7855-7860, 2001.	
	139	Clancy "Handbook of Microbiology", Vol.1: 239-242, 1974.	V .
	140	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving	V
		Biotechnology", Chapters 2-3, 1990. American Society for Microbiology.	*
	141	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes	
.		Inducible by Respiratory Mucus Derived from Cystic Fibrosis Patients", Mol.	'V.
		Microbiol. 22(5): 1005-1012, 1996. [Abstract]	
<b> </b>	142	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant	
	142	Cystic Fibrosis Transmemrane Conductance Regulator (CFTR)", Clin Exp. Immunol.	,
			V
<del></del>	142	106(2): 374-399, 1996. [Abstract]	
	143	Davies et al. "Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas	
]		Aeruginosa During Biofilm Development in Continuous Culture", Appl. Environ.	V
<u> </u>		Microbiol. 61(3): 860-867, 1995. [Abstract]	
1	144	Azghani et al. "A Beta-linked Mannan Inhibits Adherence of Pseudomonas	
1		Aeruginosa to Human Lung Epithelial Cells", Glycobiology 5(1): 39-44, 1995.	V
		[Abstract]	
	145	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman and Hall, New York,	,
1		1994, pp. 114-118, 148-153, 418-423, 420-423.	Ų.
	146	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of a	
1		Bacterial Biofilm", Science 280: 295-298, 1998.	V
	147	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill	
		Biofilms of Mucoid Pseudomonas Aeruginosa", Can. J. Microbiol. 43(11): 999-1004,	<b> </b> ,,
]		1997. [Abstract]	V
	148	Stickler et al. "An Assessment of the Ability of a Silver-Releasing Device to Prevent	<del> </del>
] !	140		l
		Bacterial Contamination of Urethral Catheter Drainage Systems", British J. Urology	V
	146	78: 579-588, 1996.	
	149	Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News 64(6):	l v
		321-322.	
	150	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular	V
<u> </u>		Lenses", J. Catatact Refract. Surg. 24: 124-129, 1998.	

	·	_
151	Pier "Rationale for Development of Immunotherapies that Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt. 98: 350-360, 1997. [Abstract]	<b>v</b>
152	Goldberg et al. "Biologic Activities of Antobodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun. 63(1): 21-26. [Abstract]	<b>&gt;</b>
153	Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in a Biofilm in vitro are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but not by Antibodies Produced During Chtonic Lung Infection in Cystic Fibrosis Patients", J. Immun. 155(4): 2029-2038, 1995. [Abstract]	>
154	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett. 130(1): 51-57, 1995. [Abstract]	N
155	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 154(4): S175-S182, 1996. [Abstract]	V
156	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl. Acad. Sci. USA, 94(22): 12088-12093, 1997.	<b>v</b>
157	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory Infection", Infect. Immun. 65(9): 3838-3846, Sep. 1997. [Abstract]	V .
158	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J. Bacteriol. 178(2): 511-523, 1996. [Abstract]	✓ .
159	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoid Pseudomonas Aeruginosa and Inflammation in a Mouse Model of Repeated Respiratory Challenge", Infection and Immunity 66(1): 280-288, 1998.	V .
160	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection with Pseudomonas Aeruginosa", J. Clin. Invest. 100(11): 2810-2815, 1997.	V
161	Mrsny et al. "Addition of a Bacterial Alginate Lyase to Purulent CF Sputum in vitro can Result in the Disruption of Alginate and Modification of Sputum Viscoelasticity", Pul. Pharmacol. 7(6): 357-366, 1994. [Abstract]	V
162	Wiils et al. "Short-Term Recombinant Human Dnase in Bronchiectasis. Effect on Clinical State and in vitro Sputum Transportability". [Abstract]	V
163	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediatr. Pulmonol. 22(6): 402-407, 1996. [Abstract]	V
164	Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Sputum: Implications to Pulminary Targeting Strategies", J. Drug. Therapy 4(4): 233-243, 1996.	V
165	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular polysaccharide of Mucoid Pseudomonas Aeruginosa", Antimicrob. Agents. Chemother. 42(4): 974-977, 1998. [Abstract]	V
166	Speert et al. "Modulation of Macrophage Function for Defense of the Lung against Pseudomonas Aeruginosa", Behring Inst. Mitt. 98: 274-282, 1997. [Abstract]	V
167	Ying et al. "Alginate, the slime Exopolysaccharide of Pseudomonas Aeruginosa, Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am. J. Cell. Moll. Biol. 15(2): 283-291, 1996. [Abstract]	V
. 168	Johansen et al. "Chronic Pseudomonas Aeruginosa Pneumonia: A new Prophylactic Principle", Behring Inst. Mitt. 90: 269-273, 1997. [Abstract]	V
169	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol. 35(2): 103-108, 1997. [Abstract]	~
170	Spencer "Invasive Streptococci", Eur. J. Clin. Microbiol. Infest. Dis., 14 Suppl. 1: S26-S32, 1995. [Abstract]	V
171	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol. 76(5): 424-430, 1994. [Abstract]	V

	172	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated with Rapidly Fatal Outcome in Taiwan", J. Formos Med. Assoc. 95(5): 364-371, 1996. [Abstract]	U
<del></del>	172	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to	
	173	Virulence in a Mucoid Strain of the Group A Streptococcus", Infect. Immun. 65(1): 64-71, 1997. [Abstract]	V
_	174	04-71, 1997. [Austraci]	
	174	Scott et al. "Visualization of an Extracellular Mucoid Layer of Treponema Denticola ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]	ν
	175	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression	
	175	in Septricemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997.  [Abstract]	V
	176	Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaluronic	
	170	Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 433-441, 1994. [Abstract]	$\sim$
	177	Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated	
	177	Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.	$\checkmark$
	178	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in	
	178	Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS Microbiol. Lett. 147(2): 195-202, Feb. 1997. Abstract.	V
	179	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the	
		Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 77(1-3): 35-44, Nov. 1992. Abstract.	<b>✓</b>
	180	Jorba et al. ["Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned	
	100	by Aminosugars"] (author's translation), Rev. Esp. Fisiol. 36(2): 155-161, 1980.  Abstract.	V
	181	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis	V
		in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]	
	182	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic Biliary	
	102	Epithelial Cells Bearing Defective (delta-f508) Cystic Fibrosis Transmembrane	,
		Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]	V
	183	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90)	
·	103	maintained in a Low Concentration of Serum)", Biochem J. 207(3): 369-379.  Abstract.	~
	184	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered	
		Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.	V
	185	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.	/
	186	Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.  Abstract.	V
	187	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.	V
	188	Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic.	
		Microbiol 34(1): 3-10, 1994. Abstract.  Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung	<u> </u>
	189		
		Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509,	<b>V</b>
		1988. Abstract.	
	190	Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England	V
		Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.	ļ
	191	Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas	v
	<del></del>	Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.	
	192	Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.	V
<del></del>	193.	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas	
	1 173.		1
		Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.	V
	104	Society Transactions 24: 406S, 1996.	V
	194		V

	<del></del>	Biotech. Adv. 12: 393-448, 1994.	ſ'
	196	Anatolii "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus	
	190	Anatoni "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus	
		Pathogenicity", Chem. Abstracts 86(17): 339, Abstr. 118714 citing Zh. Mikrobiol.	
		Epidemiol. Immunobiol. 2: 22-27, 1977.	
	197	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem.	
		& Molecular Biol., 13: 1-32, 1984.	
	198	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V.,	
		Inc., N.Y.: 1-33, 1984.	
	199	Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell	
	1	Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.	
	200	Li et al. "Immunochemical Localization of Heparanase in Mouse and Human	
		Melanomas", Int. J. Cancer 45: 1088-1095, 1990.	
	201	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma	
	1201	Cells, Mouse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int.,	
	1	39(3): 563-571, 1996.	
	- 202		
	202	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.	
	203	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and	
		Medicine", Annu. Rev. Biochem., 50: 657-680, 1981.	
•	204	Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in	
	1	Mouse Mammary Gland Development Suggests A Role in Hormone Action and	
		Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.	
	205	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human	
		Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6086, 1990.	
	206	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease",	
		J. Nat. Cancer Inst., 85: 1725-1732, 1993.	•
	207	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and	
	207	Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613,	
		1983.	
	200		
	208	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular	
		Heparanase", Molecular Biology/Biochemistry. Proceedings of the American	
		Association for Cancer Research, 37: 495, 1996.	
	209	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-	
		Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991.	
	210	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal	
	1	Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.	
	211	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on	
	1	STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10.	
	212	Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse GenBank on	
	7.2	STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10.	
	213	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	··
	213		
<del> </del>		Interscience, New York: 2.1.1-2.1.2, 1991.	
	214	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic	
		Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.	
	215	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro	
•	- 1	Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology,	
		22: 161-166, 1996.	
	216	Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92	
	. [	(Suppl.64): 6A-44S - 6A-52S, 1992.	
	217	Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4.	
	1	1970.	
	218	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-	
	1 -: "	3074, 1980. Abstract.	
	219	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate	
	219		
	1	Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway	
	-	Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.	
	220	Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial	
		Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989.	
		Abstract.	
	221	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways	
		Disease", Acta Paediatr. Scand. Suppl., 363: 25-29, 1989.	
	222	Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower	
	1	Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997. Abstract.	

	1		
	223	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	
		the Disease", Clinica Chimica Acta, 132: 143-155, 1983.	
	224	Allen "Opportunities for the Use Aerosolized at - Antitrypsin for the Treatment of	
	:	Cystic Fibrosis", Chest, 110: 256S-260S, 1996.	
	225	Schwab et al. "Increased Adherence of Staphylococcus Aures From Cystic Fibrosis	
	,	Lungs to Airway Epithelial Cells", Am. Rev. Respir., 148(2): 365-369, 1993.	
		Abstract.	
	226	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires	
		Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-	
	1	3428, 1995. Abstract.	
	227	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in	
		Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice",	
		APMIS, 105(11): 838-842, 1997. Abstract.	
	228	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected	
		With Pseudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 1997. Abstract.	
	229	Zahm et al. "Early Alterations in Airway Mucociliary Clearance and Inflamation of	
1	1	the Lamina Propria in CF mice", Am. J. Physiol. 272(3 Pt 1): C853-C859, 1997.	
		[Abstract]	
	230	Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast	
		Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.	
	231	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-	
		Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997.	
	1	Abstract.	
	232	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	
	·	Lipoprotein Lipase to Cultured Bovine Endothelial Cells", J. Clinical Invest., 68(4):	
		995-1002, 1981. Abstract.	
	233	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in	
		Feline Myocardial Ischemia-Reperfusion Injury", J. Pharm. Exp. Ther., 283(3): 1032-	
	ļ	1038, 1997. Abstract.	
	234	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattactant	
		Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-	
		560, 1997. Abstract.	
	235	Matgolies et al. "Identification of A Major Heparin-Precitable Protein in Human	
·		Serum and Its Relationship to Cystic Fibrosis", Pediatr. Res., 16(3): 181-186, 1982.	
		Abstract.	
	236	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of	
	100	Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun.,	
		66(3): 994-999, 1998. Abstract.	
	237	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J.	
		Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.	
	238	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV)	<u> </u>
		to Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
	239	Alvarez-Dominguez et al. "Host Cell Heparian Sulfate Proteoglycans Mediate	
		Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein	
	ĺ	ActA Is Involved in Heparan Sulfate Receptor Recognition", Infection & Immun.,	
]		65(1): 78-88, 1997. Abstract.	
	240	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by	
1		Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract.	
	241	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the	
		Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate	
		Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	•
	242	Inaba et al. "Effect of Heparinon Infection of Cells by Porcine Reproductive and	
		Respiratory Syndrome Virus", Am. J. Vet. Res, 58(5): 488-491, 1997. Abstract.	
	243	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target	
	ر. ـ	Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997. Abstract.	
	244	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite	
	2.77	Protein and Thrombospondin Is Mediated by Its Glycosminoglycan-Binding Region	
		and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	
	245	Robert et al. "Chondroitin-4-Sulphate (Proeoglycan), A Receptor for Plasmodium	
	273	Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial	
		Cells", Res. Immunol., 146(6): 383-393, 1995. Abstract.	
L	L	Com , 100. minumon, 140(0). 202-223, 1273. Austract.	

_			
1	246	Hеггега et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate	
•	į	Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes",	
· —		Mol. & Biochem. Parasit., 65: 73-83, 1994.	
	247	Berkow "The Merck Manual". R. Berkow, M.D., Ed-in-Chief, Merck Research	i
. —	040	Laboratories: 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.	
,	248	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of	1
		Therapies", Pediatr. Pulmonol. 28(4): 248-54, Oct. 1999. [Abstract]	
	249	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas	
		Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary	
-	250	Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	
	230	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in	
		Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol. 28(3): 159-166, Sep. 1999. [Abstract]	1
-	251	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Patients with	
	231	Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England	
		Journal of Medicine 340(1): 23-30, Jan. 7, 1999. [Abstract]	
·	252	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to	
	232	Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", Infect. Immun.	1
		64(1): 37-43, 1996. Abstract.	
	253	Bennett et al. "Effect of Uridine 5'-Triphosphate plus Amiloride on Mucociliary	
		Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 153(6 Pt.1):	ı
		1796-1801, June 1996. [Abstract]	
	254	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children with	
		Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 156(4 Pt.1): 1197-1204, 1997.	
1	ļ	Abstract.	ļ.
	255	Naparstek et al. "Activated T Lymphocytes Produce a Matrix-Degrading Heparan	
		Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984. Abstract.	
	256	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review	
		of New and Potential Interventions", Pediatric Pulmonology 24: 143-146, 1997.	İ
	257	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest 115: 1120-	
		1126, 1999.	
	258	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance",	
		Science 289: 1501-1504, 2000.	
	259	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and	
		Regeneration", Nature Biotechnology 16: 247-252, 1998.	
	260	Elkin et al. "Heparanase as Mediator of Angiogenesis,: Mode of Action", The	
		FASEB Journal 15: 1661-1663, 2001.	
	261	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	
<u> </u>		Journal, Published online, May 29, 2001.	
	262	Finkel "Potential Target Found for Antimetastasis Drugs", Science 285: 33-34, July	ļ
		2, 1999.	
- 1	263	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of a Good Thing",	}
<u> </u>		TIG 13(5): 178-182, May 1997.	
	264	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During	
	365	Endochondral Ossification", Exp. Cell. Res. 229(1): 126-136, 1996. Abstract.	<u></u>
İ	265	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as	-
İ		Osseous Cicatrizing Agents", Ann. Endocrinol. (Paris) 55(2): 121-123, 1994.	1
	266	[Abstract]  Planamort et al. "Hoperon Like Melecules Indus The Parair Of Shall Defeated."	
.	200	Blanquaert et al. "Heparan-Like Molecules Induce The Repair Of Skull Defects", Bone, 17(6): 499-506, 1995. Abstract.	1
-	267		
	207	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on	1
	268	Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract]	
	200	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302,	1
1		1996. [Abstract]	
	269	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	
	209	Associated Henrin-Rinding Growth Associated Malanula (ID) CAMUL Coll	
		Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]	.
1	270		
	-   2/0	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res.	
	1	TO THE PROPERTY OF THE PROPERT	

272	Service "Tissue Engineers Build New Bone", Science 289: 1498-1500, 2000.	
273	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase",	
	Advan. Enzyme Regul. 37: 135-144, 1997. Introduction.	
274	Bost et al. "Antibodies Against a Peptide Sequence within the HIV Envelope Protein	
 _	Crossreacts with Human Interleukin-2", Immunol. Invest. 17: 577-586, 1988.	
275	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	
1	of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J.	
 - 000	Histochem. Cytochem. 43: 881-886, 1995.	
276	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
ł	Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2):	
 077	551-557, 1987.	
277	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene	
	Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	
 278	Ross "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", Nature,	
278	362: 801-809, 1993.	
 270	Putnak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine,	
279	3(8): 828-829, 1997.	
 280	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate	
260	Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281, 1992.	
 281	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed from	
201	the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA,	
	92: 5037-5041, 1995.	
 282	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	
	Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation",	
	Cell, 79: 1015-1024, 1994.	
 283	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor:	
700	Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl.	
	Acad. Sci. USA, 84: 2292-2296, 1987.	
284	Vlodavsky et al. "Involvement of the ExtraCellular Matrix, Heparin Sulfate	
	Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and	
İ	Metastis", Tumor Angeogenesis, P.125-140, 1997.	
 285	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	
	Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry,	
	28: 1737-1743, 1989.	
 286	Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion,	
	Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met.	
	Rev., 7: 143-188, 1988.	
287	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996.	
 	Claims: 9, 10.	
288	Adams et al. "Initial Assesment of Human Gene Diversity and Expression Patterns	
	Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174,	
 	1995. GenBank Entry AA304653, 1997. Claims: 30.	
289	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share in vitro Invasive	
 	Properties of Malignant Cells", J. Cellular Physiology 136: 455-462, 1988.	
290	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta	
 201	24: 424-430, 2003.  Dempsey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular	
291	Damage", Glycobiology 10(5): 467-475, 2000. Abstract. P. 470, Col. 1 - P. 471,	
	Col. 1; P. 472, Col. 1, § 4 - Col. 2, § 2. Claims: 1-24.	
 292	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	
292	Human Placenta", Molecular Human Reproduction 8(6): 566-573, 2002.	
 293	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During	
2,33	Gestation", Reproduction 121: 573-580, 2001. Claims: 1-50.	
 294	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
274	Biochem. Journal 200: 1-10, 1981.	
 295	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary	
293	Hemochromatosis", PNAS 95(5): 2492-2497, 1998.	
 296	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive	
290	BioMedicine Online 2002 4(2): 170-175, 2002. Abstract.	
	Dioriediene Onnie 2002 4(2). 170-173, 2002. Austract.	
 297	Bean et al. "Fertilization in vitro Increases Non-Disjunction During Early Cleavage	

i

٠.				
_				<u></u> -
		298	Abstract.  Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires	
.		298	Effective Recipient Preparation, Biology of Reproduction 69: 412-420, 2003.	
			Abstract.	
ŀ	<del></del>	299	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes from Cryopreserved	
.		-,,	Primordial Mouse Follicles after Sequential In Vivo Transplantation and In Vitro	
1			Maturation", Biology of Reproduction 64: 171-178, 2001. Abstract.	
t		300	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-	
1			Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse	•
j			Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell	
L			Stage", Biology of Reproduction 66: 3810385, 2002. Abstract.	
		301	Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane	
			Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies,	
1		•	and the Development of Improved Cryopreservation Methods", Biology of	
			Reproduction 63: 1294-1302, 2000. Abstract.	
		302	Yesildaglar et al. "The Mouse as a Model to Study Adhesion Formation Following	
]			Endoscopic Surgery: A Preliminary Report", Human Reproduction 14(1): 55-59,	
ŀ		303	1999. Abstract.  Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to	
		303	Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of	
- 1		ļ	Reproduction 62: 178-185, 2000. Abstract.	
ŀ		304	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the	
		•••	Neonatal Mouse Model", Biology of Reproduction 38: 935-943, 1988. Abstract.	
f		305	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters	
1			the Ovary and Oviduct", Biology of Reproduction 28: 735-744, 1983. Abstract.	
		306	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-	
- 1		<b> </b>	2, Summer 2002.	
Ī		307	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA",	
- 1		1	Proceedings American Association for Cancer Research Annual Meeting 1992, 33:	
1			57, 1992. Abstract 343. Claims: X: 1-10, 15-18. / Y: 11-14.	
. ]		308	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical	
1			DNA by Oligonucleotides", Angew.Chem. Int. Ed. Engl. 32: 666-690, 1993.	
		309	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992.	
}		310	Abstract.  Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL	
	•	310	Antisense Oligodeoxynucleotides", Science 253: 562-565, 1991. Abstract.	
ŀ		311	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential	
		317	Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An in	
.		}	vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA 88:	
			2351-2355, 1991.	
t		312	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRN	
- 1			Block the Effects of Interleukin I in Cultured Murine and Human Fibroblasts and in	
			Mice", J. Clin. Invest. 88: 1190, 1991. Abstract.	
		313	Agrawal "Antisense Oligonucleotides As Antiviral Agents", Trends Biotechnol.,	
- 1			10(5): 152-158, 1992. Abstract.	_
- 1		314	Ngo et al. "The Protein Folding Problem and Tertiary Structure", K.Merz, Jr. and	
L			S.Le Grand, Ed Birkhauser Boston: 491-495, 1994.	
		315	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of	
ŀ		İ	Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia",	
}		216	Nature Medicine, 6(5): 568-572, 2000.	
		316	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling is Defined by	
		1	Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF", Development 125: 1591-1598, 1998.	
. }	- ·	317	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1	
- 1		31/	(Bone Morphogenetic Protein 7)", Proc. Natl. Acad, Scie., 93: 9021-9026, 1996.	
ł		318	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49:	
-			437-438, 1987.	
ŀ		319	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human	
			Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption	
- 1		1	and Formation in Organ Culture", Bone, 14: 717-720,1993.	
1				

.

		2000.	
	321	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Res., 10: 398-400, 2000.	
	322	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends in Genetics, 14(6): 248-250, 1998.	
	323	Smith et al. "The Challenges of Genome Sequence Annotation or "The Devil is in the Details", Nature Biotechn., 15: 1222-1223, 1997.	
	324	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.	
	325	Bork "Go Hunting in Sequence Databases but Watch out for the Traps", Trends in Genetics, 12(10): 425-427, 1996.	
1	326	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, 247: 1306-1310, 1990.	-
	327	??? A Genesq, Accession No. AA17083, 1999.	
<del></del>	328	Bendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Grafting", Methods, 8: 83-93, 1995.	
	329	Miao et al. "Cloning, Expression and Purification of Mouse Hearanase", Protein Expression and Purification, 26: 425-431, 2002.	
	330	Coligan et al. "Current Protocols in Immunology", Green Publishing Assoc. 1991.	
	331		
		Sasisekharan et al. "Cloning and Expression of Heparinase I Gene from Flavobacterium Heparinum", Proc. Natl. Acad. Sci., 90: 3660-3664, 1993.	
	332	Gordon-Cardo et al. "Expression of Basic Fibroplast Growth Factor in Normal	
		Human Tissues", Laboratory Investigation, 63: 832-840, 1990.	
	333	Harper "Harper's Biochemistry", 24th Ed., P. 660-685.	
	334	Boat et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-72, 1989. Abstract.	
	335	Nossuli et al. "Heparinas III Exerts Endothelial And Cardioprotective Effects In	
		Feline Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical Experimental Therapy, 283(3): 1032-1038, 1997. Abstract.	
	336	Nakajima et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.	
	337	Wands Federal Circular, 1988,	
	338	Fisher CCPA, 1970.	
	339	Carson et al. Mucin And Proteoglucan Functions In Embryo Implantation <sup>n</sup> , BioEssays, 20(7): 577-583, Abstract. P. 580, Col. 2, § 2; P. 582, Col. 1, Fig. 1. Claims: 1-24.	
	340	Clonotech Laboratories "RT-PCR Methods and Applications Book 1", Clonotech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.	
	241		
	1 141	Novagen "PET System Manual" Novagen 6th Ed. P.11 1995	
	341	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.  Engis et al. PNAS USA 87: 2833-2837, 1990.	
-	341 342 343	Ennis et al. PNAS USA, 87: 2833-2837, 1990. Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An	
-	342 343	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.	
	342	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.	
	342 343	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.	
	342 343 344	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. &	
	342 343 344 345	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia	
	342 343 344 345 346	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.	
	342 343 344 345 346 347	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.  Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.  Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing	
	342 343 344 345 346 347 348	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.  Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.  Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.  Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged	
	342 343 344 345 346 347 348 349 350	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.  Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.  Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.  Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.	
	342 343 344 345 346 347 348 349	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.  Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.  Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.  Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.  Sambrook et al. "Molecular Cloning", CSH Laboratory Press, 1989.  Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression",	
	342 343 343 344 345 346 347 348 349 350 351	Ennis et al. PNAS USA, 87: 2833-2837, 1990.  Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", J. Exp. Med., 181: 1929-1934, 1995.  Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.  Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.  Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.  Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.  Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.  Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.  Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.  Sambrook et al. "Molecular Cloning", CSH Laboratory Press, 1989.	

	1989.	
356		
357	867-869, 1991.	
358	Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Basic Membranes: Cellular and Molecular Aspects, P. 327-343, 1993.	
359		
360		
361		
362		
363		
364		
365	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.	
366	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.	
367		
368	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", FEBS Letters, 117(1): 203-206, 1980.	
369	Sudhalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem., 254(12): 6892-6897, 1989.	
371	Inoue et al. "Selective N-Desulfation of Heparin with Dimethyl Sulfoxide containing Water or Methanol", Carbohydrate Research, 46:67-95, 1976.	
372		
373	Matia Bar-New et al. Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.	
374	by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.	
375	Derived Factors", Blood, 78: 789-796, 1991.	
376	Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis Rev., 9: 203-226, 1990.	
377	Compounds", J. Bioactive and Compatible Polymers, 8:317-337, 1993.	
378	Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds", Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
379		
380	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparain-Mimicking Polyaromatic Compound", J. Clin. Invet., 99(7): 1565-1575, 1997.	
381	Benezra et al. "Reversal of Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, 52:5656-5662,	

		1992.	
	382	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate	
		Specific Endo-β-glucuronidase (Heparanase) of Metastatic melanoma Cells",	
_		Biochemistry, 25:5322-5328, 1986.	
	383	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated	
		Polysaccharides", Int. J. Cancer, 39: 82-88, 1987	
	384	Ornitz et al. "Heparin is Required for Cell-Free Binding of Basic Fibroblast Growth	
		Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	
		Cellular Biology, 12:240-247, 1992.	
	. 385	Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required For Binding of	
		Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64: 841-848,	
		1991.	
	386	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate	
	1	Proteoglycans that Promote Binding of Basic Fibroblast Growth Factor to its	
		Receptor:, J. Bio. Chem., 269(1):114-121, 1994.	
	387	Bartlett et al. " Comparative Analysis of the Ability of Leucocytes, Endothelial Cells,	
	ļ	and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for	
	- 1	Cytokine Dependence and Detection of a Novel Sulfatase", Immunology and Cell	
		Biol., 73: 113-124, 1995.	
	388	Nakajima et al. " A Solid-Phase Substrate of Heparanase: Its Application to Assay of	
		Human Melanoma for Heparan Sulfate Degradative Activity", Analytical	
		Biochemistry, 157: 162-171, 1986.	
	389	Oosta et al. "Purification and Properties of Human Platalets Heparitinase", J. Biol.	
		Chem., 257(19): 11249-11255, 1982.	
	390	Sewell et al. "Human Mononuclear Cells Contain an Endoglycosidase Specific for	
		Heparan Sulfate Glycosaminoglycan Demonstrable with the Use of a Specific Solid-	
		Phase Metabolically Radiolabelled Substrate", Biochem J., 264: 777-783, 1989	
	391	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian	
		Heparanase Activity", Biochem J., 325: 229-237, 1997.	
	392	Mullings et al. "New Reducing Sugar Assay for the Study of Cellulases", Enzyme	
		Microb. Technol., 6:491-496, 1984.	
	393	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and a	
		Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.	
	394	Linhardt "Capillary Electrophoresis of Oligosaccharides", Methods in Enzymology,	
		230:265-280, 1994.	· · · · · · · · · · · · · · · · · · ·
	395	Basu et al. " Analysis of Glycospingolipids by Fluorophore-Assisted Carbohydrate	
		Electrophoresis Using Ceramide Glycanase from Mercenaria mercenaria", Analytical	
		Biochemistry, 222:270-274, 1994.	
	396	Jackson "The Use of Polyacrylamide-gel Electrophoresis for the High-Resolution of	
		Seperation of Reducing Saccharides Labelled with the Fluorophore 8-	
		aminonaphtalene-1,3,6-trisulphonic Acid", Biochem J., 270: 705-713, 1990.	
	397	Coquet et al. "Applications of a Post-Column Fluorigenic Reaction in Liquid	
		Chromotagraphy for the Determination of Glucose and Fructose in Biological	
		Matrices", Analytica Chemia Acta, 252: 173-179, 1991.	
	398	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell-	
		Specific Agt11 Library Using Antibodies Directed Against A Putative Heparanase	
		Amino-Terminal Peptide", Int. J. Cancer, 56:286-294, 1994. Claims: 1, 3, 5-7, 15-17.	
	399	Zsolnai et al. "Directional Immobilization of Heparin onto Nonporous Surface of	
		Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	400	Bellott et al. "Closing the Loop in Combinatorial Chemistry", European	
		Pharmaceutical Contracotr, 1997.	
	401	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by	
		Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.	
	402	Yen et al. "Potentialities of a new Class of Anticlotting and Antihemorrhagic	
	1	Polymers", J. Macromol. Sci., Chem., 4(3), pp. 693-714 in Chem. Abst. AN, 1970	
		418456	
	403	Mes et al. "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of	
		Sugars and Sugar Derivatives Reported in Glycoproteins", J. Chromatogr.,	
		43(\$),pages 480-486, 1969.	
	404	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and	
É		Differentiation of Sugars and Sugar Derivatives in Glycoproteins", J. Chromatrogr.,	

.

.

*)* 

405	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
	Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell. 19: 607-616, 1980.	
406	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", Annu. Rev. Biochem., 58:.575-606, 1989.	
407	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.	
408	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix", J. Clin. Invest., 90: 2013-2021,	
409	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - Is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393-400,	
410	Folkman et al. "Angiogenic Factors", Science, 235: 442-447, 1987.	
412	Matzner et al. "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils", J. Clin. Invest. 76(4): 1306-1313, Oct. 1985.	
413	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem. J., 327: 917-923, 1997.	
414	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.	
415	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin- Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.	
416	Rapraeger et al. "Requirement of Heparan Sulfate For bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252: 1705-1709, 1991.	
417	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J. Biol. Chem., 268(14): 10160-10167, 1993.	
418	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998.	
419	Schoepe et al. "Neutralization of Hemolytic and Mouse Lethal Activities of C. Perfringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by	
420	Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997.  Chiba et al. "Generation of Neutralizing Antibody to the Reserve Transcriptase of Human Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious	
421	Vaccinia Virus Recombinant", J. Immunological Methods, 207:53-60, 1997.  Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and	
421	Number:, Genetic Engineering News: 23-49, 1998.	
422	Sherman-Gold "Monoclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997.	
423	Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997.	
424	Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 95: 8910-8915, 1998.	
425	Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Epidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997.	•
426	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980	·
427	Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 157-167, 1988.	
428	Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495.	
429	Colman "Effects of amino Acid Sequence Changes on Antibody-antigen Interactions", in Research in Immunology, 1994; 145(1): 33-36.	·
430	Abaza et al. "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of	

· ·

-

.

	<del></del>	Myoglobin", in Journal of Protein Chemistry, 11(5): 433-444, 1992.	-
<del></del>	421	Lederman et al. "A Single amino Acid Substitution in a common African allele of the	
	431	CD4 Molecule Ablates Binding of the Monoclonal antibody, OKT4", Molecular	
		Immunology 28: 1171-1181, 1991)	ĺ
	432	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from	
	432	other Biological Activities", PNAS 77: 3211-3214, 1980)	
	422	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion:	
	433	Selected Enhancement of Heparanase Activity and Heparanase Degradation of	
	Ì	Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996.	
		also in: Advances in Enzyme Regulation, 37: 111-134, 1997.	
		Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", J.	
	434	Rosir et al. Human Prostate Calcinolia Cens Froduce Extracentum Treparamase, 3.	
	125	Surg. Res., 67: 98-105, 1997.  Koehler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined	
	435		
	420	Specificity", Nature 256: 495-497, 1975.  Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene",	
	438	Biochemical and Biophysical Research Communication 261(1): 183-187, 1999.	
		Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrotrophin	
	439	Walch et al. "Correlation of Overexpression of the Low-Attituty p/3 reduction in Human Malignant	
		Receptor with Augmented Invasion and Heparanase Production in Human Malignant	
		Melanoma Cells", Int. J. Cancer 82: 112-120, 1999.	
	440	Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar	
		Enzymes", Biochem J. 342: 361-368, 1999.	
	441	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in	
		Biochemistry and Molecular Biology, 30(5): 387-444, 1995.	
	442	Zhou et al. "A 182 bp Fragment of the Mouse proal(11) Collagen Gene is Sufficient	
		to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-	
		3684, 1995.	
	443	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First	
		Intron in Expression of the al (I) Collagen Gene.", Mol Cell Biol., 18(6): 3368-	
		3375,1998. Abstract.	
	444	Chow et al. "Development of an Epithelium-Specific Expression Cassette with	
	-	Human DNA Regulatory Elements for Transgene Expression in Lung Airways",	
		Proc. Natl. Acad. Sci., 94:14695-14700, 1997.	
	445	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine",	
		Molecular Medicine Today: 431-437, 1998.	
	446	Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol,	
		7(1):11-14, 1999. Abstract.	
	447	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms	
		in Rat Tissues", Biochimica et Biophysica Acta, 1172: 37-42, 1993.	
	448	Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase	
		in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. natl. Acad. Sci.,	
		94: 5332-5337, 1997.	
	449	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects",	
		Blood 92(3): 712-736, 1998.	
	450	Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular	
		and Cellular Biochemistry, 181: 163-179, 1998.	
	451	Carpentier et al. "DNA Vaccinaiton with HuD Inhibits Growth of a Neuroblastoma in	
		Mice", Clinical Cancer Research, 4: 2819-2824. 1998.	
	452	Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 449-484, 1998.	
	453	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene",	
		Journal of Biological Chemistry 270(10): 5276-5281, 1995.	
	454	Shekhar et al. "Correlation of Differences in Modulation of ras Expression with	
İ		Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion	
		Metastasis, 14: 27-37, 1994/5.	
<del></del>			

ł			
	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).

'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount

1 TO/SB/08a (08-03)

Approved for use throu :h 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DI PARTMENT OF COMMI

conter the P	aperwork	Reduction Act of 1995, In A IR		to respond to a c	onection of anothernoo unies.		te if Kn	
		Substitute for form 1449A/	P10		Application Num		10/722	
i	INFO	RMATION DISC	LOSU	RE	Filing Date			122, 2003
		TEMENT BY API			First Named Inve	ntor		BY-ZEEVI Oron et a
1	SIAI	IEMIENI DI AFI	LICA	N 1	Art Unit		1644	
	(ı	ise as many sheets as neo	essary)		Examiner Name			
Sheet	T	1	of	11	Attorney Docket	Vumber	26872	
-			U.S	S. PATENT	DOCUMENTS			
Examiner Initials*	Cite No.	Document Number		ration Date DD-YYYY	Name of Pate Applicant of Cited			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	Number-Kind Code <sup>2 of known</sup>				•		
	1	US-5,362,641	08-8-19		Fuks et			<del></del>
	2	US-5,399,351	01-1-19		Leshchine			
	3	US-5,550,116	01-1-19		Lormeau			
	4	US-5,667,501	01-1-19		Fowler of			
	5 US-5,739,115 01-1-1998		Fugedi e					
6 US-6,177,545 01-13-2001		Pecker et al.						
	7 US-6,348,344 02-19-2002		Ayal-Hershko		_			
	8	US-4,946,778	08-8-19		99 Zimmermann et al.			
	9	US-5,997,863	07-7-19					
	10	US-6,242,238	05-5-20		Freeman			
	11	US-5,688,679	11-18-1		Powe			
	12	US-6,387,643	05-14-2		Heinriksor			
	13	US-6,423,312	07-23-2		Yacoby-2			
	14	US-6,531,129	01-1-20		Pecker e			
	15	US-4,455,296	06-19-1		Hansen e			
	16	US-5,571,506	01-1-19		Regan e			
	17_	US-5,917,830	06-29-1		Chen et			· <del></del>
	18	US-5,859,660	01-12-1		Perkins e			
	19	US-5,600,366	04-4-19	997	Schulm	an		
	20	US-6,020,931	01-1-20	000	Bilbrey e	t al.		
	21	US-5,968,822	10-19-1	999	Pecker e	t al.		
	22	US-6.153.187	11-28-2	2000	Yacoby-Z	Zeevi		
	23	US-6,664,105	12-16-2	2003	Pecker e	t al.		
	24	US-5.145,679	08-8-19	992	Hinso	n		
	25	US-5.736,137	07-7-19	98	Anderson	et al.		
	26	US-5.194,596	03-16-1		Tischer o	t al.		
	27	US-5,350,836	09-27-1	994	Kopchick	et al.		
	28	US-6.562,950	05-13-2	2003	Peretz e	t al.		
	29	US-6,699.672	02-2-20		Pecker e	t al.		
	30	US-5.580.862	03-3-19	996	Rosen e	al.		
	31	US-5.474,983	12-12-1		Kuna et			
	32	US-2002/0102560	01-1-20		Pecker e	t al.		
	33	US-4.859.581	01-1-19		Nicholson			
	34	US-4,882.318	01-1-19		Vlodavsky			
	35	US-5,129,877	01-1-19		Gallo et			
	36	US-5,206,223	04-27-1		Vlodavsky			
	37	US-5,332.812	07-26-		Nicolson			
	<del>!</del>	<del>                                     </del>	<del>                                     </del>		<del> </del>		t	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if r of in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (VIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pate it document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check r tark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pt blic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO "HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the P	abernor	k Reduction	Act of 1995, no persons are required to resp	pond to a coll	lection of inf	ormation unless it contains a	valid OME	control number.		
		Sut	ostitute for form 1449A/PTO				ete if Kn			=
						ation Number	10/72:	<u> </u>		
	INF	ORMA	ATION DISCLOSURE	,	Filing I			t 22, 2003		]
	STA	TEMI	ENT BY APPLICANT			amed Inventor	YAC	BY-ZEEV	Oron et a	ıl
					Art Un	it	1644			
	(	(use as n	nany sheets as necessary)		Examir	ier Name				
Shect		2	of 1	l	Attorne	y Docket Number	26872			
			FOREIGN	PATEN						
Examiner Initials*	Cite No.		Foreign Patent Documents		ion Date	Name of Patentee of		Pages, Colu		Т
		Country	y Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (#known)	MM-DE	D-YYYY	Applicant of Cited Duc	ument	Where Releva or Relevant Fig.		"
	38	PCT	WO 99/57244	11-11-1	999	Ben-Artzi et al.				$\top$
	39		WO 99/57153	11-11-1	999	Pecker et al.		<u> </u>		
	40		WO 99/11798	03-11-1		Pecker et al.				7-1
	41		WO 88/01280	01-1-19	988	Nicolson et al.				$\Box$
	42		WO 95/04158	09-9-19		Hoogewerf et al.				
	43		WO 99/21975	06-6-19		Freeman et al.				
	44		WO 91/19197	12-12-1		Nicolson et al.				
	45		WO 95/04518	02-16-1		Midha et al.				
	46		WO 03/006645 A2	01-23-2		Bohlen et al.				
	47		WO 97/11684	04-4-19		Bennett et al.				
	48		WO 91/02977	07-7-19		Fuks et al.				<u>i                                     </u>
	49		WO 97/27327	07-31-1		Van Ness et al.				$oxed{oxed}$
	50		WO OO/52149	08-8-20		Yacobi-Zeevi	<b></b>			<u>                                     </u>
	51	PCT	WO 00/52178	08-8-20	900	Pecker et al.				<u></u>
	L		CTUE DRICE ARE		A (EFEN IS)	LITED AUTOE DO				┸┚
		Cita	OTHER PRIOR ART Include name of the author (in CA)							
Examine Initials	er	No. 1 item (book, magazine, journal, se		rial symposium, catalog, etc.) date, page(s), volume-issue sher, city and/or country where published.		me-issue i	umber(s).	$T^2$		
		52	"Mouse Models for Reprodu-				g/jaxmi	e : 1-2,		
			Summer 2002.							
		53	Abaza et al. "Effects of Amin							
			Protein Binding to Monoclon							
			Peptide Immunization: Demo					.·) ol		
		<u> </u>	Myoglobin", in Journal of Pro	otein Che	mistry, i	1(5): 433-444, 1992.				
	54		Adams et al. "Initial Assessment of Human Gene Diversity and Expression Fatterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174,							
			1995. GenBank Entry AA304			sequence, Nature, 3	11(034)	7): 3-174,		
		55	Agrawal "Antisense Oligonuc			ral Agents", Trends	Biotech	nol.,		
			10(5): 152-158, 1992. Abstrac	ct.				-		
		56	Agrawal "Antisense Oligonuc	leotides:					· ···.	
		57	Albus et al. "Staphylococcus							
			Infection in Patients with Cys							
			1988. Abstract.							
		58	Allison et al. "Polysaccharide	Producti	on in Pso	udomonas Cepacia"	, J. Basi	· :.		

Date

Considered

Microbiol 34(1): 3-10, 1994. Abstract.

Examiner

Signature

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak ± 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual ca: e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO HIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: thitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\(\begin{align\*} \text{/IPO Standard ST.3}\). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERC 3 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Onder the PaperWi		in Act of 1995, no persons are required to respond to a co		ns a valid QMB control number. Implete if K. wwn				
	Su	ubstitute for form 1449A/PTO	Application Number 10/7: 2,502					
INI	FORM	ATION DISCLOSURE	Filing Date	Augu st 22, 2003				
			First Named Inventor	YAC DBY-ZEEVI Oron et al				
31.	AIEW	ENT BY APPLICANT	Art Unit	1644				
	(use as	many sheets as necessary)	Examiner Name					
Chast	<del></del>			1262				
Sheet	599	of 11	Attorney Docket Number					
	399	Anatolii "Hyaluronic Capsule as one						
		Pathogenicity", Chem. Abstracts 86( Epidemiol. Immunobiol. 2: 22-27, 19		ig Zn. Mik obiol.				
···	60	Armstrong et al. "Lower Airway Infl		ung Children with				
	00	Cystic Fibrosis". Am. J. Respir. Crit.						
		Abstract.	Care (vica. 130(4) 1.1). 119	7-1204, 1997.				
	61	Bean et al. "Fertilization in vitro Incr	eases Non-Disjunction Duri	ng Farly C eavage				
	"	Divisions in a Mouse Model System'						
	1	Abstract.	;	7, 2502 2507, 2002.				
	62	Bendayan "Possibilities of False Imn	nunocytochemical Results G	enerated b / the Use				
		of Monoclonal Antibodies: The Exam						
		Histochem. Cytochem. 43: 881-886,	Histochem. Cytochem. 43: 881-886, 1995.					
	63	Bendig et al. "Humanization of Rode	nt Monoclonal Antibodies b	y CDR Gr ifting",				
		Methods, 8: 83-93, 1995.						
	64	Benezra et al. "Thrombin Enhances t						
		Extracellular Matrix by Tumor Cell I	Heparanase." Exptl. Cell. Re	s. (1992) vol.				
		201:208-215						
	65	Benjamin et al. "A Plasticity Window						
		Pericyte Coverage of the Preformed		Regulated by PDGF-				
	1	B and VEGF", Development 125: 15						
	66	Bennett et al. "Effect of Uridine 5'-Ti						
		Clearance in Adult Cystic Fibrosis",	Am. J. Respir. Crit. Care Me	ed. 153(6 F :.1):				
	67	1796-1801, June 1996. [Abstract] Berkow "The Merck Manual". R. Be	skow M.D. Ed in Chief M	arak Danas rah				
	07	Laboratories: 201, 204, 1308, 177-17						
	68	Beuth et al. "Lectin-Mediated Bacter						
	00	Microbiol. 6(5): 591-593, 1987. Abst		uc . Eur. J Cim.				
	69	Bhaskar et al. "Dysregulation of Prot		abentic Bil arv				
	"	Epithelial Cells Bearing Defective (d						
		Conductance Regulator", Hepatology						
	70	Blanquaert et al. "CMDBS, Function						
		Osseous Cicatrizing Agents", Ann. E						
	<u> </u>	[Abstract]						
	71	Blanquaert et al. "Heparan-Like Mole	ecules Induce The Repair Of	Skull Def :cts",				
		Bone, 17(6): 499-506, 1995. Abstrac						
	72	Bork "Go Hunting in Sequence Datal	bases but Watch out for the	Traps", Treads in				
		Genetics, 12(10): 425-427, 1996.						
	73	Bork "Powers and Pitfalls in Sequence: 398-400, 2000.	ce Analysis: The 70% Hurdle	e", Genom: Res., 10				
	74	Bost et al. "Antibodies Against a Pep	tide Sequence within the HI	V Envelop : Protein				
		Crossreacts with Human Interleukin-						
	75	Bowie et al. "Deciphering the Messa						
		Acid Substitutions", Science, 247: 13						
Examiner			Date					
Signature	1	e considered, whether or not citation is in conforma		idered				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n t in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (\(\lambda\) / IPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak: 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO: HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERCE in a finite partial contains a salid (AMB control purple).

		on Act of 1995, no persons are required to respond to a coll ubstitute for form 1449A/PTO	Comp	lete if K. ww	n
			Application Number	10/7: 2,5	
IN	<b>IFORM</b>	ATION DISCLOSURE	Filing Date	Augi st 2	
S	CATEM	IENT BY APPLICANT	First Named Inventor	YAC OB	Y-ZEEVI Oron et al
			Art Unit	1644	
	(use as	many sheets as necessary)	Examiner Name		
Sheet	4	of 11	Attorney Docket Number	2687 :	
	76	Brenner "Errors in Genome Annotation	n". Trends in Genetics, 15(4):	132-133, 1	999.
	77	Brinster et al. "Restoration of Fertility	by Germ Cell Transplantation	n Requises	
		Effective Recipient Preparation", Biole	ogy of Reproduction 69: 412-	420, 20 13.	
		Abstract.			
	78	Burch et al. "Oligodeoxynucleotides A			
		Block the Effects of Interleukin I in Cu		broblas s a	nd in
		Mice", J. Clin. Invest. 88: 1190, 1991.			
	79	Calabretta et al. "Normal and Leukemi			
	j	Sensitivity to Inhibitory Effects of C-n			
		vitro Study Relevant to Bone Marrow	Purging", Proc. Natl. Acad. S	ci. USA 88	:
		2351-2355, 1991.			
	80	Carpentier et al. "DNA Vaccinaiton w		Neurob ast	oma in
		Mice", Clinical Cancer Research, 4: 28		<del></del>	
	81	Carson et al. Mucin And Proteoglucan	Functions In Embryo Implan	tation",	
	82	BioEssays, 20(7): 577-583, Abstract.	1. 6 .6 .		
	82	Chow et al. "Development of an Epith Human DNA Regulatory Elements for	Tanana Summer in Luc	issette with	,,
		Proc. Natl. Acad. Sci., 94:14695-1470		ig Airw iys	·
	83	Cohen "Oligonucleotide Therapeutics"		. 97 01 10	02
	83	Abstract.	. Helias III Bioleciniology To	1. 67-91. 19	92.
	84	Coligan et al. "Current Protocols in Im	munology" Green Publishing	Assoc 19	91
	85	Colman "Effects of amino Acid Seque			<del>/ -</del>
	05	Interactions", in Research in Immunolo		ilgen	
	86	De Vouge et al. "Immunoselection of G		KNRK Ce	11-
		Specific Agt11 Library Using Antibodi			
		Amino-Terminal Peptide", Int. J. Canc		•	
	87	Dempsey et al. "Heparanase Expressio		d Acute Va	ascular
		Damage", Glycobiology 10(5): 467-47	5, 2000. Abstract.		
	88	Dempsey et al. "Heparanase, A Potent	ial Regulator of CellMatrix In	iteractio is"	
		TIBS, 25(8):349-351, 2000.			
	89	Doerks et al. "Protein Annotation: Det	ective Work for Function Pred	diction" Tr	rends
		in Genetics, 14(6): 248-250, 1998.			
	90	Drigues et al. "Comparative Studies of			
		from a Virulent Strain of Pseudomonas			nt
	- 01	Mutants", Journal of Bacteriology 162			
	91	Ducy et al. "The Osteoblast: A Sophist	icated Fibroblast under Centr	al Surveilla	ince",
	- 02	Science 289: 1501-1504, 2000.			
	92	Durand et al. "Active-Site Motifs of Ly			
		of Clan GH-A Glycosyl Hydrolases De	educed from Hydrophobic Cli	uster Analy	SIS",
	02	Glycobiology 7(2): 277-284, 1997.	pulications of Managland A	ntibodia ."	
93 Edwards et al. "Some Properties and Applications of Monoclonal Antibodie;",					
	- 1	Riochem Journal 200: 1-10-1091			1
Examiner		Biochem. Journal 200: 1-10, 1981.	Date		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\(\bar{v}\) IPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check π ark here if English language Translation is attached

Translation is attached
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak ±2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collec-

Condition 1	арегмогк кедисис	m Act of 1995, no persons are required to respond to a coll-	ection of information unless it			
	St	ubstitute for form 1449A/PTO		Complete		
1 .			Application Numb		0/7::2,:	
	INFORM	ATION DISCLOSURE	Filing Date		ugi st	22, 2003
	<b>STATEM</b>	ENT BY APPLICANT	First Named Inven	tor Y	'AC OF	SY-ZEEVI Oron et al
			Art Unit	1	644	
	(use as	many sheets as necessary)	Examiner Name			
Sheet	5	of 11	Attorney Docket N	umber 2	687 ?	
	94	Ejima et al. "Induction of Apoptosis in	Placentas of Pregnar	nt Mice Exp	osec to	
		Lipopolysaccharides: Possible Involver	ment of Fas/Fas Liga	nd System".	Biclos	gy of
		Reproduction 62: 178-185, 2000. Abstr	ract.			5,
	95	Elkin et al. "Heparanase as Mediator of	f Angiogenesis.: Mod	le of Action	". T ie	
		FASEB Journal 15: 1661-1663, 2001.			,	
	96	Ennis et al. PNAS USA, 87: 2833-283	7, 1990.			
	97	Ernst et al. "Enzymatic Degradation of	Glycosaminoglycans	s", Crit. Rev	. in	
		Biochemistry and Molecular Biology,	30(5): 387-444, 1995			
İ	98	Faber-Elman et al. "Involvement of Wo	ound-Associated Fac	tors in Rat B	rai:	
		Astrocyte Migratory Response to Axon	ial Injury: In Vitro Si	mulation", J	. Clin.	
		Invest., 97(1):162-171, 1996.				
	99	Fairbanks et al. "Processing of the Hun	nan Heparanase Prec	ursor and Ev	ide ice	that
	ŀ	the Active Enzyme is a Heterodimer", .	Journal of Biol. Cher	n.,274,(42):	29537-	-
		29590, 1999.				
	001	Farndale et al. "A Direct Spectrophotor	netric Microassay fo	r Sulfated		
	ŀ	Glycosaminoglycans in Cartilage Cultu	ires", Connective Tis	sue Researc	h 9: 24	7-248,
		1982.				
	101	Ferber et al. "Pancreatic and Duodenal	Homeobox Gene 1 I	nduces Expr	ession	of
	İ	Insulin Genes in Liver and Ameliorates	s Streptozotocin-Indu	ced Hyperg	lyce ni	a",
		Nature Medicine, 6(5): 568-572, 2000.				
	102	Finkel "Potential Target Found for Ant	imetastasis Drugs", S	Science 285:	33-34,	July
	102	2, 1999.				
	103	Fisher CCPA, 1970.				
	104	Flanagan et al. "Potent and Selective G				
	105	Oligodeoxynucleotides". Molecular and	Cellular Biochemis	try, 172: 21.	3-22 5,	1997.
	103	Freeman et al. "Evidence that Platelet a	nd Tumour Heparani	ases are Sim	ılar	
	106	Enzymes", Biochem J. 342: 361-368, 1	999.		<del></del>	
	100	Freeman et al. "Human Platelet Hepara		naracterizati	on and	
<del></del>	107	Catalytic Activity", Biochem. J., 330: 1 Gewirtz et al. "Facilitating Oligonucleo	341-1330, 1998.		<del>-</del> -	
	107	its Promise" Prog. Natl. Agad. Soi. US.	Mae Delivery: Helph	ig Antisense	De ive	er on
·····	108	its Promise", Proc. Natl. Acad. Sci. US. Gewirtz et al. "Nucleic Acid Therapeut	ing: State of the A-t o	o, April 199	<u>0.</u>	1-11
	108	Blood 92(3): 712-736, 1998.	ics. State of the Art a	na ruture P	rost eci	is".
	109	Godder et al. "Heparanase Activity in C	Cultured Endothelial	Calle! Journ	101 c C	
	1.07	Cellular Physiology, 148: 274-280,199	i i i i i i i i i i i i i i i i i i i	cens , Journ	iaiti	
Goldberg et al. "An Improved Method for Determining Pr					untk esi	zed by
	110	Chondrocytes in Culture", Live Tissue	Research 24: 265-27	1990	yiiti. Cai	zed by
	111	Goshen et al. "Purification and Characte	erization of Placental	Henaranase	and It	9
		Expression by Cultured Cytotrophoblas				
		679-684, 1996.	, ,	Itapioudo		(*).
	112	Green et al. "Antisense Oligonucleotide	s: An Evolving Tech	nology for t	he	
		Modulation of Gene Expression in Hun				
		Surgery, 191(1): 93-105, 2000.	, - ,			
Examiner	-			Date		
Signature	:			Considered	l	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n. t in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (V/IPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pui-lic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak+ 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cat and the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office: U.S. D. PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMI control number.

#### Complete if K town Substitute for form 1449A/PTO Application Number 10/7 !2.502 INFORMATION DISCLOSURE Filing Date Augi st 22, 2003 First Named Inventor YAC OBY-ZEEVI Oron et al STATEMENT BY APPLICANT Art Unit 1644 (use as many sheets as necessary) Examiner Name Sheet 11 Attorney Docket Number 113 Haimov-Kochman et al. "Localization of Hepranase in Normal and Patholc gical Human Placenta", Molecular Human Reproduction 8(6): 566-573, 2002 114 Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-5 0. 115 Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Thro 1gh the Extracellular polysaccharide of Mucoid Pseudomonas Aeruginosa". Antimicrob. Agents. Chemother. 42(4): 974-977, 1998. [Abstract] 116 Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat T aumatic Shock", American Journal of Physiology 275:H23-H30, 1998. 117 Hida et al. "Antisense ETAF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132, 1997. Abstract. 118 Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Alte ed Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract. 119 Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1976. 120 Hillier et al. "The WashU-Merck EST Project". No. N30824, Database Gen Bank on STN, US National Library of Medicine (Bethesda MD), 1996. 121 Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse Genf ank on STN, US National Library of Medicine (Bethesda MD), 1996. 122 Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-B nding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] 123 Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes", J. Biol. Chem., 270(7):3268-3277, 1995. 124 Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First Intron in Expression of the at (1) Collagen Gene.", Mol Cell Biol., 18(6): 3. 68-3375,1998. Abstract. 125 Hulett et al. "Cloning of Mammalian Heparanase, an Important Enzyme in Junor Invasion and Metastasis". Nature Medicine: 5(7): 803-809, 1999. Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Aatrix-126 Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Jell. Biol. 143(4): 1113-1128, 1998. [Abstract] 127 Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutroph Is, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracel ular Matrix". Cell Regulation, 1: 833-842, 1990. 128 Jayaraman et al. "RationalSelection and QuantitativeEvaluation of Antisens: Oligonucleotides", Biochimica et Biophysica Acta 1520: 105-114, 2001. Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human 129 Melanomas", Int. J. Cancer, 45: 1088-1095, 1990. 130 Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA". Proceedings American Association for Cancer Research Annual Meeting 1992, 33: 57, 1992. Abstract Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\*\*IPO Standard ST.3\*). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual ca: e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office. U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO \* HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OML control number.

### Complete if Known Substitute for form 1449A/PTO Application Number 10/7 :2,502 INFORMATION DISCLOSURE Filing Date Aug: st 22, 2003 First Named Inventor YAC OBY-ZEEVI Oron et al STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) **Examiner Name** Sheet 11 Attorney Docket Number 131 Jorba et al. ["Variations in the P. Aeruginosa Polysaccharide Synthesis Cor ditioned by Aminosugars"] (author's translation). Rev. Esp. Fisiol. 36(2): 155-161, 1980. 132 Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain from an Inhibitor to a Potent Activator of FGF-2". Nature Medicine, 4(6):611-697, Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-133 Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage", Biology of Reproduction 66: 3810385, 2002. Abstract. 134 Kiberstis et al. "Bone Health in the Balance", Science 289: 1497, 2000. 135 Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta". Placenta 24: 424-430, 2003. 136 Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During Gestation", Reproduction 121: 573-580, 2001 137 Koehler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Fredefined Specificity", Nature 256: 495-497, 1975. 138 Konstan et al. "Current Understanding of the Inflammatory Process in Cyst 2 Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 139 Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies", Pediatr. Pulmonol. 28(4): 248-54, Oct. 1999. [Abstract] 140 Korb et al. "Stimulation of Gene Expression by Introns: Conversion of an It hibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research 21(25): 5901-5908, 1993. 141 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase". Molecular Biology/Biochemistry. Proceedings of the America 1 Association for Cancer Research, 37: 495, 1996. 142 Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997. 143 Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996. 144 Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset". Blood, 91(3): 852-862, 1998. 145 Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene, Journal of Biological Chemistry 270(10): 5276-5281, 1995. 146 Kussie et al. "Cloning and Functional Expression of a Human Heparanase Cene", Biochemical and Biophysical Research Communication 261(1): 183-187, 1999. 147 Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 449-484, 1! 98. 148 Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephro, 7(1):11-14, 1999. Abstract. 149 Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine B-Lymphocytes". International Journal of Cancer 47(1): 92-98, Jan. 1991. Examiner Date Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number 'optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\(\clinif{IPO}\) Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. 5 by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check ri ark here if English language Translation is attached.

Considered

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual ca: e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office.

U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. D. PARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMI control number.

Juder the Paper	work Reduction	Act of 1995, no persons are required to respond to a coll	Con	plete if h	gown
	Sut	ostitute for form 1449A/PTO	Application Number		22.502
IN	EODM	ATION DISCLOSURE	Filing Date		ısı 22, 2003
			First Named Inventor		<b>OBY-ZEEVI</b> Oron et al
5	IAILWI	ENT BY APPLICANT	Art Unit	1644	
	(use as i	many sheets as necessary)	Examiner Name		
Sheet	18	of 11	Attorney Docket Number	268	2
Sileet	150	Le Fur et al. "Selective Increase in Spe			
	130	in Murine Melanomas: A Projected Ba	isis for Immunotherapy". Pr	oc. natl.	Acad. Sci.,
		94: 5332-5337, 1997,			
	151	Lederman et al. "A Single amino Acid	Substitution in a common a	African a	lele of the
		CD4 Molecule Ablates Binding of the	Monoclonal antibody, OKT	'4", Mol	cular
		Immunology 28: 1171-1181, 1991)			
	152	Li et al. "Immunochemical Localization	on of Heparanase in Mouse a	and Hum	ın
		Melanomas", Int. J. Cancer 45: 1088-	095, 1990.		
	153	Li et al. "β-Endorphin Omission Anal	ogs: Dissociation of Immun	oreactiv	ly from
		other Biological Activities", PNAS 77	: 3211-3214, 1980)	and Drole	position of
	154	Lider et al. "Suppression of Experiment Allograft Survival by Treatment of Ar	timate With Law Doses of I	Blu Flott Jenarin''	I Clin
			minais with Low Doses of i	терапп .	, J. Ciii.
	. 155	Invest., 83: 752-756, 1989.  Linhardt et al. "Polysaccharide Lyases	" Applied Biochemistry an	d Biotec	inology
	. 133	12: 135-176, 1986.	TAPPHED BIOCHEMISTY W.	0 5.000	
	156	Liu et al. "Live Offspring by In Vitro	Fertilization of Oocytes from	n Cryop	eserved
	130	Primordial Mouse Follicles after Sequ	ential In Vivo Transplantati	on and I	:i Vitro
	ļ	Maturation", Biology of Reproduction	64: 171-178, 2001. Abstrac	c1.	
	157	Loredo et al. "Regulation of Glycosan	tinoglycan Metabolism by E	3one	
		Morphogenetic Protein-2 in Equine C	artilage Explant Cultures". 4	Am. J. V	·t. Res.
		57(4): 554-559, 1996.			
	158	Luft " Making sense out of Antisense		ery: Get	ling there is
		Half the Fun". J. Mol. Med. 75-76. 19	98.	Jan Fan	and .
	159	Macone et al. "Mucoid Escherichia co	oli in Cystic Fibrosis. The r	new Eng	and
	1.60	Journal of Medicine 304(24): 1445-14  Marchetti et al. "Neurotrophin Stimul	utim of Human Malanama	Call Inve	zion
	160	Selected Enhancement of Heparanase	Activity and Henaranase D	eoradatio	n of
		Specific Heparan Sulfate Subpopulati	ons" Cancer Research, 56:	2856-28	3, 1996.
		also in: Advances in Enzyme Regulat	ion, 37: 111-134, 1997.		:
	161	Marty et al. "Influence of Nutrient Me	edia on the Chemical Comp	osition o	the
	'`'	Expolysaccharide from Mucoid and n	on-Mucoid Pseudomonas A	eruginos	a". FEMS
		Microbiol. Letters, 77(1-3): 35-44, No.	ov. 1992. Abstract.		
	162	Massague "The TGF-BETA Family of	f Growth and Differentiatio	n Factor	:", Cell, 49:
		437-438, 1987.		<del></del>	
	163	Menezo et al. "Mouse and Bovine Mo		oductive	;
		BioMedicine Online 2002 4(2): 170-	75, 2002. Abstract.		luctain
	164	Miao et al. "Cloning, Expression and	Purification of Mouse Hear	ranase",	rotein
		Expression and Purification, 26: 425-	451, 2002.	riv Doc	dative
	165	Mollinedo et al. "Major Co-Localizat Enzymes Heparanase and Gelatinase	ion of the Extracellular-Mat	nan Neu	conhils"
		Biochem J., 327: 917-923, 1997.	in remary Granules of Hull	nan 140U	· Opinio ,
	166	Motokuni et al. "In Vivo Transfer Eff	iciency of Antisense Oligor	nucleotid	s into the
	100	Myocardium Using HVJ-Liposome N	1ethod", Biochemical and B	iophysic	: Il Research
		Communications 231: 540-545, 1997		, ,	
Examiner			Dat	.e	
Signature		ce considered, whether or not citation is in conforma		sidered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation inot in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter codi (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pi tent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a chec : mark here if English language Translation is attached.

Translation is attached
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to ake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Off cer, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Approved for use thro igh 07/31/2006, OMB 0651-0031

U.S.Patent and Trademark Office; U.S. D. PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OM 3 control number.

		at Act of 1993, to persons are required to respond to a eo	THE THE THE THE THE THE THE THE THE THE	Complete i			
	Sı	ubstitute for form 1449A/PTO	Application Number		77 22,		
11	<b>NFORM</b>	ATION DISCLOSURE	Filing Date			22, 2003	
		IENT BY APPLICANT	First Named Invent			BY-ZEEVI Oron et al	
5	IALEM	IENT DI ATTEICANI	Art Unit	16		o. EED. ( Oldir ct ui	
	(use as	many sheets as necessary)	Examiner Name		<u> -</u>		
Sheet	9	of 11	Attorney Docket N	umber 26	8. 2	<del></del>	
	167	Muir et al. "Histomorphometric Analy	vsis of the Effects of S	tandard Hen:	ri 10	n	
		Trabecular Bone in vivo", Blood 88(4	0: 1314-1320 Anougt	15 1996 IA	he raz	11	
	168	Mullings et al. "New Reducing Sugar	Assay for the Study of	f Cellulases"	1 07	vme	
	ļ	Microb. Technol., 6:491-496, 1984.	thisky for the thirdy o	. centulases		yiiic	
	169	Nakajima et al. "Heparanases and Tur	nor Metastis", J. Cell	Biochemistry	-, 60	2): 157-	
		167, 1988.					
	170	Naparstek et al. "Activated T Lympho	ocvies Produce a Matri	x-Degrading	Hepa	aran	
		Sulphate Endoglycosidase", Nature, 3	10(5974): 241-244, 19	984. Abstract			
	171	Newbold et al. "Exposure to Diethylst	ilbestrol During Pregn	nancy Permar	ei tly	Alters	
		the Ovary and Oviduct". Biology of R	eproduction 28: 735-7	744, 1983. At	st ac	t.	
	172	Ofek et al. "Bacterial Adhesion to Cel	ls and Tissues", Chapi	man and Hall	, Hev	v York.	
		<u>  1994, pp. 114-1</u> 18, 148-153, 418-423,	, 420-423,			ĺ	
	173	Oldberg et al. "Characterization of a P	latelet Endoglycosida	se Degrading	F epa	arin-	
		Like Polysaccharides", Biochemistry	19: 5755-5762, 1980.		•		
	174	Parish et al. "Evidence That Sulphated	l Polysaccharides Inhi	bit Tumor M	eta sta	isis by	
		Blocking Tumor-Cell-Derived Hepara	mases", Int. J. Cancer,	40: 511-517.	1 )87	7.	
	175	Pasquier et al. "Implication of Neutral	Polysaccharides Asso	ciated to Alg	in ite	in	
		Inhibition of Murine Macrophage Res	ponse to Pseudomonas	s Aeruginosa	", FE	MS	
		Microbiol. Lett. 147(2): 195-202, Feb.	. 1997. Abstract.				
	176	Pfaff et al. "Cryobiology of Rat Embr	yos I: Determination o	f Zygote Me	nl rai	ne	
		Permeability Coefficients for Water ar	nd Cryoprotectants, Th	neir Activatio	n Ene	ergies,	
		and the Development of Improved Cry	opreservation Method	ds", Biology	of		
	177	Reproduction 63: 1294-1302, 2000. A	bstract.				
	'''	Pilbeam et al. "Comparison of the Effe	ces of Various Length	is of Syntheti	c Hui	man	
		Parathyroid Hormone-Related Peptide	(nPTHrP) of Maligna	incy on Bone	R :so	orption	
	178	and Formation in Organ Culture", Bor Prahalada et al. "Diethylstilbestrol-Ind	le, 14: 717-720,1993.		- ,-		
	178	Neonatal Mouse Model", Biology of R	luced Cervical and Va	ginal Adenos	is Us	ing the	
	179	Prockop "Marrow Stromal Cells as Ste	ceproduction 38: 933-	943, 1988. A	os rac	il.	
	'''	Science 276: 71-74, 1997.	eni Cens for Nonnema	topotetic Tis	sues".	,	
	180	Rahmoune et al. "Chrondroitin Sulfate	in Sputum Erom Doti	anta With Co.		::I ! -	
	1.00	and Chronic Bronchitis", Am. J. Resp.	Cell & Mol Biol 50	ans with Cy	SH 7 F 10 ) 1	ibrosis	
		Abstract.	cen as Mon. Dion., M	4). 313-320.	1971.	•	
	181	Rajur et al. "Covalent Protein-Oligonu	clentide Conjugates fo	or Elfficient	De liv	ery of	
	1,0,	Antisense Molecules". Bioconjugate C	them 8 935-940 199	or Entreient	Denv	ery or	
	182	Ramos et al. "Relationship Between G	lycolysis and Exopoly	saccharide B	io vn	thesis	
		in Lactococcus Lactis", Appl. Environ	Microbiol 67(1): 33-	-41 2001 [A	he ra	rtl	
	182	Reddi "Role of Morphogenetic Protein	is in Skeletal Tissue Fi	ngineering ar	14	<u> </u>	
		Regeneration", Nature Biotechnology	16: 247-252, 1998				
	184	Richardson et al. "Regulation of Basic	Fibroblast Growth Fa	ctor Binding	an T		
		Avtivity by Cell Density and Heparan	Sufate", J. Biological	Chemistry 2	30.3 74.19	D):	
		13534-13540, 1990.	, 5.0.05.001	, 2		<i>''</i>	
xaminer			1	Date		1	
Signature	[		-	Considered			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (1/IPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater t document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual ca: e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office. U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperv	vork Reductio	n Act of 1995, no persons are required to respond to a coll	ection of information unless it contains a v	ralid OMB control number.  Lete if K. lown
	Su	bstitute for form 1449A/PTO	Application Number	10/7: 2,502
IN	FORM	ATION DISCLOSURE	Filing Date	Augi st 22, 2003
			First Named Inventor	YAC DBY-ZEEVI Oron et al
51	AIEW	ENT BY APPLICANT	Art Unit	1644
	(use as	many sheets as necessary)	Examiner Name	
Sheet	10	of II	Attorney Docket Number	2687 !
	185	Sasisekharan et al. "Heparinase Inhibit		
		91:1524-1528, 1994.		
	186	Selvan et al. "Heparan Sulfate in Immu 139, 1996.	·	
	187	Service "Tissue Engineers Build New	Bone". Science 289: 1498-150	00. 200 ).
	188	Shastry "Gene Disruption in Mice: Mo and Cellular Biochemistry, 181: 163-1	odels of Development and Dis-	
	189	Shekhar et al. "Correlation of Differen		ression with
		Metastatic Competence of Mouse Man Metastasis, 14: 27-37, 1994/5.		
	190	Shimazu et al. "Syndecan-3 and the Co		
		Endochondral Ossification", Exp. Cell		
	191	Skolnick et al. "From Genes to Protein		
		Computational Approaches in the Gen	omic Era", Trends in Biotech.	18: 34-39.
		2000.		
	192	Smith et al. "The Challenges of Genon		he Dev I is in the
	102	Details"", Nature Biotechn., 15: 1222-		
	193	Sutherland "Structure-Function Relation	onships in Microbial Exopolys	saccharites".
-	194	Biotech. Adv. 12: 393-448, 1994.  Szczylik et al. "Selective Inhibition of	Laukawia Call Proliferation k	NI DCD ADI
	124	Antisense Oligodeoxynucleotides". Sc		
	195	Tang et al. "Contribution of Specific P		
	173	Pathogenesis of Pneumonia in a Neona		
		64(1): 37-43, 1996. Abstract.	ata. Moase Moaer of Infection	, miles ii viiinani
	196	Tatnell et al. "Characterisation of Algi	nates from Mucoid Strains of	Pseudo nonas
		Aeruginosa", Biochemical Society Tra		
	197	Tatnell et al. "Chemical Analysis of A		of Pseu Iomonas
		Aeruginosa", Biochemical Society Tra		
	198	Tatnell et al. "Colonisation of Cystic F		id Pseudomonas
		Aeruginosa - Characterisation of the A		
		Society Transactions 24: 406S, 1996.		
	199	Thuong et al. "Sequence-Specific Reco		
		DNA by Oligonucleotides", Angew.Cl		
	200	Toyoshima et al. "Human Heparanase:	: Purification, Characterization	n, Cloni 1g, and
		Expression", J. of Biolog. Chemistry, 2		
	201	Uno et al. "Antisense-Mediated Suppre		
		Inhibits Pleural Dissemination of Hum	ian Cancer Cells", Cancer Res	search 6 (21),
	200	7855-7860, 2001.		
	202	Vlodavsky et al. "Inhibition of Tumor	Metastis Inhibiting Species of	t Hepari i", Inv.
	202	Metast., 14(1-6): 290-302, 1994/95.	G. Cl. : E	- I F
	203	Vlodavsky et al. "Mammalian Heparar		
Examiner	_	in Tumor Progression and Metastasis"	, Nature Medicine, 5(7): 793-	002, 19: 9.
Signature			Consid	lerad
Jighalare			Consid	iciou

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (1 VIPO Standard ST.3).
For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pate it document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

Iranstation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak ÷ 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual called a e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office , U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO HIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

information unless it contains a valid OMI control number.

nder the Papers	ork Reduction	Act of 1995, no persons are required to respond to a colle	Com.	plete if i	'nown
	Sub	stitute for form 1449A/PTO	Application Number		!2.502
	DODA	THOM DISCLOSUDE	Filing Date		ıst 22, 2003
		ATION DISCLOSURE	First Named Inventor	YAC	OBY-ZEEVI Oron et al
ST	ATEM	ENT BY APPLICANT	Art Unit	1644	
	(	nany sheets as necessary)	Examiner Name	<del>                                     </del>	
	(use us i			2687	7
heet	11	of   11	Attorney Docket Number		
	204	Vogel et al. "Production of Proteoglyca maintained in a Low Concentration of	Emmy" Diocham L 207(3):	360-3.	9
			Setuin), Biochem 3, 207(3).	507 5	<i>"</i>
		Abstract.  Vukicevic et al. "Induction of Nephrro	ganic Mesenchyme by Osteo	venic F	rotein I
	205	(Bone Morphogenetic Protein 7)", Prod	Natl Acad Scie 93: 9021	<b>-9026</b> .	1996.
	206	Walch et al. "Correlation of Overexpre	ession of the Low-Affinity p7	5 Neut	otrophin
	200	Receptor with Augmented Invasion an	d Henaranase Production in	Human	Malignant
		Melanoma Cells", Int. J. Cancer 82: 1	12-120, 1999.		
	207	Walton et al "Prediction of Antisense	Oligonucleotide Binding Aft	inity to	a
	1207	Structured RNA Target", Biotechnolog	gy and Bioengineering, 65(1)	i: 1-9I	<del>1</del> 99
	208	Wang "Basic Fibroblast Growth Facto	r for Stimulation of Bone Fo	rmation	in j
	-00	Osteoinductive or Conductive Implant	s". Acta Orthop Scand Suppl	. 269: 1	-33, 1006
		(abstract)			
	209	Webster et al. "FGFR Activation in Sk	eletal Disorders: Too Much	of a Go	od Thing",
		TIG 13(5): 178-182, May 1997.			
	210	Welch et al. "Complex Saccharide Me	tapolism in Cystic Fibrosis F	ibrobla	ists".
		Pediatr. Research, 9(9): 698-702, 1975	5.		
	211	Weller "Implications of Early Inflama	tion and Infection in Cystic I	ibrosis	A Review
		of New and Potential Interventions", I	Pediatric Pulmonology 24: 14	13-140.	Hughmania
	212	Wessels et al. "Effects on Virulence o	f Mutations in a Locus Essen	uai 101	423 441
	1	Acid Capsule Expression in Group A	Streptococci, miect. immun	1. 02(2)	433-441,
		Whitelock et al. "The Degradation of	Hamon Endothelial Cell-Der	ived Pe	lecan and
	213	Release of Bound Basic Fibroblast Gr	with Factor by Stromelysin	Collag	:nase.
		Plasmin, and Heparanases". Journal o	f Biological Chemistry, 2710	17):100	79-10086.
		1996.	Trionglem enemions		<u> </u>
	214	Yagel et al. "Normal Nonmetastatic H	Iuman Trophoblast Cells Sha	re in vi	ro Invasive
	214	Droparties of Malienant Cells"   Cel	lular Physiology 136: 455-46	2, 1981	
	215	Yazaki et al. "The Structure and Expr	ession of the FGF Receptor-	I mRN.	, lsoforms
	-13	in Rat Tissues" Biochimica et Biophy	ysica Acta, 1172: 37-42, 199	s	
	216	Ye et al. "Targeted Gene Correction:	A New Strategy for Molecul	ar Med	zine",
	1	Molecular Medicine Today: 431-437.	. 1998.		
	217	Vocildadar et al. "The Mouse as a M	odel to Study Adhesion Forn	nation f	ollowing
	-	Endoscopic Surgery: A Preliminary F	Report", Human Reproduction	n 14(1)	: 55-59,
		1000 Abetiget			
	218	Zhou et al. "A 182 bp Fragment of the	e Mouse proal(11) Collagen	Gene 1	OS. 3677-
		to Direct Chondrocyte Expression in	Transgenic Mice", J. Cell Sc	ience 1	110. 30//-
		3684, 1995.	Lara Maura Madal of Hara	ditary	
	219	Zhou et al. "HFE Gene Knockout Pro	oduces Mouse Model of Here	and y	
		Hemochromatosis", PNAS 95(5): 24	92-2497, 1990.		
				Consid	red
Signature				Consid	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Trans ation is attached.

1. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by this public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including usathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individua case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Or icer, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ Approved for use through 10/21/00 (2) AP 0.651 (02)

Approved for use through 10/31/99 OMB 0651-0031

Signature

Pitent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Urder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control in imber. Substitute for form 1449A/PTO Complete if Known Application Number 10/645,659 INFORMATION DISCLOSURE Filing Date 08/22/2003 STATEMENT BY APPLICANT First Named Inventor YACOBY-ZEEVI Group Art Unit 1635 (use as many sheets as necessary) Examiner Name Sheet ī Of Attorney Docket Number 26128 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue numt er(s). No.1 Initials T? publisher, city and/or country where published. Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., vol. 274, No. 42, pp. 29517-29590, 15 Oct. 1999. Hulctt et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7):803-809, 1999 Toyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, vol. 274. No. 34, pp. 24153-24160, 20 Au<sub>3</sub>. Miao et al, "Cloning. Expression, and Purification of Mouse Heparanase", Protein Expression and Purification, 26:425-431, 2002 Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity". Biochem J., 330(3): 1341-1350, 1998. Examiner Date


Considered

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

E irden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

O NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC::0231.



Please type a plus sign (+) inside this box

Signature

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number 10/456,573 Substitute for form 1449A/PTO 06/09/2003 Filing Date INFORMATION DISCLOSURE Iris PECKER First Named Inventor STATEMENT BY APPLICANT 1646 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25677 Of 1 Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines, Where Relevant Date of Publication of Passages or Relevant Figures Name of Patentee or Applicant Cite Number Examiners Cited Document (if known) Appear of Cited Document No. Initials MM-DD-YYYY 01-23-2001 Pecker et al 6.177,545 10-19-1999 Pecker et al 5,968,822 12-16-2003 Pecker et al 6,664,105 06-05-2001 Freeman et al 6,242,238 FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines. Date of Publication of Name of Patentee or Where Relevant т6 Cite Examiners Cited Document Applicant of Cited Document Kind Code5 Office3 Number<sup>4</sup> Passages or Relevant MM-DD-YYYY Initials (if known) Figures Appear 01-23-2003 IMCLONE : YSTEMS 03/006645 WO Date Examiner Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time vill vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: A :sistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applical t.

Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. If Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible Applicant is to place a check mark here if English language Translation i attached.

Please type a plus sign (+) inside this tox  $\rightarrow \boxtimes$ Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

| Control of the Proposed Reduction Act of 1995, no persons are required to respond to a collection of i

er the Paperwork	Reduction Ac	et of 1995, no persons are required to respond to a collection of i formation unless	Complete i	f K nown				
		stitute for form 1449A/PTO	Application Number	10/456,573				
			Filing Date	06/09/2003				
		DRMATION DISCLOSURE	First Named Inventor	Iris PECKER				
	STA	TEMENT BY APPLICANT	Group Art Unit	1646				
			Examiner Name					
	(	use as many sheets as necessary)		25677				
heet	72	Of 2	Attorney Docket Number	25677				
	i	OTHER PRIOR ART – NON PATENT LITER	ATURE DOCUMENTS	of the				
xaminer nitials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTER ·), title of the item (book, magazine, journal, serial symposium, c tialog, etc.) depublisher, city and/or country where p	oublished.	1				
		Vlodavsky et al, "Inhibition of tumor meta tasis by he	paranase inhibiting specie	s of				
	1	heparin' Invasion Metastasis, 1994-95:14 1-6):290-3	02 (abstract)					
		Parish et al "Evidence that sulphated poly: accharides	inhibit tumour metastasis	by				
	- }	blooking remove cell-derived benaranases'. Int J Cano	cer. 198 / Oct 15;40(4):51	1-0.				
	T	Lider et al "Suppression of experimental autoimmune	diseases and prolongation	n oi.				
		allograft survival by treatment of animals with low do	ses of heparins, J Clin II.	ivest.				
		1090 1492(3):752 6						
		Gewirtz et al, "Nucleic acid therapeutics: state of the a 1998 Aug 1;92(3):712-36.						
		Hida et al "Antisense ELAF transfection restrains ora	I cancer invasion by redu	cing				
	ļ	matrix metalloproteinase activities", Am J Pathol. 199	97 Jun;150(6):2125-32					
		(abstract)						
		Thuong et al, "Sequence-specific recognit on and modification of double-helical						
		DNA by oligopycleotides" Angew Chem Int. Ed. Et.	igi., 32:000-090, 1993					
		Cohen, JS, "Oligonucleotide therapeutics', Trends Bi	otechnol., 10(3):87-91, 1	.9992				
	)	(abstract)						
		Szczylik et al, "Selective inhibition of leu emia cell p	proliferation by BCR-AE	L.				
	1	antisense oligodeoxynucleotides", Science, 1991 Aug	(2:253(5019):362-3. (abs	tract)				
		Calabratia at al "Normal and leukemic he natopoietic	c cells manifest differentia	a i				
		sensitivity to inhibitory effects of c-myb a itisense oli	godeoxynucleotides: an u	n viuo				
		study relevant to bone marrow purging", 1'roc Natl A	caa Sci U S A. 1991 Wat					
		Burch et al "Oligonucleotides antisense to the interle	cukin I receptor mRN blo	ck the				
		effects of interleukin 1 in cultured murine and hum to	broblats and in mace", $J$	un				
		Invest 88(4):1190-1196 1991 (abstract						
		Agrawal S., "Antisense oligonucleotides : s antiviral						
		Uno et al. "Antisense-mediated suppression of huma inhibits pleural dissemination of human concer cells" 1:61(21):7855-60.	n heparanase gene expres '. Cancer Res. 2001 Nov	sion				
	<del>i</del>							
		!	Date					
Examiner	i		Considered	. i				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance; ith MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>.</sup> Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if Enç ish language Translation is attached.

Buiden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

plus sign (+) inside this box  $\rightarrow$  +

# PTO/SB/08A (10-96)

Approved for use through 19/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of a formation unless it contains a valid OMB control number. Complete if Known 10/371,218 Application Number Substitute for form 1449A/PTO 02/24/2003 Filing Date INFORMATION DISCLOSURE Zcharia First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1652 Examiner Name (use as many sheets as necessary) 25783 Attorney Docket Number 2 U.S. PATENT DOCUMENTS Sheet Pages, columns, lines. U.S. Patent Document Where Relevant Date of Publication of Passages or Relevant Name of Patentee or Applicant Kind Code Number Cited Document Figures Appear Cite Examiners (if known) of Cited Documer t MM-DD-YYYY **Initials** No. 11-08-1994 Fuks et al 5,362,541 10-19-1999 Pecker et al and le 5,968,322 01-23-2001 Pecker et al 204 **→** 6,177,545 02-19-2002 Ayal-Hershkovitz et al 6,348,344 FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines, Date of Publication of Name of Patentee or Where Relevant Cited Document MM-DD-YYYY Applicant of Cited Document Cite Examiners Passages or Relevant Number4 Kind Code5 Office3 Figures Appear Initials (if known) 11-11-1999 Ben-Artzi et al 99/57244 -WO 11-11-1999 Pecker et al 99/57153 WO 03-11-1999 Pecker et al 99/11798 WO Date Examiner Considered

Signature \*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Signature

## PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Considered

Under the Paperwork Reduction Act of 995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete it Known 10/371,218 Substitute for form 1449A/PTO Application Number 02/24/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Zcharia STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25783 | 2 Of Sheet OTHER PRIOR ART - NON PATI NT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTER i), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, c italog, etc.) date, page(s), volume-issue number(s), T<sup>2</sup> No.1 publisher, city and/or country where published. Initials Vlodavsky et al, "Mammalian Heparanase Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Na. ure Medicine, 5(7):793-802, 1999 Kussie et al, "Cloning And Functional Excression Of A Human Heparanase Gene", Biochem Biophys Res Commun., 261(1):183-187, 1999 Hulett et al, "Cloning Of Mammalian Heparanase, An Important Enzyme In Tumor Invasion And Metastasis", Nat Med., 5(7): 303-09, 1999 LToyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. Biological Chemistry, 274-34):24153-24160, 1999 Fairbanks et al, "Processing Of The Huma 1 Heparanase Precursor And Evidence That The Active Enzyme Is A Heterodime ", J Biol Chem., 274(42):29587-29590, Dempsey et al, "Heparanase, a Potential R egulator of Cell-Matrix Interactions". TIBS, 25(8):349-351, 2000 Niwa et al, "Efficient Selection For High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2):193-19, 1991 Clark, AJ, "The Mammary Gland as a Bicreactor: Expression, Processing, and Production of Recombinant Proteins", J. Mammary Gland Biol. And Neoplasia. 3(3):337-350, 1998 Mirault et al, "Transgenic Glutathione Peroxidase Mouse Models for Neuoprotection Studies", Ann NY Acad Sci, 738:104-115. 1994 Lampard et al, "Secretion Of Foreign Proteins Mediated By Chicken Lysozyme Gene Regulatory Sequences", Biochem Cell Bic l., 80(6):777-788, 2002 Harvey et al, "Expression of Exogenous Frotein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002 Morrison et al, "Sequences In Antibody Molecules Important For Receptor-Mediated Transport Into The Chicken Egg Yolk", A fol Immunol., 38(8):619-625, 2002 Clark et al, "Pharmaceuticals from Trans; enic Livestock", TIBTECH, 5:20-24, 1987 Richards et al, "Construction And Prelim nary Characterization Of The Rat Casein And Alpha-Lactalbumin Cdna Clones", J Biol Chem., 256(1):526-32, 1981 Campbell et al, "Comparison Of The Whey Acidic Protein Genes Of The Rat And Mouse", Nucleic Acids Res. 1984 Nov 26.12(22):8685-8697. Gorodetsky et al, "Isolation and Characte ization of the Bos Taurus β-Casein Gene", Gene, 66:87-96, 1988 Alexander et al, "Complete Sequence of the Bovine β-Lactoglobulin cDNA". Nucleic Acids Research, 17(16):6739-6744, 1989 Examiner

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Uraw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number, 2. Applicant is to place a check mark here if En Ilish language Translation is attached.

Examiner

Signature

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/341,582 01/14/2003 Filing Date INFORMATION DISCLOSURE Ilan et al First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25449 4 Of Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines. Where Relevant Date of Publication of Kind Code Name of Patentee or Applicant Passages or Relevant Cite Number Examiners Cited Document Figures Appear of Cited Document Initials MM-DD-YYYY 12-07-1999 Zimmermann et al 5.997,863 11-08-1994 Fuks et al 5,362.641 06-05-2001 Freeman et al 6,242,238 10-19-1999 Pecker et al 5.968,822 11-18-1997 Powell 5,688,679 05-14-2002 Heinrikson et al 6,387,643 FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines, Date of Publication of Name of Patentee or Where Relevant Cite Cited Document MM-DD-YYYY Examiners Kind Code5 Applicant of Cited Document Passages or Relevant Office3 Number<sup>4</sup> Initials Nο (if known) Figures Appear 02-09-1995 Hoogwerf et al WO 95/04158 Date

Considered

<sup>\*</sup>EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Recuction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/341.582 Application Number Substitute for form 1449A/PTO 01/14/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Ilan et al STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 4 Of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), Cite  $T^2$ Examiner publisher, city and/or country where published. **Initials** No. Richardson et al, "Regulation of Basic Fibroblast Growth factor Binding and Activity by Cell Density and Heparan Sulfate", J. Biological Chemistry, 274(19):13534-13540 Hayward et al, "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", American Journal of Physiology 275: H23-H30, 1998. Sasisekharan et al, "Heparinase Inhibits Neovascularization", Proc. Natl. Acad. USA, 91:1524-1528, 1994 Whitelock et al, "The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", J. Biological Chemistry, 271(17):10079-10086, 1996 Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", Invasion Metastasis, 12:112-127, 1992 Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor from Extracellular Matrix", Cell Regulation, 1:833-842, 1990 Godder et al, "Heparanase Activity in Cultured Endothelial Cells", J. Cellular Physiology, 148:274-280, 1991 Kato et al, "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain frim an Inhibitor to a Potent Activator of FGF-2", Nature Medicine, 4(6):691-697, Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", Critical Rev. in Biochemistry and Mol. Biology, 30(5):387-444, 1995 Linhardt et al, "Polysaccharide Lyases", Applied Biochemistry and Biotechnology, 12:135-176, 1986 Kosir et al, "Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", J. Surgical Res., 67:98-105, 1997 Jin et al, Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer, 45:1088-1095, 1990 Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., 274(42):29587-29590, 1999 Hoogewerf et al, "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparain/Heparan Sulfate-degrading Enzymnes", J. Biol. Chem., 270(7):3268-3277, 1995 Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from "The Protein Folding Problem and Tertiary Structure Prediction", Merz and LeGrand, Eds., Birkäuser, Boston, 1994 Oldberg et al, "Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", Biochemistry, 19:5755-5762, 1980 heparician for Nett Aird VIA Considered Apr 193 Susisekhork Examiner

Signature | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Considered | Consid

<sup>1.</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number Substitute for form 1449A/PTO 10/341,582 01/14/2003 Filing Date INFORMATION DISCLOSURE Ilan et al First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25449 Of Sheet 3 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), Cite  $T^2$ Examiner publisher, city and/or country where published. No. Initials Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", Biochem. And Biophysical Res. Comm., 261:183-187, 1999 Walch et al, Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82:112-120, 1999 Okamoto et al, "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cancer, 79(6):560-564, 1998 (abstract only) Zhou et al, "A 182 bp Fragment of the Mouse proα1(11) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108:3677-3684, 1995 Hormuzdi et al, "A Gene-Targeting Approach Identifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", Mol. Cell Biol., 18(6):3368-3375, 1998 (abstract Only) Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene", Mol Cells, 8(3):259-265, 1998 (abstract only) Chow et al, "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Nat. Axad. Sci. USA, 94:14695-14700, 1997 Gottschalk et al, "Somatic Gene Therapy. Present Situation and Future Perspective", Arzneimittelforschung, 48(11):1111-1120, 1998 (Abstract only) Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, Oct. 1998, pp 431-437 Lai et al, "Homologous Recombination Based Gene Therapy", Exp Nephrol, 7(1):11-14, 1999 (abstract only) Yazaki et al, "The structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissue", Biochemica et Biophysica Acta, 1172:37-42, 1993 Le Fur et al, "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci. USA. 94:5332-5337, 1997 Guriec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary N0M0 Breast Carcinaomas", Breast Cancer Res Treat, 44(3):261-268, 1997 (abstract only) Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood, 92(3):712-736, 1998 Hida et al, "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", Am J Pathol, 50(6):2125-2132, 1997 (abstract only) Shastry, BS, "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181:163-179, 1998 Date Examiner Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here If English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/341,582 Application Number 01/14/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Ilan et al STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number | 25449 Of 4 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LEITERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s),  $T^2$ No. Initials publisher, city and/or country where published. Carpentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", Clinical Cancer Research, 4:2819-2824, 1998 Lai, et al, "DNA Vaccines", Critical Reviews in Immunology, 18:449-484, 1998 Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cancer Research, 56:2856-2863, 1996 DeVouge et al, "Immunoselection of GRP94/Endoplasmin from a KNRK Cell-Specific \(\lambda\)gtll Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 56:286-294, 1994 Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Advances in Enzyme Regulation, 37:111-134, 1997 Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem., 327:917-923, 1997 Freeman et al, "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem. J., 342:361-368, 1999 Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7):803-809, 1999 Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7):793802, 1999 Toyoshima et al, "Human Heparanase", J. Biol. Chem., 274(34):24153-24160, 1999 Korb et al, "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

RNA Levels". Curr Opin Biotechnol, 9(5):486-496, 1998 (Abstract)

Faber-Elman et al, "Involvement of Wound-associated Factors in Rat Brain Astrocyte

Durand et al, "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Htdrolases Deduced from Hydrophobic Cluster Analysis",

Shekhar et al, "Correlation of Differences in Modulation of ras Expression with Metastatic Competence of Mouse Mammary Tumor Subpopulations", Invasion

Kurachi et al, "Role of Intron I in Expression of the Human Factor IX Gene", J.

Zheng et al, "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell

Welch et al., "Expression of Ribozymes in Gene Transfer Systems to Modulate Target

Date

Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin. Invest.,

Biological Chemistry, 270(10):5276-5281, 1995

Acids Research, 21(25):5901-5908, 1993

Glycobiology, 7(2):277-284, 1997

Metastasis, 14:27-37, 1994-5

Res, 7(1):21-9, 1997 (Abstract)

97(1):162-171, 1996

Examiner

considered, include (0.3) of this form with hext communication to applicant.

Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ 

Examiner

Signature

PTO/SB/08A (10-96) Approved for use through 10/31/99 OMB 0651-0031

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Date

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number 10/163,993 Substitute for form 1449A/PTO Application Number June 7, 2002 Filing Date INFORMATION DISCLOSURE Yacobi-Zeevi First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02/23884 6 of Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines. Where Relevant Date of Publication of Name of Patentee or Applicant Kind Code<sup>2</sup> Passages or Relevant Cite Number Examiners Cited Document Figures Appear of Cited Document No. Initials MM-DD-YYYY 11-18-1997 5,688,679 Powell 1 AA FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines, Date of Publication of Name of Patentee or Cite Where Relevant Examiners Cited Document Applicat t of Cited Document Office3 Number Kind Passages or Relevant No. 1 MM-DD-YYYY Initials Code<sup>5</sup> Figures Appear known) Australian Nat'l University 05-06-1999 99/21975 **PCT** AB

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and riot considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Fatent and Trademark Office.

Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent D ocuments. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ΑP

Approved for use through 10/31/99 OMB 0651-0031

Paten and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Papeavork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contains a valid OMB control number

Paperwork Reduction Act of 1993, no persons are required	Complete ii Ki	
Substitute for form 1449A/PTO		10/163,993
	Filing Date	June 7, 2002
INFORMATION DISCLOSURE	First Named Inventor	Yacobi-Zeevi
STATEMENT BY APPLICANT	Group Art Unit	1652
	Examiner Name	
(use as many sheets as necessary)	Attorney Docket Number	02/23884

Attorney Docket Number Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s)  $T^2$ Cite Examiner publisher, city and/or country where published. No. Initials "The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories. AD) 1997, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601. /Konstan et al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of Therapies". Pediatr Pulmonol, 1999, Oct; 28(4):248-54 (Abstract) ΛE Frederiksen et al, "Antibiotic Traetmen of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infectio 1 and Prevents Deterioration of Pulmonary AF, Function in Cystic Fibrosis", Pediatr P almonol, 1997 May; 23(5):330-335 (Abstract) Frederiksen et al, "Changing Epidemio ogy of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974- 995)", Pediatr Pulmonol, 1999 Sep: AG Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with 28(3):159-166 (Abstract) Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", N. Eng. J. Med., AH 1999 Jan 7; 340(1):23-30 (Abstract) Matzner et al, "Degradation of Hepara's Sulfate in the Subendothelial Extracellular Matrix by a Readiliy Released Heparanase from Human Neutropjils. Possible Role in Al Invasion Through Basement Membranes", J. Clin. Invest., 1985 Oct; 76(4):1306-1313 Ú Bennett et al, "Effect of Uridine 5'-Tr:phosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am J Respir Crit Care Med, 1996 Jun; 153(6 Pt ĀJ Vlodavsky et al, "Expression Heparanase by Platelets and Circulating Cells of the 1):1796-7801 (Abstract) Immune System: Possible Involvement in Diapedesis and Extravasation", Invasion AK Metastasis, 1992; 12(2):112-127 (Abstract) Naparstek et al, "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidase", Nature, 1984 July 19-25: 310(5974):241-244 (Abstract) AL . Armstrong et al, "Lower Airway7 Inflamation in Infants and Young Children with Cystic Fibrosis', Am J Respir Crit Care Med, 1997 Oct; 156(4Pt 1):1197-1204 AM: Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to (Abstract) Pathogenesis of Pneumonia in a Neo ratal Mouse Mcdel of Infection", Infect Immun. AN 1996 Jan; 64(1):37-43 (Abstract) Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed., √D AO McGraw-Hill Professional 1998, Chap. 57, pp 667-679

	1	i	Sciences. 797:127-139, 1996	 	
ļ	L	_i		 	
				 Date	i l
	Examiner			Considered	
	Signature			 	

Selvan et al. "Heparan Sulfate in Immune Responses". Annals New York Academy of

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Pater t and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Pater t and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info	Complete if Kı	nown
Substitute for fcrm 1449A/PTO	Application Number	10/163,993
	Filing Date	June 7, 2002
INFORMATION DISCLOSURE	First Named Inventor	Yacobi-Zeevi
STATEMENT BY APPLICANT	Group Art Unit	1652
	Examiner Name	1
(use as many sheets as necessary)	Attorney Docket Number	02/23884
Sheet 3 of 10		

	Τ	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  it le of the article (when appropriate), title of	
	Cite	OTHER PRIOR ART - NON PATENT LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS).	$T^2$
Examiner		Include name of the author (in CAPITAL LETTERS), title of the author (with application), the item (book, magazine, journal, serial symptosium, catalog, etc.) date, page(s), volume-issue the item (book, magazine, journal, serial symptosium, catalog, etc.) date, page(s), volume-issue the item (book, magazine, journal, serial symptosium, catalog, etc.) date, page(s), volume-issue	1
Initias	No.1	the item (book, magazine, journal, serial symposium, etc.) number(s), publisher, city an I/or country where published.	
	AQ	The state of Early Inflamation and Infection in Cystic	
	1,43	Weller, Peter H., "Implications of Early fill Manuaton and Potential Interventions", Pediatric Pulmonology, Fibrosis: A Review of New and Potential Interventions", Pediatric Pulmonology,	
	1		
		Wanter Alichael W. "Current Unders anding of the Inflamatory Flocess in	
	AR		
	1	Rubin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease",	
	A\$	Rubin, Bruce K., "Emerging Therapies for System 1895	
	12 "	Chest, 115:1120-1126, 1999	
	AT	Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of Marty et al, "Influence of Nutrient Media on the Chemical Composition of N	
	1	Evonolysaccharide from Mucoid and Pion-Mucoid Escudoni Act against	
V	/ <b> </b>		
	, AU	The state of Neutral Polysacchanges Associated to 115 mm.	
	/ AU	Inhibition of Murine Macrophage Response to recudindias Actualities	
		1 CENCE Minumbial Latt 100 / Pen 15: 16 // 21.175-202 (Mostrate)	
		tudies of LipopolySaccharide and	
	AV	Drigues et al, "Comparative Studies of Epopolysacomonas Solanacearum and Exopolysaccharide From a Virulent Strain of Pseudomonas Solanacearum and	
	.]	Exopolysaccharide From a Virulent Strain of 4 school of the Strain of 4 school of	
	j	for Three Avirulent Mutants", J Bacte iol, 1985 May; 162(2):504-509	
	1		
	AW	- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	
	1	Conditioned by Aminosugars (author's transl), Rev Esp Fisiol, 1980 Jun;	
	J	ac(a) 155 1(1 (Abstract)	
		- 1 "Dulationship Datween Clycosis and Exopolysactifation	1
	J AX	Ramos et al, "Relationship Between Chycosts and Microbiol, 2001 Jan; Biosynthesis in Lactococcus Lactis", Appl Environ Microbiol, 2001 Jan;	
	<b>"</b>		
l		67(1):33-41 (Abstract)  Bhaskar et al, "Dysregulation of Prote oglycan Production by Intrahepatic  Compared to the Solar Control of Protection	
	AY	Bhaskar et al, "Dysregulation of Profit Ogrycan Profit of Profit Ogrycan Profit of Profit Ogrycan Profit Ogryca	1
	زا	Epithelial Cells Bearing Detective (detta-1506) Cystic Floresis Francisco	
	ľ	1 C Learne Deculator" Handfology (990 Jan. 27(1).1-1-4 (1000000)	
<del></del>	AZ		
!		(IMR-90) Maintained In A Low Concentration Of Setulit , Blockem 1 102	
			· · · · · · · · · · · · · · · · · · ·
	BA	- the Court Sulfation Of (avcosaminoglycal) And	į
	ΙBA	Altered Extracellular Matrix In A Mouse Model Of Cystic Fibrosis". Biochem	Ţ
Į.	- J		
		Welch et al, "Complex Saccharide Metabolism In Cystic Fibrosis Fibroblasts"	
	BB	Welch et al, "Complex Saccharide Wetabolish in Cystic Visions 1970 (Abstract)	
	1	n tr	
	BC	B. L. Lange et al. "Chondroitin Sulfate in Spullin Flori Fallents With System	
		Fibrosis and Chronic Bronchitis", Am J Respir Cell Mol Biol. 1991	1
	į ·	Oct;5(4):315-20. (Abstract)	
1		Oction 13 25 to the second	

		1
	Date	ļ
Examiner	Considered	
Signature		

Sheet

Approved for use through 10/31/99 OMB 0651-0031
Pa ent and Trademark Office U.S. DEPARTMENT Of COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respon to a collection of information unless it contains a valid OMB control number

#### Substitute for form 1449A/PTO Complete if Known Application Number INFORMATION DISCLOSURE 10/163,993 Filing Date STATEMENT BY APPLICANT June 7, 2002 First Named Inventor Yacoby-Zeevi Group Art Unit (use as many sheets as necessary) 1652 Examiner Name 4 of

		i of	15	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<del></del>
				Attorney Docket Number	02/23884
		OTHER PRIOR ART – NON PA	ATERTLITED	ATURE BOOK	
Examiner	Cite	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial se	TTER 3) title of the	ATURE DOCUMENTS	
Initials	No.1				
	BD	Reuth et al. "Lostin Martin L. Reuth et al. "Lostin Martin L.	y and/or country wh	ere published	T <sup>2</sup>
	1	J Death et al., Lectin-Wedlated Bacter	ial A lheeinn To	Human Tissue", Eur J	
	BE				
	100	Allison et al, "Polysaccharide Produc	ction n Pseudon	nonas Cepacia", J Basic	
	BF				
	0.	Albus et al, "Staphylococcus Aureus To Lung Infection In Patients With C	Capsular Types	And Antibody Response	
	1 "		ystic Fibrosis",	J Clin Microbiol, 1988	
	BG .				
- 6 <del>)</del>	100	Macone et al, "Mucoid Escherichia C	Coli Ir Cystic Fil	prosis", N Engl J Med.	
	BH				
2 +		Golberg et al, "An Improved Method Synthesized by Chondroovers in G. Iv	For Determinin	g Proteoglycans	
2	٠ ا	Synthesized by Chondrocytes in Culti 24:265-275, 1990	ure", Connective	e Tissue Research	
	BI				
	J.	Farnsdale et al, "A Direct Spectropho	tome⊧ric Microa	issay for Sulfated	
	V	Glycosaminoglycans in Cartilage Cul 9:247-248, 1982	tures' , Connecti	ive Tissue Research.	
	BJ /			The state of the s	
	BJ 🕖	Sutherland, Ian W., "Structure-Function Expression of the Property of the Prop	on Relationships	s in Microbial	
	BK	2 Ropolysaccitatines . Biorpen 4 do 1	<i>)</i> -302 440 1064		i
}	/	Tatnell et al, "Characterisation of Alg	inates from Muc	coid Strains of	
	BL /	1 secucional Aeruginosa Riochem	Sou Teams 24.	4040 1004	
[	v	Tatnell et al, "Chemical Analysis of A	Igina:es from M	lucoid Strains of	
	ВМ	Pseudomonas Aeruginosa", Biochem.	Soc. <i>Frans.</i> , 22:	310S, 1994	
	V	Tatnell et al, "Colonisation of Cysytic	Fibresis Patient	s by Non-Mucoid	
	١	Pseudomonas Aeruginosa – Character Variants", Biochem. Soc. Trans., 24:40	isation of the Al	ginate from Mucoid	
		Z - Trink Jarai	IAN TOUA	· · · · · · · · · · · · · · · · · · ·	
	1	P. Ducy et al "The Osteoblast: A Sop Surveillance Science Vol. 380 Same	histicated Fibro	blast under Central	
	BO	Surveillance, Science, Vol. 289, Septe	mber 1, 2000, p	p. 1501 – 1504	}
1	ľ	Drigues et al, "Comparative Studies of Exopolysaccharide from a Viruleant Sc	Lipopolysaccha	aride and	
		Exopolysaccharide from a Virulaent St from Three Avirulent Mutants", J Bacch Macone et al. "Muscid Foots."	rain of Pseudon	nonas Solanacearum and	
	BP	Macone et al. "Mucoid Eschariobia Co	eriology, May,	1985, pp 504-509	
		Macone et al. "Mucoid <i>Escherichia Co</i> Medicine, 304(24):14445-1449	u in Cystic Fibr	osis". New England J	
(	BQ	Ofek et al, "Bacterial Adhesion to Cell	and Tigoua" C		
\		Pub. 1994, pp 114-118, 148-153, 418-4	s and Tissue", C	napman & Hall, N.Y.,	
			10.740-423		

Examiner		
Signature	Date	
	Considered	

Sheet

# PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trudemark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB centrol number. Substitute for form 1449A/PTO Application Number 10/163,993 June 7, 2002 Filing Date INFORMATION DISCLOSURE Yacoby-Zeevi First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1552 Examiner Name (use as many sheets as necessary) C2/23884 Attorney Docket Number

6

of

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
·		Lada a series of the author (in CADITAL LETTERS), little of the article (when	
Examiner	Cite		$T^2$
Initials	No.	date page(s) volume-issue number(s), publisher city and/or country where published	
	BR,	Reddi, A. Hari, "Role of Morphogenetic Proteins in Skeletal Tissue	
		Engineering and Regeneration", Nature Liotechnology, Vol. 16, March	
		1998, pp. 247 – 252	
,	BS I	L.A. Dempsey et al., "Heparanase, A Poter tial Regulator of Cell-Matrix	
<i>J</i>		Interactions", Trends in Biochem Sci, 25:349-351, 2000	
	(BT)	Elkin et al., "Heparanase as Mediator of Angiogenesis,: mode of action",	
		The FASEB Journal, 15: 1661-1663, 2001	
	BU !	Elkin et al., "Heparanase as Mediator of Angiogenesis,: mode of action",	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	The FASEB Journal. Published online May 29, 2001	
::	BV	E. Finkel, "Portential Target Found for Antimetastasis Drugs", Science.	
	$ BV_j $	Vol., 285,	
		July 2 1999 pp. 33 – 34	
	BW	L Vlodavsky, et al. "Mammalian Heparanase: Gene Cloning, Expression	
7	,	and Function in Tumor Progression and Metastasis", Nature Medicine,	
$\cdot \mathcal{J}$	J . V	Vol. 5, No. 7, July 1999, pp. 793 – 802	
	(DV)	Webster et al., FGFR Activation in Skeletal Disorders: too much of a	
	(BX	good thing, <i>TIG</i> , May 1997, Vol. 13, No. 5, pp. 178 – 182	
	BY	Procken D.I. "Marow Stromal Cells as Stem Cells for	
√	D.	Nonhematopoietic Tissues" Science, Vol. 276, 4 April 1997, pp. 71 - 74	
	BZ)	Syndecan-3 and the control of chondrocyte promeration	
	150	during endochondral ossification", Exp. Cell. Res. 1996 Nov. 25:229:1,	1
		nn 126 - 136 (Abstract)	
	CA	E. Blanquaert et al. "CMDBS, functional analogs of sulfate heparanes,	
		used as osseous cicatrizing agents", Ann. Endocrinol (Paris) 1994 55:2	
		pp 121 – 123 Abstract)	
	CB;	F. Blanquaert et al., "Heparan-like molecules induce the repair of skull	
1		defects" Rone 1995. December 17:6 pp. 499 – 506 (Abstract)	<del></del>
	CC	Muir et al. 'Histomorphometric Analys's of the Effects of Standard	1
		Heparin on Trabecular Bone in vivo", Flood, August 15.	
		1996:88(4):1314 - 1320 (Abstract)	L

		1
	Date	1
Examiner	Considered	1
Signature	Considered	.1

Sheet

6

of

# PTO/SB/08A (10-96)

02/23884

Approved for use through 10/31/99 OMB 0651-0031

Attorney Docket Number

Patent and Trademark Office; U.S. DEPARTMENT Of COMMERCE

6

Cite No. <sup>1</sup>	title of the item (book, magazine, journal, serial s/mposium, catalog, etc.) date, page(s)	T²
CD)	Hoffman et al, "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J.	
CE \	Imai et al, "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule	
CF	Loredo et al. "Regulation of Glycosamino glycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am J Vet Res, 57(4):554-559, 1996	
<u>c</u> G	Kiberstis et al, "Bone Health in the Balance", Science, 289:1497, 2000	
(CH)	Service, R.F., "Tissue Engineers Build New Bone", Science, 289:1498-1500, 2000	
<del> </del>		
	CD :	title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s) volume-issue number(s), publisher, city and/or country where published.  CD Hoffman et al, "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem., 237(1):295-302, 1996 (Abstract)  CE Maie et al, "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J Cell Biol., 143(4):1113-1128, 1998 (Abstract)  CF Loredo et al, "Regulation of Glycosamino glycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am J Vet Res, 57(4):554-559, 1996  CG Kiberstis et al, "Bone Health in the Balance", Science, 289:1497, 2000  CH) Service, R.F., "Tissue Engineers Build New Bone", Science, 289:1498-1500, 2000

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAM/INER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burder Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office. Washington, EC 20231.

DO NCT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached



Approved for use through 10/21/99 OMB 0651-0031

Pate it and Trademark Ciffice U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Application Number T10/137,351 Substitute for form 1449A/PTO May 3, 2002 Filing Date INFORMATION DISCLOSURE Ayal-Hershkovitz et al First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit

		(use as t	nany she	ets a.	s necessa	(ירָ <i>י</i> )	1		er Name			
Sheet	Tī	(		$\neg$	of		1	Attorney	Docket Number	02/2	23665	
oneet												
					U.S.	PATENT I	OCUMENT	<del>5</del>				
		U.S. Patent Document			4						Pages, columns, lines, Where Relevant	
Examiners nitials	Cite No.	Number Kind Code (if known)			Name of Patentee or Applicant of Cited Document		or Applicant :ument	Date of Publication of Cited Document MM-DD-YYYY		of	Passages or Relevant Figures Appear	
	AA	4,946,	778 T		Ladner e	et al			08-07-1990			
	AA	1,710,				cope -	1-10					
	ļ	<del> </del>										
	ļ											
	ļ	ļ										
											<del> </del>	
					ļ			-+			<del> </del>	
	<u> </u>			L	<u> </u>							
					EODE	ICN PATE	NT DOCUM	IENTS		•		
		Fore	ign Patent	Docu		IGNIAIL	III Bocom					1
Examiners Initials	Cite No. 1		Number <sup>a</sup>		ind Code? if known)		of Patentee or of Cited Docum	ient	Date of Publication of Cited Document MM-DD-YYYY		Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	1
	+	<del> </del>										+-
	+	<del> </del>		$\top$								╁╴
	-+									-+		+-
	<u> </u>	1										+
				_ _		!						+
			<u></u>	L_		<u></u>			l			
Examine	r								Date Considered			

Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible Sapplicant is to place a check mark here if English language Translation is attached.

File Copy

Please type a plus sign (+) inside this box → 🗵

# PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 09/988.113 Application Number March 1, 1999 Filing Date INFORMATION DISCLOSURE First Named Inventor Pecker et al STATEMENT BY APPLICANT Group Art Unit 1652 Hutson, Richard G. Examiner Name (use as many sheets as necessary) Attorney Docket Number 01/22781 3 of Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines. Where Relevant Kind Code<sup>3</sup> Date of Publication of Name of Patentee or Applicant Number Examiners Cite Passages or Relevant Cited Document Figures Appear of Cited Document Initials MM-DD-YYYY 10-19-1999 5.968.822 Pecker et al 11-08-1994 5,362,641 Fuks et al 05-14-2002 Heinrikson et al 6,387,643 11-18-1997 Powell et al 5,688,679 06-05-2001 Freeman et al 6,242,238 FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines. Date of Publication of Name of Fatentee or ፐ Examiners Where Relevant Cited Document MM-DD-YYYY Applicant of Cited Document Office3 Number\* Initials Passages or Relevant Code<sup>2</sup> Figures Appear (if known) 02-09-1995 Hoogwerf et a WO 95/04158 Date Examiner Considered Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651 0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE formation unless it contains a valid OMB control number

der the Paperwo		Act of 1995, no persons are required to respond to	a contection of information a	Complete	if Known							
		stitute for form 1449A/PTO	Application Number	09/988,								
	TRITIC	DRMATION DISCLOSUI	R IE	Filing Date	March							
	INFC	JRIMATION DISCLOSES	NT	First Named Inventor	Pecker	et al						
	STA	TEMENT BY APPLICAN	11	Group Art Unit	1652	<del></del>						
	,	use as many sheets as necessary)		Examiner Name	Hutson	, Richard G.						
	·	·	3	Attorney Docket Number	01/227	81						
heet	2	of	ON DATENT LITER	RATURE DOCUMENT	S							
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scrial symposium, catalog, etc.) date, page(s), volume-issue number(s).										
xaminer	Cite				nber(s).	L;						
nitials	No.											
	1	Ernst et al, "Enzymatic Degradati	ion of Glycosamino	grycans , Crincai rev. s	•							
	_ <u>i</u>	Biochemistry and Mol. Biology, 3	30(5):38 -444, 1993	chamistre and Biotechno	logy,							
		Linhardt et al, "Polysaccharide Lyases", Applied Biochemistry and Biolectinology										
		12:135-176, 1986  Kosir et al, "Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", J.										
		Surgical Res., 67:98-105, 1997  Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degrative  Consular of Human Neutrophils"										
		Mollinedo et al, "Major Co-Localization of the Extracellulal-Matrix Begiant Benzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils",										
		l n: 1 227.017 023 1007										
	_}	To Tr 1 "Immunocelectic	on of GR 294/Endopl	asmin from a KNRK								
	1	1 C-11 Chanific 2 at 11 Library Usir	ng Antibodies Direct	ed Agamsi a i dianve								
		L I I Amino Torminal Pe	ntide lill J. Cance	7. 30.200-27-17-1								
		Heparanase Amino-Terminal Peptide", Int. J. Cancer, 56:286-294, 1994  Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion:										
		late the second of Hangrange ACIIVIIV And riedal allase Degladation of										
		G C II Culfoto Suppopulations" (ancer Research, 50.2050-2005, 1225										
		Marchetti et al, "Neutrotrophin Stimulation of Human Melanonia Cent invasion."										
	Ì	a to the band mont of Hengrange Activity and Heparaliase Degradation of										
	-	Specific Heparan Sulfate Subpopulation:; , Advances in Enzyme Regulation,										
		00.11.124.1007										
		Jin et al, Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer, 45:1088-1095, 1990										
		Melanomas", Int. J. Cancer, 45 Fairbanks et al, "Processing of	:1088-1093, 1990	ase Precursor and Evide	nce that							
		T - Ileterne	limet"   KIOI (NP)	カー・ムノサいサムト・ムフンロフニケノンノ	·							
		Toyoshima et al, "Human Hepa	range" I Riol Ch	em. 274(34):24153-241	60, 1999	L						
		Hoogewerf et al, "CXC Chemo	okines Connective T	issue Activating Peptide	-III and							
		Neutrophil Activating Peptide-	2 are Heparain/Hepa	aran Sulfate-degrading								
		22 1 Dial Cham 27	10(7) 326X-3277. 19	90		<del> </del>						
		Freeman et al, "Evidence that I	Platelet and Tumour	Heparanases are Simila	r							
, 		1 - 1 - 1 - 1 - 1 - 1 - 1 - 2 d O t 2 d	11.16X 1000									
	<del></del>	Translation 1 1 163 (amounting	Hanaranuse (iene (	Cloning, Expression and	runction	1						
		l · m D and Met	actacie" Nature Nec	alcine, $oralling or oralling or oralling or oralling or oralling or oralling or or or or or or or or or or or or or $		+						
<del> </del>		II less at al "Cloning of Mami	malian Henaranase,	an important Litzyme m	ıumor							
		1 Material Control of the State	we Medicine 31/13	ひろ-00プ、1フフフ		+						
		- 1	melavity Profesh SII	menne rieuleuon, and a	it rtian:							
1		La Line Danadow' Chan 14	trom "Tre Protein I	Olully I loolem and Ic.	uury							
		Competence Production' Merz and Leurand, Eds., Blikauser, Boston, 1991										
		Oldborg et al. Characterization of a Platelet Endogrycosidase Degrading										
į			" Dinchemictor 14"	7/77-1/0Z. 170V	Gene"							
		Vuccia et al "Cloning and Fut	nctional Expression	of a riuman ricparanase	Jone ,							
1	<u> </u>	Biochem. And Biophysical Res. Comm., 261:183-187, 1999										
Examine	- 1			Conside		1						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2 () hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE aformation unless it contains a valid OMB control number.

r the Paperwor	k Reduction	Act of 1995, no persons are required to respond to	a conection of information uni	Complete	if Known							
		stitute for form 1449A/PTO	Application Number	09/988,1								
			R)F.	Filing Date	March 1,							
	INFO	DRMATION DISCLOSU		First Named Inventor	Pecker et	al						
	STA	TEMENT BY APPLICAN	Z I	Group Art Unit	1652	<del></del>						
		use as many sheets as necessary)		Examiner Name	1	Richard G.						
	(		13	Attorney Docket Number	01/2278	1						
eet	3	of OTHER PRIOR ART – No	ON DATINIT LITER	ATURE DOCUMENTS								
	<u></u>	OTHER PRIOR ART - NO	1 LETTERS), title of the	article (when appropriate), title	of the	$T^2$						
aminer	OTHER PRIOR ART - NOIN PATENT LITERATION.  Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.											
itials	No.	publisher. c	ity and/or country where p	ablished.	hin							
	<del> </del>	Walch et al. Correlation of Overe	expression of the Low	roduction in Human Ma	lignant							
	1	December with Anomented Invasi	on and resparations	ioduction in realist								
		Melanoma Cells", Int. J. Cancer, 82:112-120, 1999  Melanoma Cells", Int. J. Cancer, 82:112-120, 1999  Melanoma Cells", Int. J. Cancer, 82:112-120, 1999  Melanoma Cells", Int. J. Cancer, 82:112-120, 1999										
		Samples from Patients with Orotherial Carter by CD-4740										
		RT-PCR", Int. J. Cancer, 79(6):500-304, 1998 (abstract only)										
		Zhou et al. "A 182 bp Fragment	of the Middle product	" 1. Cell Science,								
	1	to Direct Chondrocyte Expression										
		108:3677-3684, 1995 Hormuzdi et al, "A Gene-Target	ing Approach Identif	ies a Function for the Fi	rst							
		Hormuzdi et al, "A Gene-Target Intron in Expression of the Alph	a 1(I) Collagen Gene	", Mol. Cell Biol.,								
		18(6):3368-3375, 1998 (abstract Only)  18(6):3368-3375, 1998 (abstract Only)  19										
	1											
		Human DNA Regulatory Elements for Transgelle Expression in Europe										
		Proc. Nat. Axad. Sci. USA, 94:14695-14700, 1997  Gottschalk et al, "Somatic Gene Therapy. Present Situation and Future Perspective",										
		1 11 al "Samatic Gene	- Therapy, Present 51	tuation and Future Persp	ective",							
		Ve et al "Targeted Gene Corre	ction: A liew sualeg	y for Molecular Medicir	ne",							
		Molecular Medicine Today, Oc Lai et al, "Homologous Recom	bination Based Gene	Therapy", Exp Nephrol	,							
		7(1):11-14, 1999 ( abstract onl	y)		C							
		Warning at al. "The structure and	d Expression of the r	GF Receptor-1 mRNA I	soiorms							
	1	in Rat Tissue", Biochemica et	Biophysica Acta, 117	2:37-42, 1993	irocinace	<u> </u>						
					Acad Sci	ļ						
		in Murine Melanomas: A Proje	ected Bas s for Immu	notherapy", Proc. Nati.	acuu. Dei.	1						
		USA, 94:5332-5337, 1997		CD-i NION	In Breast							
		Curios et al "CD44 Isoforms	with Exon v6 and Me	tastasis of rhinary indiv	10 Dieast							
		Gewirtz et al, "Nucleic Acid T	Therapeutics: State of	the Art and ruture rios	p.c ;							
						1						
			Fransfection Restrains	s Oral Cancel Invasion of I Parkol 50(6):2125-2	132, 1997							
		Reducing Matrix Metalloprote	emase Activities, An	IJ I uinor, 50(0).	•	<u> </u>						
		(abstract only) Shastry, BS, "Gene Disruptio	n in Mice Wodels of	9 1998	•	1						
	_	Molecular and Cellular Biochemistry, 181:163-179, 1998  Molecular and Cellular Biochemistry, 181:163-179, 1998										
		Competier et al "DNA Vaccination with Hull little of own of a state of the competition of										
	_\_	Mice", Clinical Cancer Research, et al, "DNA Vaccines",										
		Lai, et al, "DNA Vaccines",	Critical Keviews in In	Date								

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief I information Officer, Patent and Trademark Office, Washington, DC 20231 amount of time you are required to complete this form should be sent to the Chief I information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

# Please type a plus sign (+) inside this box $\rightarrow \boxtimes$

(10-96)

PTO/SB/08A

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Inder the Pape	work Red	uction Act of	1995, no pers	sons are required to	respond to a confection of information	Complete	:fV	$\neg \neg$
		Substitute	for form 144	19A/PTO		Application Number	09/978,297	$\dashv$
	117	ATTECO TO A	# A TOT C	N DISCL	OCUDE	Filing Date	10/17/2001	
						First Named Inventor	Yacobi-Zeevi	一
	S	TATE	MENT	BY APPI	LICANT	Group Art Unit	1633	-
		luse	ns manus	heets as nece	ssarv)	Examiner Name		
		(use a	- many s		4	Attorney Docket Number	01/22716	-
Sheet		<del></del>		Of	S. PATENT DOC JMEN'		101/22/10	-+
	,	II C Doton	t Document		S. PATENT DOC MEN	15	·	
Examiners Initials	No. (ii known)			je² Non	ne of Patentee or Apj licant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, line: Where Relevant Passages or Relevan Figures Appear	
	AA	5,688	,679	Powell		11-18-1997		
,	i			·				$\longrightarrow$
		<u> </u>						
_								
	_							
		Ţ						
	1							
					EIGN PATENT DOCUM	IENTS		<del></del> .
		Fore	ign Patent	Documents		Date of Publication of	Pages, columns, lines,	1
Examiners Initials	No. 1	O:Tice <sup>3</sup>	Numbe	r <sup>4</sup> K <u>in</u> d Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cite. Docum	1 17	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
·	AB	PCT	99/219		Australian Nat'l Jniver	sity 05-06-1999		
		<del> </del>						
								1
		1						
		<del> </del>						<u> </u>
		1	T				!	<u> </u>
Examine						Date Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent at d Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Ass stant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3 <sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the paten; document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if pos: ible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE pwork Reduction Act of 1995, no persons are required to respond to a collection of in ormation unless it contains a valid OMB control number.

Under the Paperwork	Reduction A	Act of 1995, no persons are required to respond to a col	lection of in ormation u	mless it contains a valid OMB control  Complete	of number.						
	Subs	titute for form 1449A/PTO		Application Number	09/978						
	T 170 C	STATE OF DIGGE COLUMN		Filing Date	10/17/						
		DRMATION DISCLOSURE		First Named Inventor	<del></del>	oi-Zeevi					
	STA	TEMENT BY APPLICANT		Group Art Unit	1633	91-Zeevi					
				Examiner Name ,	1033						
	(	use as many sheets as necessary)									
Sheet	2	Of	4	Attorney Docket Number		716					
		OTHER PRIOR ART – NON	PATEN'" LITEI	RATURE DOCUMENTS	3						
Examiner	Cite					2					
Initials	No.1					T <sup>2</sup>					
	BA	"The Merck Manual", R. Berkow, M	.D. Ed-in-Chief,	Merck Research Labora	tories,	}					
		1997, pp 201, 204, 1308, 177-179, 10	)16-101*, 194-1	97, 885, 601.							
	BB	Konstan et al, "Patterns of Medical P	ractice in Cystic	Fibrosis: Part III. Use of							
	<u> </u>	Therapies", Pediatr Pulmonol, 1999,	Oct; 28(4):248-	54 (Abstract)							
	BC	Frederiksen et al, "Antibiotic Traetm	ent of In tial Co.	ionization with Pseudomo	onas						
	i	Aeruginosa Postpones Chronic Infec	tion and Prevent	S Deterioration of Funito	herraet)						
	<u> </u>	Function in Cystic Fibrosis", Pediatr	Pulmon 11, 1991	manas Asmainasa infa	usuaci)						
	BD	Frederiksen et al, "Changing Epidem Danish Cystic Fibrosis Patients (197	11010gy of Pseudi	omonas Aerugmosa miet	tion m						
	1	28(3):159-166 (Abstract)	4-1995) . realai	ir raimonoi, 1999 Sep,							
	DE	Ramsey et al, "Intermittent Administ	ration of Inhale	d Tobramycin in Patients	with						
	BE	Cystic Fibrosis. Cystic Fibrosis Inha	led Tobranycin	Study Group" N Eng. J	Med.						
			ica rooi unyeur	Stady Group , m. 211g. o							
	BF	1999 Jan 7; 340(1):23-30 (Abstract)  Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular									
	DI.	Matrix by a Readiliy Released Hepa	ranase from Hur	nan Neutropiils. Possible	Role in						
		Invasion Through Basement Membr	anes", J. Clin. Ir	vest., 1985 Oct;							
		76(4):1306-1313 (Abstract)	,								
	BG	Bennett et al, "Effect of Uridine 5'-	riphosphate plu	s Amiloride on Mucocili	ary						
		Clearance in Adult Cystic Fibrosis",	Am J Respir Cr	it Care Med, 1996 Jun; 1	53(6 Pt						
		1):1796-7801 (Abstract)				<u> </u>					
	ВН	Vlodavsky et al, "Expression Hepar	anase by Platelet	ts and Circulating Cells o	f the						
		Immune System: Possible Involvem	ent in Di∶pedesi	is and Extravasation", Im	asion						
		Metastasis, 1992; 12(2):112-127 (A	bstract)			<u> </u>					
	BI	Naparstek et al, "Activated T Lymp	hocytes I roduce	a Matrix-Degrading Hep	oaran						
		Sulphate Endoglycosidase", Nature	, 1984 Ju y 19-2:	5; 310(5974):241-244 (A	bstract)						
	BJ	Armstrong et al, "Lower Airway7 In	ntlamation in Inf	tants and Young Children	i with						
		Cystic Fibrosis', Am J Respir Crit C	:are Mea 1997 (	Oct; 156(4Pt 1):1197-120	<i>)</i> 4						
		(Abstract)	- D	A amoinean Mindaga E-	etere to						
	BK	Tang et al, "Contribution of Specifi	c rseudo nonas a	Aeruginosa viruience ra	Insmun						
į		Pathogenesis of Pneumonia in a Ne	onatat ivi juse ivi	oder of fiffection, inject	ımmuri,						
	- PI	1996 Jan; 64(1):37-43 (Abstract)  Murray et al, "The Extracellular Ma	triv" found in L	Jamer's Riochemistry 2	4 <sup>th</sup> Ed						
	BL	Murray et al, "The Extracellular Ma McGraw-Hill Professional 1998, Cl	101X, 1011110 III F han 57 rn 667-	ται μοι ο υποσποπητού y, 2. 679	,						
ļ	DNA	Selvan et al, "Heparan Sulfate in In	mune Rusnonse	s" Annals New York Ac	ademy of	-					
	BM	Sciences, 797:127-139, 1996	anune in sponse	, //////////////////////////////////							
ļ	BN	Weller, Peter H., "Implications of F	arly Influmation	and Infection in Cystic	Fibrosis:						
	DIN	A Review of New and Potential Int	erventiors". Ped	diatric Pulmonology. 24:	143-146.						
1		1997			,						
Examiner	+			Date							
				Considered							
Signature	1					ermance and not cons					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance witl MPEP 609. Draw line through citation if not in conformance and not considered. In

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*\*</sup> Indeed the state of the patent documents and the state of the state attached.

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

14nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it centains a valid OMB control number.

Inder the Paperwork	Reduction	Act of 1995, no persons are required to respond to a colle	ection of information	unless it con	tains a valid OMB contro	number.
	Sub	stitute for form 1449A/PTO		A ==1:	Complete cation Number	
		SALL MIGHT BEGGE COUNTY				09/978,297
	INFO	DRMATION DISCLOSURE		Filing		10/17/2001
	STA	TEMENT BY APPLICANT			Named Inventor	Yacobi-Zeevi
					Art Unit	1633
	;	(use as many sheets as necessary)		Exam	iner Name	
Sheet	3	Of	4	Attorr	ney Docket Number	01/22716
	CA	Konstan, Michael W., "Current Under	standing of the	e Inflama	tory Process in Cy	stic
		Fibrosis", Pediatric Pulmonology, 24:	137-1-2, 1997	7		
	CB	Rubin, Bruce K., "Emerging Therapie	s for Cystic Fi	ibrosis Lu	ng Disease", Ches	st,
		115:1120-1126, 1999				
	CD	Pasquier et al, "Implication of Neutral	Polys iccharic	des Assoc	iated to Alginat	
. /		Inhibition of Murine Macrophage Res			Aeruginosa", FEI	us
		Microbiol Lett, 1997 Feb 15; 147(2):1	95-20: (Abstr	ract)		
7	CE	Marty et al, "Influence of Nutrient Me	edia on the Ch	emical Co	omposition of	_
_ (/		Exopolysaccharide from Mucoid and			Aeruginosa", FEA	AS
	<u> </u>	Microbiol Lett, 1992 Nov 1; 77(1-3):3	35-44 (Abstrac	<u>:t)                                    </u>		
/	CF	Drigues et al, "Comparative Studies o	of Lipopolysac	charide a	nd Exopolysaccha	ride
v/		From a Virulent Strain of Pseudomon	as Sola nacear	um and to	or Three Avirulent	
		Mutants", J Bacteriol, 1985 May; 162	2(2):50 1-509 (	Abstract	2 1 1 0 141	
	CG	Jorba et al, "Variations in the P. Aeru	ginosa Polysa	ccharide :	Synthesis Condition	hatract
<i>V</i>		by Aminosugars (author's transl), Rev	v Esp F (SIOI, I	980 Jun;	36(2):133-101 (A)	ostract)
$\nu$	СН	Ramos et al, "Relationship Between (	Jlycos's and E	xopolysa	ccharide Biosynu	iesis in
		Lactococcus Lactis", Appl Environ M	nerobiol, 2001	bation by	Introhonatio Enit	holial
/	CI	Bhaskar et al, "Dysregulation of Proto Cells Bearing Defective (delta-f508)	Custia Eibrosi	a Transm	mitanepatic Epiti	ance
~		Regulator", Hepatology, 1998 Jan; 27			emorate conduct	ance
<del></del>	CJ	Vogel et al, "Production Of Proteogly	veans F v Hum	ian I ung	Fibroblasts (IMR-	.90)
	103	Maintained In A Low Concentration	Of Serim" R	iochem J	1982 Dec 1:	
	İ	207(3):369-379. (Abstract)	Or Ser im , D	.001.011.0	., .,	
	CK	Hill et al, "Organ-Specific Over-Sulf	ation C f Glyc	osaminos	lycans And Altere	ed
LA C		Extracellular Matrix In A Mouse Mo	del Of Evstic	Fibrosis"	Biochem Mol Me	ed.,
U'	.	1997 Oct;62(1):113-22. (Abstract)			•	
	CL	Welch et al, "Complex Saccharide M	letaboli m In	Cystic Fil	rosis Fibroblasts"	
للمحملا		Pediatr Res. 1975 Sep:9(9):698-702.	(Abstr ict)			
	CM	Rahmoune et al, "Chondroitin Sulfat	e In Sp itum F	rom Patie	ents With Cystic F	ibrosis
		And Chronic Bronchitis", Am J Resp	oir Cell Mol Bi	iol. 1991	Oct;5(4):315-20.	
	.1	(Abstract)				
/	CN	Beuth et al, "Lectin-Mediated Bacter	rial Adl esion	To Huma	n Tissue", Eur J C	lin
V		Microbiol, 1987 Oct;6(5):591-3. (Ab	ostract)			
10	CO	Allison et al, "Polysaccharide Produc	ction in Pseud	omonas (	Cepacia", J Basic	
<i>V</i>		Microbiol, 1994; 34(1):3-10 (Abstra	ct)			
/	/ CP	Albus et al, "Staphylococcus Aureus	Capsu ar Typ	es And A	intibody Response	: То
V	-	Lung Infection In Patients With Cys	tic Fibr (sis ", .	J Clin Mi	<i>crobiol.</i> 1988 Dec	;
· <del></del>		26(12):2505-9. (Abstract)				
$\overline{}$	CQ	Macone et al, "Mucoid Escherichia	Coli In Cystic	Fibrosis"	, N Engl J Med. 1	981 Jun
		11;304(24):1445-9. (Abstract)				<del></del>
Examiner					Date	
Signature					Considered	!
I. IFVALABLES			Tables with MOTO	COO Draw	no through citation if a	ot in conformance and not con

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will lary depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent an : Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assiltant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3 For Japanese patent documents, the indication of the year of the reign of the Emperor nust precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Diegce type a nius s	cion (+) in	side this box $\rightarrow \boxtimes$	PTO/SB/08A (	10-96)
riedse type a plus :	31511 ( · ) 111.			ough 10/31/99 OMB 0651-0031
•		Patent a	nd Trademark Office: U.S. DI	PARTMENT OF COMMERCE
Linder the Paperwork	Reduction .	Act of 1995, no persons are required to respond to a collection of a tformation un	less it contains a valid OMB contro	if V nour
	Subs	stitute for form 1449A/PTO	Complete	
			Application Number	09/978,297
	INFO	DRMATION DISCLOSURE	Filing Date	10/17/2001
		TEMENT BY APPLICANT	First Named Inventor	Yacobi-Zeevi
	SIA	TEMENT DI ALI EICANI	Group Art Unit	1633
	(	use as many sheets as necessary)	Examiner Name	1
Sheet	3	Of 4	Attorney Docket Number	
	DA	Golberg et al, "An Improved Method For De ermining	Proteoglycans Synthesis	zed by
\/		Chondrocytes in Culture", Connective Tissue Research	, 24:265-275, 1990	
<del></del>	DB	Farnsdale et al, "A Direct Spectrophotometric Microas	say for Sulfated	
\ \/		Glycosaminoglycans in Cartilage Cultures", Connectiv	re Tissue Research, 9:24	7-248,
		1982		
<del></del>	DC	Sutherland, Ian W., "Structure-Function Relationships	in Microbial	
	DC	Exopolysaccharides", Biotech Adv., 12:393-48, 1994	1	
<u>v</u>	DD	Tatnell et al, "Characterisation of Alginates rom Muc	oid Strains of Pseudomo	orias
1	טט	Aeruginosa", Biochem. Soc. Trans., 24:4045, 1996	old Bilding of 7 bendenie	
	<u> </u>	Tatnell et al, "Chemical Analysis of Alginates from M	usoid Strains of Pseudo	monas
	DE	Tamell et al, "Chemical Analysis of Algulatics from the	deold Saains of 1 seado	montas
<i>y</i>	<u> </u>	Aeruginosa", Biochem. Soc. Trans., 22:3105, 1994	a har Nam Musaid	
part.	DF	Tatnell et al, "Colonisation of Cysytic Fibro is Patient	s by Non-Mucold	innto"
V	[	Pseudomonas Aeruginosa - Characterisation of the A	iginate from Mucold Va	riants ,
L	<u> </u>	Biochem. Soc. Trans., 24:406S, 1996	in IP	
	‡∑DG	Drigues et al, "Comparative Studies of Lipo polysacch	aride and Exopolysacch	aride
+		from a Virulaent Strain of Pseudomonas Soi anacearu	m and from Three Aviru	nent
		Mutants", J Bacteriology, May, 1985, pp 50 4-509		
	DH	Macone et al, "Mucoid Escherichia Coli in Cystic Fib	rosis", New England J	l l
V	4	Medicine, 304(24):14445-1449		
	DI	Ofek et al, "Bacterial Adhesion to Cells and Tissue",	Chapman & Hall, N.Y.,	Pub.
or .	[	1994, pp 114-118, 148-153, 418-418, 420-423		
	DJ			
Examiner	<del>                                     </del>		Date	
Signature			Considered	
Cignature				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through ditation if not in conformance and not considered, in this form with next communication to applicant.

yrden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will hary depending upon the needs of the individual case. Any comments on the amountuired to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. To NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number, 2. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ 

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT O 'COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requ nd to a collection of information unless it contains a valid OMB control number.

### Complete if Known Substitute for form 1449A/PTO Application Number 119/978,297 INFORMATION DISCLOSURE Filing Date October 17, 2001 First Named Inventor Yacoby-Zeevi STATEMENT BY APPLICANT Group Art Unit .652 **Examiner Name** Richard G. Hutson (use as many sheets as necessary) Attorney Docket Number 01/22716 of Sheet

ILS. PATENT DOCUMENTS

					U.S. PATENT DOCUMENTS		
		U.S. Pat	ent Docur	nent			
Examiners Initials	Cite No.	Numbe	ner Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines Where Relevant Passages or Relevant Figures Appear
RU	AA	5,96	8,822		Pecker et al	10-19-1999	
						RI	CEIVED
					·	M	(_0_1_ <sub>2003</sub>
						TECH CL	TER 1600/2900
				-			
		İ					
			0	THER	PRIOR ART - NON PATENT LITER	ATURE DOCUMENTS	
Examiner Cite Include name o			Include r	ok, mag	the author (in CAPITAL LETTERS), title of the a azine, journal, serial symposium, catalog, etc.) da publisher, city and/or country where pr	article (when appropriate), title of te, page(s), volume-issue numb or ublished.	(s), T <sup>2</sup>
	A	B	Cizaki, e	t al, E	epression of Heparanase mRNA in Bov	ine Placenta During Gest it	ion,
1 0 1					oduction and Fertility, 2001, Vol. 121,		

Initials	No.	publisher, city and/or country where published.	
	AB	Kizaki, et al, Expression of Heparanase mRNA in Bovine Placenta During Gest tion,	
RV		Journal of Reproduction and Fertility, 2001, Vol. 121, pp. 573-580	
			www.marre.com.com.com.com.com.com.com.com.com.com
	<b> </b>	1	

		71 L	F/II			
Examiner	/	11	1	10/	Date	119/03
Signature	[7	111.1	18/ 6	4	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Wilshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, CC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO). Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

				OIY!	She	et	2_of_2_					<del></del>
Form P1	ΓO-1	449	(Modified	) ( MAX 5 2	2000 25		Atty. Docket No. Application No. 910/26 09/487,716					
INI	FOR	MA SFI	TION DI IN AN A	ISCLOSURE OF PPLICATION HEETS IF NEO	CITATION		oplicant: (aty AYAL-)	HERSHKOVI	TZ e	et al		٠.
. (	JUL :	J.D.	Did Lo Gi	IDDION NDC			ling Date: inuary 19, 20	000		Group Ar	t Unit	
	-				U.S. PA	TEN	NT DOCUM	ENTS				
	EXA		NER	DOCUMENT NUMBER	DAT	E		NAME		CLASS	SUB- CLASS	FILING DATE
ВА									į			
					FOREIGN	PA:	TENT DOCU	JMENTS				
	DOCUMENT DATE NUMBER					С	OUNTRY	CLASS	ຮບ	B-CLASS	TRANS	SLATION
										`	YES	NO
88			<del></del>									
	1			OTHER AR	T (Including	Aut	hor, Title, Da	ite, Pertinent Pa	iges,	Etc.)		
BCC	Ϊ_	1	nd the Ba 2883, 19	asement Memb	orane Form of	Нер	paran Sulfate	reen the Alzeim Proteoglycan",	, J Bi	olog Chen	n, 266(20)	r Proteins :12878-
BD	Ц.							J Cellular Bioc				
BE <sub>.</sub>		D	Prnitz et : Krisaccha	al, "FGF Bindi rides", <i>Science</i>	ing and FGF I e, 268:432-43	Rece <sub>]</sub>	ptor Activation	on by Synthetic	Нер	aran-Deri	ved Di- an	d
BF		W	Rapraege Differenti	r et al, "Require tation", Science	rement of Hep e, 252:1705-1	aran 709,	Sulfate for l	FGF-Mediated	l Fib	roblast Gr	owth and I	Myoblast
BG		M	Vlodasky Extracelli	et al, "Lymph	oma Cell Me	diate Tum	d Degradation	on of Sulfated Pustasis", Cancer	roted Res	oglycans in ., 43: 2704	n the Sube 1-2711, 19	ndothelial 83
ВН			Vlodavsk 24:464-4	y et al, "Invol	vement of He	parar	nase in Tumo	or Metastasis an	ıd Ar	ngiogenesi	s", Israel	J. Med Sci,
ВІ		V	/ Zhong-Sl E-Enrich	neng et al, "Ro ed Remnant L	le of Heparan	Sul:	fate Proteogl tured Cells",	ycans in the Bi	nding 1, 26	g and Upta 8(4):10160	ke of Apo 0-10167, 1	lipoprotein 993
BJ		M	/ Vlodavsk	cv et al. "Extra	cellular Matri	x-Bo	ound Growth	Factors, Enzyr nes, Academic	nes,	and Plasm	a Proteins	,,
BK	M	- 233						Arteriosclerosi				
BL		7		<del></del>								
ВМ		$\top$	_									
BN	T	1										
ВО	-	+										
EXA		ER		lees	00_		DATI	E CONSIDERE	D	4/29/	7	
EXAN	MINI	ER:	Initial if r	eference consid	ered, whether o	or not	citation is in	conformance wit	th MI	PEP 609; D	raw line th	ough citatio
if not	in co	nfo	rmation a	nd not considere	ed. Include cop	y of t	inis form with	next communica	auon	to applican	l.	

			ام ن	U	SHE	;⊭l I UI	۷				
Form F	PTO-	1449	(Modified)			Atty. Docket 910/16	Applicat 09/260		(II		
		I	TION DISCLOS N AN APPLICA ERAL SHEETS I	TION PROTE	\	Applicant: Maty AYA	L-HERSHK(	OVITZ (	t al	<del>U</del>	<del>[</del> ]
•	002	SB,		Ye in		Filing Date: March 2, 1	999		Group A	art Unit:	
				المُحَاثِ	S. PA	TENT DOCU	MENTS				
		CAMINER DOCUMENT DATE NAME INITIAL NUMBER							CLASS	SUB- CLASS	FILING DATE
AA											
,	·L			FORE	IGN	PATENT DO	OCUMENTS				
		-	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB-0	LASS	TRANS	LATION
			NUMBER					YES	NO		
AB				<u> </u>			-				
			OTHE	R ART (Inclu	ding /	Author, Title,	Date, Pertinent	t Pages,	Litc.)		
AC	W	pl~	Burgess et al, " Biochem, 58:57		Bindin	ig (Fibrob¹ast	) Growth Facto	r Family	of Protei	ns", Annu	Rev
AD		٠.	Campbell et al, Phenotype". Ex	"Heparan Suli Sperimental Ce	fate-E	Degrading Enz	ymes Induce N 5-167, 1992	Modulati	n of Smo	ooth Musc	le
AE		;	Gordon-Cardo Laboratory Inv	et al, "Express estigation, 63:	ion o 832-8	f Basic Fibrob 340, 1990	olast Growth Fa	actor in 1	ormal H	uman Tiss	ues",
AF		,	Eisenberg et al Surface and Ex	, "Lipoprotein tracellular Ma	Lipas trix",	e Enhances B J. Clin. Inves	inding of Lipo 1., 90:2013-202	proteins 21, 1992	o Hepara	an Sulfate	on Cell
AG			Folkman et al, Within Baseme	"A Heparin-Bi ent Membrane"	nding ', <i>Am</i> .	Angiogenic  J. Path., 130	Protein-Basic I (2):393-400, 1	Fibroblas 988	Growth	Factor-Is	Stored
AH			Folkman et al,	"Angiogenic F	actor	s", Science, 2	35:442-447, 19	87			
Al		``.	Gitay-Goren et on Cell Surface	al, "The Bindi -Associated H	ng of epari	Vascular End n-Like Molec	dothelial Grow ules", <i>J. Biol.</i> (	th Factor	to its Re (7(8):609	ceptors is 93-6098, 1	Dependent 992
AJ		:	/Ishai-Michaeli Grwoth Factor 2088, 1992	et al, "Importa from the Vasc	nce o ular F	of Size and Su Endothelium a	lfation of Hepa nd Extracellula	arin in Re ar Matrix	e ease of l	Basic Fibromistry, 31	oblast :2080-
AK			Jackson et al, " Phsiological Pr	Glycosaminog ocesses", Phys	lycan iolog	s: Molecular gical Rev, 71(2	Properties, Pro 2):481-539, 19	tein Inte 91	ractions,	and Role i	n 
AL		,	Kjellen et al, "	Proteoglycans:	Struc	ctures and Inte	eractions", Ann	u Rev B	icchem, 6	0:443-475	, 1991
AM			Liotta et al, "T 1983	umor Invasion	and t	he Extracellu	lar Matrix", La	boratory	v Investig	ation, 49(6	5):636-647,

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to a pplicant.

Readily Released Heparanase from Human Neutrophils", J. Clin Invest, 76:1306-1313

Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes

AN

ΑO

MAR

**EXAMINER** 

1997

pmo

Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial E2 tracellular Matrix by a

Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem J., 327:917-923,

DATE CONSIDERED

11/20/00

Sheet \_\_2\_\_ of \_\_\_2\_ Form PTO-1449 (Modified) Atty. Docket No. Application No. 09/260,038 910/16 Applicant: INFORMATION DISCLOSURE CITATION Maty AYAL-HERSHKOVITZ e. al IN AN APPLICATION F (USE SEVERAL SHEETS IF NECESSAR) Filing Date: Group Art Unit: V. ... March 2, 1999 1652 **W.S. PATENT DOCUMENTS** DOCUMENT **EXAMINER** DATE NAME CLASS **FILING** SUB-NUMBER INITIAL DATE **CLASS** BA FOREIGN PATENT DOCUMENTS **TRANSLATION** DOCUMENT DATE COUNTRY **CLASS** SUB CLASS NUMBER NO YES BB OTHER ART (Including Author, Title, Date, Pertinent Pages, Ec.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", J Biolog Chem, 266(20):12878-BCC 12883, 1991 Nakajima et al, "Heparanases and Tumor Metastasis", J Cellular Biochem, 30:157-167, 1988 BD ΒE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 Rapraeger et al, "Requirement of Heparan Sulfate for bFGF-Mediated Fibrol last Growth and Myoblast BF Differentiation", Science, 252:1705-1709, 1991 Vlodasky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteogly cans in the Subendothelial BG Extracellular Matrix: Relationship to Tumor Ccll Metastasis", Cancer Res., 43: 2704-2711, 1983 Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angio genesis", Israel J. Med Sci, BH 24:464-470, 1988 Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein BI E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem. 268(4:10160-10167, 1993 Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", BJ Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-2(, 1989) BK BL вм RN во 11,20,00 Lueis DATE CONSIDERED **EXAMINER** 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ('09; Draw line through citation

if not in conformation and not considered. Include copy of this form with next communication to applicant.

if not in conformation and not considered. Include copy of this form with next communication to applicant.

· :.	1449 (N	Nodified)			Atty. Docket	No.			c ication No. / 260,037		
	IN	ON DISCLOSU AN APPLICAT RAL SHEETS IF	ION		Applicant: Oron YAC	OBY-ZEEVI	et al	- <b>-</b>			
_					Filing Date: March 2, 1	999		Gro 164		art Unit:	-
			U.S	. PAT	TENT DOCU	MENTS		ــــــ			
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE		ŀ	NAME		CLAS	s	SUB- CLASS	FILING DATE
ВA											
			FOREI	GN F	PATENT DO	OCUMENTS					
		DOCUMENT NUMBER	DATE	С	COUNTRY	CLASS	SUB-0	CLASS		TRANS	LATION
				<u> </u>						YES	NO
13B											
	· · · · · · · · · · · · · · · · · · ·	OTHER	ART (Includi	ng A	uthor, Title.	Date, Pertinent	Pages,	Etc.)			
BC	]	Pomahac et al, "	Tissue Enginee	ering	of Skin", Cri	it Rev Oral Bio	l Med, 9	(3): 3:	3-3	344, 1998	(abstract)
BD	Benathan et al, "Living Epidermal and Dermal Substitutes for Treatment of Sc verely Burned Patients", Rev Med Suisse Romande, 118(2): 149-153, 1998 (Abstract- art in I rench)										ed
BE	1	Wang et al, Basic Fibroblast Growth Factorn Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", J. Orthop Res, 14(2): 316-23, 1996 (abstract)									
BF	/ i	Duffy et al, "Maximizing Flap Survival in a Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", <i>Microsurgery</i> , 17(4): 176-179, 1996 (abstract)									
E.G	1	Garner WL, "Ep .35-139, 1998 (a	idermal Regula abstract)	ation	of Dermal Fi	broblast Activ	ity", Pla	st Rec	ms	tr Surg, 1	02(1):
E.H	I	Raghunath et al, Surg Int, 12(7):	Cultured Epith 178-483, 1997	elial (absti	Autografts: I	Diving from Su	irgery in	to Ma	rix	Biology"	, Pediatr
ВІ	19	Myers et al, "Tra 33, 1995 (abstrac	insplantation o	f Ker	atinocytes in	the Treatment	of Wou	nds", <i>,</i>	lm	J Surg, 17	70(1): 75-
200	H	Kawaja et al, "Er Central Nervous	mployment of I System", Gene	Fibrol et Eng	blasts for Ge g (NY), 13: 2	ne Transfer: A 05-220, 1991 (	pplication	ons for )	Gr	afting into	the
EK	1 1	Maillard et al, Pr Mediated Gene	e-Treatment w Transfer to the	ith El	lastase Impro ial Media", (	ves the Efficie Gene Therapy,	ncy of F 5: 1023-	ercuta 1030,	nec 199	ous Adeno 98	ovirus-
EL	7	Vang, JS, "Basic Conductive Impl	Fibrblast Gro ants", Acta Ori	wth F	Factor for Sti Scand Suppl,	mulation of Bo 269: 1-33, 100	ne Form 06 (abstr	nation ract)	n (	Osteoindu	ctive or
ВМ	7	Wang, JS, "Basion or Corporation of The Corporation	Fibrblast Gro tanium Chamb	wth F	actor Infuse udy in Rats",	d at Different 7	Γimes D Scand, 6	uring 1 7(3): 2	  }on  29-	e Graft 236, 1996	5 (abstract)
BN	I	nui et al, "Local Segmental Bony	Application of	f Basi	ic Fibrblast C						<del></del>
во											
EXAM	IINER				DATE	CONSIDERE	D				
EXAM if not in	INER: Initia conformatio	if reference cons on and not conside	idered, whether ered. Include cop	or not	t citation is in this form with	conformance wi	th MPEP ation to a	609; I	rav	v line thro	igh citation

Sheet 3 of 4

	09/2 50,03 /	
Applicant: Oron YACOBY-ZEEVI et al		

· · · · · ·	П	N AN APPLICA	URE CITATION TION F NECESSARY)		Applicant: Oron YAC	OBY-ZEEVI	et al			
•					Filing Date: March 2, 1	999		Grou > A 1643	Art Unit:	
			U.S	. PA	TENT DOCU	MENTS	·			
	EXAMINEI INITIAL	DOCUMENT NUMBER	DATE		l	NAME		CLAS:	SUB- CLASS	FILING DATE
C:A										
			FOREI	GN	PATENT DO	OCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB-0	CLASS	TRANSI	_ATION
		· · · · · · · · · · · · · · · · · · ·							YES	NO
C:B										
	н — — — — — — — — — — — — — — — — — — —	OTHE	R ART (Includ	ing A	Author, Title,	Date, Pertinent	Pages, l	Etc.)		
CD			Bone Regenerati Iomaterials, 19(1				actor Co	mplex-:d	with Biode	gradable
CE			l, " Stimulates E , 1989 (abstract		Formation. B	one Induction	Studied	in Rats',	Acta Ortho	op Scand,
CF	J	Aspenberg et a in Rats", Acta	l, "Dose-Depen Orthop Scand, 6	dent 52(5)	Stimulation o : 481-484, 19	f Bone Induction of Bone Induc	on by Ba	isic Fil rb	olast Growt	h Factor
CG	1		Evaluation Of C J Gastroenterol				ed Gastr	ric Ulcı r	Therapy: F	indings in
СН			"The Developr or Limb Ischaen							mal
C:I		Aplin, JD, "Ad	lhesion Molecul	es in	Implantation	", Rev Reprod,	2(2): 84	-93, 1997	7	
Cl		Lessey et al, "I Receptivity", J	Paracrine Signal Reprod Immun	ing ing ol, 3°	n the Endome 9(1-2): 105-1	trium: Integrin 16, 1998 (abstr	s and the	Estab is	hment of U	Jterine
CK		Burrows et al, 2(4): 307-321,	"Trophoblast M 1996	igrat	ion During H	uman Placenta	l Implan	tation" F	łum Reprod	d Update,
CL			The Regulation pantation', Contr							
СМ			xpression of He ing Normal and							
CN		Abrahamsohn 1993 (abstract)	et al, "Implantal )	tion a	and Deciduali	zation in Roder	nts", <i>J E</i>	xp Zoo',	266(6): 603	3-628,
со			Purification and rophoblasts", M					e and i s	Expression	by
СР										

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; I raw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER** 

* :	+49 (MC	odified)			Atty. Docket	No.		Appli :a 09/2 50	tion No. ),037	
•	IN A	ON DISCLOSUI AN APPLICATI AL SHEETS IF I	ION		Applicant: Oron YAC	COBY-ZEEVI	et al	<u> </u>		
•			,		Filing Date: March 2, 1	999		Grou ) A	Art Unit:	
			U.S.	PAT	ENT DOCU					
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE			NAME		CLASS	SUB- CLASS	FILING DATE
DA					· · · · · · · · · · · · · · · · · · ·				<b></b>	
			FOREIG	N P	ATENT DO	DCUMENTS		L		<u> </u>
	C	OCUMENT NUMBER	DATE	C	OUNTRY	CLASS	SUB-	CLASS	TRANS	LATION
						•			YES	NO
DB										
		OTHER	ART (Includin	g A	uthor, Title,	Date, Pertinent	Pages,	Etc.)	<u> </u>	
	Y Pr	oshida, S., "Effe eimplantation E	ects of Basic Fi Embryos", Nipp	brol	olast Growth Sanka Fujink	Factor on the I	Develor	oement of	Mouse 5 1996 (al	ostract)
DE	l w	atson et al, "A (eprod, 50(4): 72	Growth Factor	Phe	notype Map					
DF	C.	arlone et al, "En eprod, 49(4): 65	nbryonic Modu 3-665, 1993 (a	ılatio bstr	on of Basic F act)	ibroblast Grow	th Fact	or in the I	Rat Uterus'	', Biol
DG	w D	ordinger et al, 'uring the Initial	'The Immunolo Statges of Emb	ocali oryo	zation of Bas Implantation	sic Fibroblast C n", Growth Fac	Growth	Factor i: 1	the Mouse 186, 1994	Uterus (abstract)
DH	Sc 43	chultz et al, "Gre 3-81, 1993 (abst	owth Factors in ract)	Pre	eimplantation	Mammalian E	mbryos	s", Oxf I e	v Reprod E	Biol, 15:
DI	Fi Bi	reeman et al, "Hochem J., 330:	uman Platelet I 1341-1350, 199	Hepa 98	aranase: Puri	fication, charac	cterizati	ion and Ca	atalytic Ac	tivity",
Díl	Es 10	sko et al, "Tumo 196, 1988 (abstr	or Formation Deact)	eper	ndent on Pro	eoglycans Bios	ynthesi	s", Sciei c	e, 241(486	9): 1092-
DK										
Dl.									: :	
DM										
DN					=					
DO										
DP										
DQ										
DR										
DS										
EXAM	IINER				DATE	CONSIDERE	D			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 3 Application No. Atty. Docket No. lodified) 09/186,200 910/12 **APPLICANT** .NFORMATION DISCLOSURE CITATION Tuvia PERETZ et al IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY) Group Art Unit Filing Date **U.S. PATENT DOCUMENTS CLASS FILING** DATE NAME SUB-DOCUMENT EXAMINER DATE INITIAL NUMBER **CLASS** AA FOREIGN PATENT DOCUMENTS **TRANSLATION** SUB-CLASS DATE COUNTRY CLASS DOCUMENT NUMBER YES NO AB OTHER ART (Including Author, Title, Date, Pertinent Pages. Etc.) Wight et al, "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", Curr. Opin. Cell AC Biol., 4:793-801, 1992 also 20437 Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions and Role in Phsiological AD Processes", Physiol. Rev., 71:481-539, 1991 201632 Wight et al, "Cedll Biology Of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 ΑE Kjellen et al, "Proteoglycans: Structgures and Interactions", Annu. Rev. Bioche.n., 60: 443-475, 1991 AF Ruoslahti et al, "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991 AG Vlodavsky et al, "Extracellular Matrix-Bound Growsth Factors, Enzymes and I lasma Proteins" In AΗ Basement Membranes: Cellular and Molecular Aspects (eds. Rohrbach and Tiripl), Ac ademike Press, Inc., Orlando, Fla., 327-343, 1993 Vlodavsky et al, "Expresasion of Heparanase by Platelets and Circulating Cells of the Immune System: ΑI Possible Involvement in Diapedesis and Extravasation", Invasion & Metastasis, 12: 112-127, 1992 20437 Vlodavsky et al, "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", AJ Invasion & Metastasis, 14: 290-302, 1995 20437 Nakajima et al, "Heparanase and Tumor Metastasis", J. Cell Biochem., 36: 157-167, 1988 ΑK 20437 Liotta et al, "Tumor Invasion and the Extracellular Matrikx", Lab. Invest., 49: (39-649, 1983) AL 20437 Vlodavsky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteoglycans in the AM Subendothelial Extracellular Matrikx", Cancer Res., 43: 2704-2711, 1983 Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiog mesis", Is. J. Med., 24:204 37 AN 464-470, 1988 DATE CONSIDERED **EXAMINER** 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3

Form	FTO-1	449 (Modifie	d)			Atty. Docket I 910/12	10.	Ar plicat 05/186		
•		IN AN A	ISCLOSURE APPLICATIO SHEETS IF NEC	Ν		APPLICANT Tuvia PER	ETZ et al			
	•				,	Filing Date		Gr sup A	Art Unit	
				L	J.S. PATE	ENT DOCUI	MENTS			
	EXA	MINER IAL	DOCUMENT NUMBER		DATE		NAME	CLASS	SUB- CLASS	FILING DATE
ВА	<u> </u>									
				FOF	REIGN PA	ATENT DOC	UMENTS			
		DOCUM NUMBE	. —	D	ATE	COUNTRY	CLASS	SUB-CL# SS	TRANS	SLATION
									YES	ОИ
вв										
		ОТ	HER ART (	Inclu	ding Auth	nor, Title, Da	te, Pertinen	t Pages, Etc.)	)	
ВС	\		ıl, "Evidence tl leparanase", <i>In</i>					1etastasis b / Blo	ocking Tu	mor Cell-
BD	\	Vlodavsky Tumor Ce	y et al, "Morph lls Maintained	ologic on Ex	cal Appear	ance, Growth Matrix vs. Pl	Behavior and I	Migratory Activ 2: 607-616, 980	ity of Hun	nan عوريم
BE	Ì	Vlodavsky		ellula	r Sequestra	tion and Rele	se of Fibrobla	st Growth I acto		latory ¿ 6 4 i
BF	1		et al, "Heparai e", Exp. Cell R				Induce Modul	ation of Smooth	Muscle	2 e-4 3.7
BG			ent of Animals					Prolongatio 1 of e Heparanas e'', .		
вн	\	Thunberg 117: 203-2		ecular	Size of the	e Antithrombi	n-Binding Seq	uence in He ara	in", <i>FEBS</i>	Lett.,
ВІ	`		et al, "An Impi Connective Tis				Proteoglycans	synthesized by	Chondroc	ytes in
ВЈ	`.	Hudson, P	J, "Recombina	ınt An	tibody Fra	gment", Curr.	Opin. Biotech	., 4: 395-402, 19	98	
BK	ì		ultaneous Bloc					ties of C. Perfrinding		
BL		Immunode		Турс	1 by Imm	unizing of Mi	e with an Infe	nscriptase of Huctious Vaccinia		
вм			"Monoclonal ag News, July,			rapeutic Appli	cations Grow i	n Promise and N	Number",	Genetic
EXAN	IINE	R				DATE	CONSIDER	ED		
609; ເ	Draw	line throu		f not	in confor			n conformanc red. Includ e co		

Sheet \_3\_\_ of 3 Form PTO-1449 (Modified) Atty. Docket No. Application No. 910/12 0.7/186,200 **APPLICANT** INFORMATION DISCLOSURE CITATION Tuvia PERETZ et al IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY) Filing Date G:oup Art Unit U.S. PATENT DOCUMENTS **EXAMINER DOCUMENT** DATE NAME CLASS **FILING** SUB-INITIAL NUMBER DATE **CLASS** CA CB CD CE CF CG CH CI CJ FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-CLASS **TRANSLATION** NUMBER YES NO CH OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) ĊΙ Sherman-Gold, R., "Monoclonal Antibodies: The Evolution from '80s Magic bu lets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News, August, 1997, pp 4, 35 CJ Danheiser, SL, "Rituxin Leads Line Of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News, October, 1997, pp 1.6.33,38 CK Rader et al, A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 95: 8910-8915, 1998 CL Mateo etal, "Humanization of a Mouse Monoclonal Antibody that Blocks the Epi lermal Growth Factor Receptor: Recovery Antagonistic Activity", Imunotechnology, 3: 71-81, 1997 CM CN CO CP **EXAMINER** DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Includ ≥ copy of this form with next communication to applicant.

Application No. Atty. Docket No 1odified) 09/140,888 910/10 Applicant: DISCLOSURE CITATION Oron YACOBY-ZEEVI AN APPLICATION LEVERAL SHEETS IF NECESSARY) Group Art Unit: Filing Date: 1633 August 27, 1998 U.S. PATENT DOCUMENTS SUB-**FILING** CLASS DATE NAME **EXAMINER** DOCUMENT **CLASS** DATE INITIAL NUMBER KΑ FOREIGN PATENT DOCUMENTS SUB-CLASS TRANSLATION CLASS DATE COUNTRY DOCUMENT NUMBER YES NO JР 09009962 A 14/1/97 AΒ OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) "Handbook of Microbiology", Vol. 1, 1974, pp 239-242, article by Clancy, C.I. AC "Pseudomonas: biotransformations, pathogenesis, and evolving biotechnology", Eds. Silver etal. .AD American Society for Micribiology, 1990, Chps 2,3. Wang et al, "Isolation and Characterization of Pseudomonas Aeruginosa Gene; Inducible by ΛE Respiratory Mucus Derived from Cystic Fibrosis Patients", Mol. Microbiol, 22(5): 1005-1012. 1996 (Abstract) Moss et al, "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis ÆF Transmembrane Conductance Regulator (CFTR)", Clin. Exp. Immunol., 106(2):374-388, 1996 (Abstract) Davies et al, "Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas Aeruginosa ΑG During Biofilm Development in Continuous Culture". Appl. Environ. Microbi al., 61(3): 860-867, 1995 (Abstract) Azghani et al, "A Beta-linked Mannan Inhibits Adherence of Pseudomonas Avruginosa to Human AH. Lung Epithelial Cells", Glycobiology, 5(1): 39-44, 1995, (Abstract) Ofek et al, "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, New York, 1994, pp 114-Αl 118, 148-153, 418-423. Davies et al, "The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm", AJ Science, 280: 295-298, 1998. Ghani et al, "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid ΑK Pseudomonas Aeruginosa", Can. J. Microbiol., 43(11): 999-1004, 1997 (Abs.ract) Stickler et al. An Assessment of the Ability of a Silver-Releasing Device to Prevent Bacterial AL Contamination of Urethral Catheter Drainage Systems", British J. Urology, 73: 579-588, 1996 Potera, C., "Bacteria in Biofilms Exchange Developmental Signals", ASM News, 64(6): 321-322  $\Delta M$ Gabriel et al, "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", J. AN Catatact Refract. Surg 24:124-129, 1998, ΑO AP DATE CONSIDERED EXAMINER EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

if not in conformation and not considered. Include copy of this form vith next communication to applic int

SHEEL

Sheet 2 of 3

rgn PT	PTO-1449 (Modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSAR)					Atty. 910/	Docket No.		Applie: tio 09/14),8		
7		IN AN A	PPLICATION			Appl Oro	icant: n YACOE	BY-ZEEVI			
, .	JSE SI	SVERAL SI	ILLION NEC	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			g Date: gust 27, 19	98	Group Ar 1633	t Unit:	
				Ţ	U.S. PA	TENT	DOCUM	ENTS			
	EXAN INITI	MINER AL	DOCUMENT NUMBER		DATE			NAME	CLASS	SUB- CLASS	FILING DATE
ВА											
				FO	REIGN	PATI	ENT DOCU	JMENTS		TRANSIA TION	
		DOCUM		DA	ATE	CC	UNTRY	CLASS	SUB-CLASS	TRAN	SLATION
		NUMBE	:K							YES	NO
c		06197	760	7/19/	/94	ЛР					
	1	<u> </u>						ate, Pertinent			
BD		Pier, G.B	B., "Rationale for sa Infrction in	or Dev Cystic	elopmer Fibrosi	nt of I s Pati	mmunothe ents", <i>Beh</i>	rapies that Tai	get Mucoid I so 98:350-360, 9	eudomona 97 (Abstra	s act)
BE		Goldberg	l. "Dialog	gic Acti	vities of	Anto	bodies to t de are Bloc	the Neutral-Po cked by O Side	lysaccharide Co Chains and 14t	mponent	of the
BF		Meluleni Antibodi Lung Inf	i et al, "Mucoi ies to the Muco fection in Cyst	d <i>Pseud</i> oid Exc ic Fibro	domona polysac osis Pati	s Aeri chari ents"	<i>iginosa</i> Gr de Capsule , <i>J. Immun</i>	owing in a Bid but not by Ar , 155(4):2029-	ofilm in vitro are atibodoes Procue 2038, 1995 (1.b	stract)	
BG		Escheric	<i>chia coli</i> Blood	i Cultui	re Isolat	es", <i>F</i>	EMS Micr	obiol Lett, 130	pe) in Klebsic II: 0(1): 51-57, 1 19	5 (NOSH 4	
ВН		Fibrosis	", Am J Respir	· Crit C	are Med	1, 154	(4): \$1/5-	5182, 1990 (7	ruginosa Infect Abstract)		
BI		Pier et a Clearand 1997 (A	II, "Cystic Fibr ce of <i>Pseudom</i> abstract)	rosis Tr ionas A	ansmen erugino	ibrane sa froi	Conductant the Lung	nce Regulatorg", Proc Natl 2	is an Epithel al Acad Sci USA 9		
ВЈ		in Clinic	cal Isolates and information gi	d Analy ven.	ysis of (	leara	nce in a M uun 199	ouse Model of	s: Characterical Respiratory in (4) ~ 3939 - 3	846.	
BK	7	Fibrosis	s Encode Hom	ologs c	of the Se	rine l	rotease H	rA', J. Bacter	ly <i>Pseudomor as</i> iol, 178(2):511-	.525, 1770	
BL.		Aerugii Immuni	<i>iosa</i> and Inflat ity, 66(1): 280-	mation -288, 1	ın a Mo 998	use M	lodel of Re	epeated Respii	learance of Mucatory Challenge	·	
ВМ		Van He Infectio	eeckeren et al, onn with <i>Pseud</i>	"Exces	ssive Inf as Aerug	lamat ginosa	ory Respo	nse of Cystic I Invest, 100(11	ibrosis Mice to ): 2810-2815, 1	Broncho 997	pulmonary
-							<del></del>				
BN								TE CONSIDE			

Sheet 3 of 3

Form P	TO-1449 (Modified)	Atty. Docket No. 910/10	Ap <sub>l</sub> lication No.
I	FORMATION DISCLOSURE CITATION IN AN APPLICATION USE SEVERAL SHEETS IF NECESSARY)	Applicant: Oron YACOBY-ZEEVI	09,140,888
		Filing Date: August 27, 1998	Grc up Art Unit: 16: 3
ļ	OTHER ART (Including A	uthor, Title, Date, Pertinen	Pages, Etc.)
CA	Mrsny et al, "Addition of a Bacterial Al Disruption of Alginate and Modification (Abstract)	Iginate I wase to Pumilant Cl	
СВ	Wiils et al, "Short-Term Recombinant l- vitro Sputum Transportability", (Abstra	luman Dnase in Bronchiect act) no further information.	asis. Effect or Clinical State and in
СС	Cai et al, "Comparison of Sputum Proce 402-407, 1996 (Abstract)		Fibrosis", Pe liatr Pulmonol. 22(6):
CD	Randall et al, "Distribution of DNA and Pulmonary Targeting Strategies", J Drug	Alginate in Purulent Cystic g Therapy. 4(4): 233-243, 1	: Fibrosis Spu:um: Implications to
<b>J</b> Ē	Hatch et al, "Alginate Lyase Promotes I polysaccharide of Mucoid <i>Pseudomonas</i> 1998 (Abstract)	Diffusion of Aminophysosid	or Through the Fig.
CF	Speert et al, "Modulation of Macrophage Aeruginosa", Behring Inst Mitt, 98: 274-	e Function for Defense of the 282, 1997 (Abstract)	ne Lung again it Pseudomonas
CG	Ying et al, "Alginate, the slime Exopoly, Leukocyte Elastase, Retards Inhibition b Secretory Leukoprotease Inhibitor", Am	saccharide of <i>Pseudomonas</i>	itor and Appelantes Intitities t
СН	Johansen et al, Chronic Pseudomonas Ae Inst Mitt, 90: 269-273, 1997 (Abstract)		
CI	Pina et al, "The Role of Fluoroquinolone Resistance in <i>Pseudomonas Aeruginosa</i> "	es in the Promotion of Algir , Curr Microbiol. 35(2): 1	ate Synthesis and Antibiotic
CJ	Spencer, RC, "Invasive Streptococci", Ed (Abstract)		
<b>■</b> k	Mengistu et al, "Continuous Culture Stud Pneumoniae K1", J Appl Bacteriol, 76(5)	dies on the Synthesis of Cap ): 424-430, 1994 (Abstract)	osular Polysac charide by <i>Klebsiella</i>
CL	Hsuch et al, "Invasive Streptococci Pneu Taiwan", J Formos Med Assoc, 95(5):36-	moniae Infection Associate	·
СМ	Moses et al. "Relative Contributions of H Strain of the Group A Streptococcus", In	Hyaluronic Capsule and M I fect Immun, 65(1):64-71, 1	Protein to Virt lence in a Mucoid 997 (Abstract)
CN	Scott et al. Visualization of an Extracellu Surface Sugar Lectin Analysis of Some 7 1997 (Abstract)	ular Mucoid Laver of Treno	nama Dantino's ATCC 25405
СО	Nilsson et al. " The Role of Staphylococc Septic Arthritis", Infect Immun, 65(10): 4	cal Polysaccharide Microca 4216-21, 1997 (Abstract)	psule Express on in Septricemia and
СР	Wessels et al. "Effects on Virulence of M Expression in Group A Streptococci", Inf	lutations in a Locus Essent	al for Hyalurcnic Acid Capsule . 1994 (Abstract)
			<u> </u>
EXAMINI		DATE CONSIDERED	
EXAMINI if not in co	ER: Initial if reference considered, whether or not onformation and not considered. Include copy of the	citation is in conformance with his form with next communication.	h MPEP 609: Draw line through citation tion to applicar :.

EXAMINER ON Phile DATE CONSIDERED 30 Sq :79

EXAMINER: Unital if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Form -	Form PTO-1449 (Modified)  INFORMATION DISCLOSURE CITATION DISCLOSU									Atty. Docket N 910/8	0.		Applicati 09/113.		
1					IN AN A	ISCLOSURE PPLICATION HEETS IF NE	1			Applicant: Hanna BEN	ARTZI et al				· ,
								ŕ		Filing Date: July 10, 1998	3		Group A		
							-	U.S. PA	TE	NT DOCUM	IENTS				
			X.A		INER L	DOCUMENT NUMBER		DATE	E		NAME		CLASS	SUB- CLASS	FILING DATE
ВА															
	FOREIGN PATENT DOCUMENTS													<u></u>	
					DOCUM! NUMBER	_	D	ATE	(	COUNTRY	CLASS	SUE	3-CLASS	TRANS	LATION
YES													YES	NO	
88															
	_					OTHER AR	T (In	cluding /	Aut	hor, Title, Da	ite, Pertinent Pa	ages, I	Etc.)		
ВС			1	,	Vlodavsky Mechanisn	et al, "Extrac n?", <i>Trends Bi</i>	ellula iocher	r Sequest n. <i>Sci.</i> , 1	trati 6: 2	ion and Relea	ase of Fibroblas	st Gro	wtrh Facto	r: A Regi	ılatory
BD		-	:	jo	Campell et Exp. Cell R	al, "Heparin Res., 200: 156-	Sulfat	e-Degrac 1992	ling	g Enzymes In	duce Modulati	on of	Smooth M	I uscle Phe	notype",
BE				/I	Lider et al,	"Suppression ent of Animals	of Ex	perimen Low Do	tal	Autoimmune	Diseases and I	Prolon	gation of	Allograft	Survival
BF			1		– Thunberg e					,	in-Binding Sec			·	Letters,
BG	Ť			S	Sudhalter e	et al, "Importa Growth Facto	nce of	f Size, Su leparin".	ılfa J. I	tion and Ante	ocoagulant Act 254(12): 6892-	ivity i:	n the Pote	itiation o	f Acidic
вн			1	/I	shai-Mich	aeli et al, "Im	portar	ice of Siz	ze a	nd Sulfation	of Heparin in I	Releas	e of Basic	Fibroplas	t Growth
ВІ			Ť	ľ	noue et al,		Desu	lfation of	f He	eparin with D	Dimethyl Sulfox				1772
'n	Ī	7	·	/ 1	Vagasawa (	et al, "Solvoly	rtic De	esulfation	n of	Glycosamin	oglycuronan S ch, 58: 47-55, 1	ulfates	With Dir	ethyl Su	foxide
ВК		T		11	Matia Bar-l	New et al, "In	hibitie	on of He	para	anase-Media	ted Degradation 7, 70(2): 551-55	of E	xtracellula	□ Matrix I	Heparin
BL		1		C	Gospodaro		imula	tion of C	om	eal Endothel	ial Cell Prolife			y Fibrobla	st and
ВМ		-	٦	/ F	laimovits- 8: 789-79	Friedman et a 6, 1991.	l, "Ac	tivation	of I	Platelet Hepa	ritinase by Tun	nor Çe	ll-Derive	d Factors'	, Blood,
ви (		X		T	/lodavsky umor Met	et al, "Extrace atastis and Ar	ellular ngioge	Matrix-	Res Can	sident Growth	h Factors and E	nzym 203-2	es: Possib 26, 1990	l: Involve	ment in
EXAN	ΛI	N	EI			n P	(Ve	les		<del>:</del>	CONSIDERED		o Sep	99	
EXAM if not it	III n (	NE co	ER nf	lı orr	nitial if refer	rence considere	d, who	ether or no	ot ci	itation is in co	nformance with	MPEP	609; Draw	line throug	h citation

Form P	Form PTO-1449 (Modified)  INFORMATION DISCLOSURE CITATION AND ADDITIONAL PROPERTY OF THE PROPE								y. Docket No 0/8	).		Application 09/113,1		
-				IN AN A	ISCLOSURE ( PPLICATION HEETS IF NEC	i			plicant: unna BEN A	ARTZI et al				
									ng Date: ly 10, 1998			Group Art	Jnit:	
							U.S. PA	TEN	T DOCUM	ENTS				
			IAI	NER -	DOCUMENT NUMBER		DATE			NAMIE		CLASS	SUB- CLASS	FILING DATE
CA														
						FC	REIGN	PAT	ENT DOCU	JMENTS				`
				DOCUM NUMBER		D	ATE	C	DUNTRY	CLASS	SUE	3-CLASS	TRANS	LATION
	L												YES	NO
СВ														
	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
CC	CC Regan et al, "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compc ands", J.  Bioactive and Compatible Polymers, 8: 317-337, 1993													
CD														
CE			I J	Katz et al, Ieparain-	"Antiprolifera Mimicking Po	ative A	Activity to natic Ani	o Gl	omerular M Compound	esangial Cells a	and R	eceptor Bi	r ding of a 638-1697	a , 1997
CF			1	Angiogeni	, "Modulation ic Activity by i5-1575, 1997	of Fil a Syn	oroblast ( thetic He	Grow parai	rth Factor-2 in-Mimickin	Receptor Bind ng Polyaromati	ing, I c Con	Dimerization pound",	oi, Signal I. Clin. In	;ing, and vest.,
CG										nediated Autoci 5656-5662, 199		Cell Transfe	o: mation	by
СН										tors of Heparan ells", Biochemi				
CI		1	10	Coombe e	t al, "Analysis 9: 82-88, 1987	of the	e Inhibiti	on o	f Tumour M	letastasis by Su	lphat	ed Polysac	c narides'	, Int. J.
Cl		[:	O I	Ornitz et a Receptor a	al, "Heparin is and for Mitogo	Requ encsis	ired for C in Whole	Cell-l Cel	Free Bindin ls", <i>Molecu</i>	g of Basic Fibralar and Cellula	oblasi <i>ir Bio</i>	t Growth Fology, 12: 2	a :tor to a 40-247, 1	Soluble 992
CK					al, "Cell Surfa ts High Affini					Required for E 8, 1991.	Bindin	ng of Basic	l'ibrobla	st Growth
CL			I							Heparin and H its Receptor",				
СМ (		H.	1	Degrade ti		elial B	asement	Men	nbrane: Evi	Leucocytes, Endence for Cytol 13-124, 1995.				
CN				Α	A									
EXAM	111	٧E	3	13	WW	lle		· ·	DATE	CONSIDERED	32	Sgo	79	
										onformance with ext communicati			line throu	igh citation

-sorm P	TO-14	149 (Modified	i)			ty. Docket No. 0/8	Applicatio 09/113,1					
•		IN AN A	ISCLOSURE CITAT PPLICATION HEETS IF NECESSA			oplicant: anna BEN ARTZI et al						
						ling Date: Ily 10, 1998	Group Art	Unit:				
				U.S. PA	ΓEN	T DOCUMENTS						
	EXA INIT	MINER IAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	FILING DATE			
DA												
-			OTHER ART (In	cluding A	uth	or, Title, Date, Pertinent Pages	, Etc.)	. <del> </del>				
DB	94	Nakajima for Hepar	et al, "A Solid-Phas an Sulfate Degradati	e Substar ve Activi	te o	of Heparanase: Its Application to Analytical Biochemistry, 157:	o Assay of I 162-171, 19	uman Mo	elanoma			
DC	DC Oosta et al, "Purification and Properties of Human Platalet Heparitanase", J. Biol. Che n.", 257(19): 11249-11255, 1982.											
DD												
DE			et al, "A Rapid Quar J., 325: 229-237, 19		\ssa	y for the Detection of Mammal	ian Heparar	ıse Activ	rity",			
DF		Mullings 6:491-490		g Sugar A	Assa	ay for the Study of Cellulases",	Enzyme Mi	c -ob. Tech	inol.,			
DG		Taylor et	al, "A colorimetric onic Acid", Analytica	Method for al Bioches	or th	ne Quantitation of Uronic Acids	s and a Spec	i ic Assay	for			
DH	11,	Linhardt,	R.J., lary Electroph	oresis of	Olig	gosaccharides", Methods in Enz	mology, 230	265-280	), 1994.			
DI	Π,	Basu et a Ceramide	l, "Analysis of Glyce Glycanase from Mo	ospingoli ercenaria	pids <i>me</i>	s by Fluorophore-Assisted Carb rcenaria", Analytical Biochemi	ohydrate El stry, 222:27	e etrophore	esis Using 194.			
DJ		Reducing	P., "The Use of Poly Saccharides Labell J., 270: 705-713, 19	ed with th	de-g ne F	gel Electrophoresis for the High luorophore 8-aminonaphthalen	n-Resolutior e-1,3,6-trisu	of Separa Aphonic A	ation of ceid",			
DK		Coquet e Determin 1991	t al, "Applications o action of Glucose an	f a Post-c d Fructos	oluı e in	mn Fluorigenic Reaction in Liq Biological Matrices", Analytic	uid Chromo a Chemica	ot igraphy Acta, 252:	for the 173-179,			
DL		DeVouge Using Ai 286-294,	ntobodies Directed A	ction of ( Against a	GRP Puta	P94/Endoplasmin From a KNRI ative Heparanase Amino-Termi	Cell-Spec nal Peptide'	itic λgt11 '. Int. J. C	Library ancer, 56:			
DM	DM Zsolnai et al, "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.											
DN		Bellott e Aug., 19		op in Cor	nbii	natorial Chemistry", European	Pharmaceu	tical Cont	ractor,			
DO	THE STATE OF THE S		g et al, "An Improve , Live Tissue Resear			r Determining Proteoglycans Sy 275, 1990.	nthesized b	Chondr	ocytes# in			
EXA	MINE	R	on P. W	eles		DATE CONSIDERED 3	30 Sep	4.9				
EXA if not	MINE	R: Initial if r	eference considered, v	vhether or lude copy	not of th	citation is in conformance with Minister form with next communication	PEP 609; Dra to applicant.	v line thro	ough citation			

1	-	/	6	IPE	She	et1 of	_4			- (0	4)
Form f	PTO-1449	(Modified)	AUG	0 7 1998 7		Atty. Docket 910/4	No.		Applicati		
	]	TION DISCLO IN AN APPLIC ERAL SHEETS	ATI	ON	1	Applicant: Oron Yaco	by ZEEVI				
(	USE SEF	EKAL SHEETS	IF I	VECESSAI(I)		Filing Date: March 25,	1998		Group A 1652	urt Unit:	÷
				U.S	. PA	TENT DOCU	MENTS				
	EXAMINE INITIAL			DATE			NAME	(	CLASS	SUB- CLASS	FILING DATE
AA											
AB										. ~ * : :	
AC											
AD									AUG	1 0 togs	
				FOREI	GN	PATENT D	OCUMENTS				
		DOCUMENT NUMBER	T	DATE		COUNTRY	CLASS	SUB-CL	ASS	TRANS	LATION
		NOMIBER								YES	NO
AE											
н		ОТН	ER A	ART (Includ	ing A	Author, Title,	Date, Pertinent	Pages, Et	c.)		
AF	RP			ortunities for 110: 256S - 2			zed α <sub>1</sub> - Antitry	psin for th	ne Trea	tment of C	ystic
AG	RP			urrent Unders 137-142, 199		ling of the Inf	lammatory Proc	ess in Cy	stic Fib	rosis", <i>Ped</i>	iatric
АН	RP	Dasgupta et a Treatment wi	l, "F th N	teduction in Vacystelyn and	/isco	oelasticity in ( ONase", <i>Pedic</i>	Cystic Fibrosis S atric Pulmonolog	Sputum <i>In</i> gy, 22:16	<i>Vitro</i> 1 1-166,	Using Con 1996	nbined
Al	RP	Crystal, R.G. 44S - 6A-525	Gei	ne Therapy St	trate	gies for Pulm	onary Disease",	Am. J. M	ledicine	, 92(supp	64): 6A-
AJ	RP					se of Mucoly	tic Agents, Am.	J. Medici	ne, 49(	1): 1-4, 19	70
AK	RP	Boat et al, "B (Abstract)	ioch	emistry of Ai	irwa	y Mucus Seci	retions", Fed Pr	oc, 39:13	: 3067-	3074, 1980	)
AL	RP	Intracellular 1 38(1): 42-48,	nor 199	ganic Sulfate 5 (Abstract)	Con	itent in Cystic	coconjugates, bu Fibrosis Airwa	y Epitheli	al Cells	s", Pediatr	Res,
AM	RP	Boat et al, "In with Cystic F	ibro	ased Sulfation sis", J. Clin I	n of Inves	Glycoconjuga st., 84(1):68-7	ates ny Cultured 2, 1989 (Abstra	Nasal Ep	oithelial	Cells from	n Patients
AN	RP			elial Cell Dys Suppl, 363:25-			c Fibrosis: Impl	ications fo	or Airw	ays Disea	se", Acta
AO	RP	Welch et al,	'Coı	mplex Saccha	ride	etabolism in	Cystic Fibrosis	Fibroblas	ts", Pe	diat Res, 9	:698-702,

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Schwatz et al "CpG Motifs in Bacterial DNA Cause Inflamation in the Lower Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997 (Abstract)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

. оп	nPIO	-1449 (Modif	ied)	₩.		Applicati 09/046							
		IN AN	DISCLOSURE APPLICATIO SHEETSAF (VE	N			pplicant ron Yacob	y ZEEVI					
		AL	(6 0 7 1998 S)			M	ling Date: [arch 25, 1			Group A 1652	rt Unit:		
<b> </b>			SPEMASY SKA		U.S. P.	ATEN	IT DOCUM	MENTS					
	IN	AMINER ITIAL	DOCUMENT NUMBER	Г ———	DAT	E		NAME		CLASS	SUB- CLASS	FILING DATE	
CA		_								_			
-				FO	REIGN	PAT	ENT DOC	UMENTS	<b></b>			<u> </u>	
		DOCUI		D/	ATE	CC	DUNTRY	CLASS	SUB	-CLASS	TRAN	SLATION	
СВ											YES	NO	
<b> </b>	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
CC	T	2 22										<u>.</u>	
	H	140(8): 2	n et al, "Identil 708-2713, 1988	ication  (Abst	of Cho	ndroi	tin Sulfate	E in Human Lu	ng Ma	st Cells",	J. Immui	ıol.,	
CD	RP	Giuffre et		Adhes	sion to A	Activa 6(4): 9	ted Aortic	Endothelium: R	Role of	L-Selecti	in and He	paran	
CE	RP	Shimada e	et al, "Involven	nent of	Cell Su	rface	Henarin Si	ılftae in the Bir	iding o	f Lipopro	tein Lipa	se to	
CF	00	1						8(4): 995-1002					
	KT	Bronchitis	, Am J Kesp (	Cell &	Mol Bio	n Spu l, 5(4	tum from I ): 315-320,	Patients with Cy 1991	∕stic Fi	brosis and	d Chronic	;	
CG	RP	i <del>11033Uli</del> et	al, "Heparinas	e III E: jury", .	xerts En I. Pharn	idothe n Exp	lial and Ca	ardioprotective 3 (3): 1032-1038,	Effects	in Feline	Myocar	lial	
CH	RP	Yamaguch	ni et al, "Neutro	ophil E	lastase l	Inhibi	tor Reduce	s Neutrophil Cl 112(2): 551-56	remosi	tactant D	roduation	After	
CI	RP	Matgolies	et al, "Identific	ation o	of a Mai	or He	narin-Prec	iitable Protein i l-186, 1982 (Al	n LJun	on Comm			
CJ	RP	Leong et a	l, "Diffrent Cla	isses of	f Proteo	glyca	ns Contriut	te to the Attachi 6(3): 994-999,	ment o	f Rorralia	Burgdo	rferi to	
СК	RP	Asagoe et		Ieparin				Equine Arteri			Med Sci,	59(8):	
CL	RP.	Krusat et a	<del></del>	pender	nt Attac	hmen	t of Respira	atory Syncytial	Virus	(RSV) to	Host Cel	ls", Arch	
СМ	RP	Alvarez-D Listeria M	ominguez et al	, "Host and the	Cell He	eparia al Sur	tace Protei	Proteoglycans M in ActA is Invo	fediate	Attachm Heparan	ent and E Sulfate F	Entry of Receptor	
CN	Memoraites" Int. I Paragital 27(5), 525 520 Above 2 (6)												
со				- , - , (			1	171 .					
СР										<del></del>			
EXAM	INER	Rober	ca Print	1_	-		DATE CO	ONSIDERED 7	7-21	49	<del></del>		
EXAM if not in	NER: confo	Initial if refe	rence considered	d, wheth Include	ner or no copy of	t citati this fo	ion is in con	formance with M	ADED 4	00. D 1	ine throug	h citation	

Form	PTO	-1449 (Modifie	d)		****		tty. Docket N 10/4	lo.	15 }	Applicati 09/046,		
		- IN AN	DISCLOSURE APPLICATION AFETS IF NE	V			pplicant: Fron Yacob	y ZEEVI				-
		AUG 0 7 1998	JC17	0200	,		lling Date: Iarch 25, 1	998		Group A	rt Unit:	<u> </u>
	1	The same of	7		U.S. PA	TE	VT DOCUM	ENTS		<u> </u>		
		AMINER TIAL	DOCUMENT NUMBER		DAT	E		NAME		CLASS	SUB- CLASS	FILING DATE
DA	<u> </u>											
		<del></del>		FC	DREIGN	PAT	ENT DOC	UMENTS			-	•
		DOCUM! NUMBER		D	ATE	С	OUNTRY	CLASS	SUE	B-CLASS	TRANS	LATION
<u> </u>	-									, 7, .5	YES	NO
DB												
		<del></del>						ite, Pertinent Pa				
DC	RP	Lipoproteir	et al, "Dual In 1 Receptor-Re , 1996 (Abstra	lated.	on of the Protein (	: Ma LRP	laria Circun ) and Hepar	nsporozoite Pro an Sulfate Prot	tein w	vith the Locans", JE	w Density xp Med, 1	/ 84(5):
DD	RP	Inaba et al,		parino	on Infect 8-491, 1	ion c 997	of Cells by I (Abstract)	Porcine Reprodu	ıctive	and Resp	iratory Sy	ndrome
DE	RI	Chen et al,		s Infe	ctivity D			lope Protein Bi	n to T	arget Cell	Heparan	Sulfate",
DF	RP	1 nrombosp	"Cell Adhesic ondin is Medi (31): 19205-19	ated b	y its Glv	COST	ninoglycan-	llaria Circumsp Binding Region	orozo n and	ite Protein not by CS	and VTCG",	l Biol
DG	ep	Robert et al Infected Ert 93, 1995. (A	inrocyte Adhe	1-4-Su rence	ilphaate on Brair	(Proc	eoglyc <del>asaa</del> a crovascular	n), a receptor for Endothelial Ce	or Pla lls", R	smodium Res Immun	Falciparui iol, 146(6)	n- ): 383-
DH	RP	Herrera et a and Penetri	l, "Mediation n Counter-Rec	of Try	ypanoson s on the	<i>na С</i> Тгур	<i>ruzi</i> Invasio anosomes",	on by Heparan S Mol & Biocher	Sulfat m Par	e Receptor	rs on Host 3-83, 199	Cells
DI												
DJ					-							
DK		= -										
DL		<del> </del>					<u> </u>				•	
DM												
CN												
со		_										
СР												
EXAMI			eca Por	<del>- /-</del>						1199		
EXAMI if not in	NER: confo	Initial if refer	ence considered ot considered.	i, whe Include	ther or no e copy of	this	tion is in cor form with ne	nformance with Next communication	/IPEP n to a	609; Draw	line throug	h citation

Sheet \_\_2\_\_ of \_\_4\_\_\_

Form PTO-1449 (Modified)							. Docket No.			Applica ion No. 08/922 170			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)							Applicant: Iris PECKER et al  Filling Date: September 2, 1997  ENT DOCUMENTS  O8/922 170  REC  Group AFR  Group AFR  1652						
	J. 70 . 72	., 5,0,2					Filing Date: Group, vision Group of Gro						
				U.	S. PA	LEN.	T DOCUM	ENTS			180		
	EXAN	/ III. 12.11			DATE NAME				CLASS	SUB- CLASS	FILING DATE		
ВА													
L				FORE	EIGN	PAT	ENT DOC	JMENTS	<del></del>				
		DOCUM		DAT	E	C	DUNTRY	CLASS	SUB-CLASS	TRAN	SLATION		
		1.052								YES	NO		
ВВ						-							
	·	<u>. I </u>	OTHER AR	RT (Inclu	uding	Auth	or, Title, D	ate, Pertinent P	ages, Etc.)				
BC	RP	Narindrasorasak et al, "High Affinity Interactions between the Alzheimer's β-Amy oid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", <i>J. 1 ioi. Chem.</i> , 266(20): 12878-12883, 1991											
BD	RP	Chen et al, "Dengue Virus Infectivity Depends opn Envelope Proteion Bin to Target Cell Heparan Sulfate". Nature Medicine, 3(8): 866-871, 1997											
BE	RP	Shieh et al, "Cell Surface Receptors for Herpes Simplex Virus are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell Biol., 116(5): 1273-1281, 1992											
BF	RP	Eisenber Surfaces	rg et al, "Lipos and Extracellu	protein L ular Matr	Lipase rix", J.	Enha Clin	ances Bindi a. <i>Invest.</i> , 90	ng of Lipoprote 0: 2013-2021, 1	eins to Hepara 992	11 Sulfate o	n Cell		
BG	RP	Rapraeg Differen	S. L. C. LECT M. L. a. L. C. Level and Mychlest								Myoblast		
ВН	B	Lider et Matrix l	Lider et al, "A Disaccharide that Inhibits Tumor Necrosis Factor α is Formed from the Extracellular Matrix by the Enzyme Heparanase", <i>Proc. Natl. Acad. Sci. USA</i> , 92:5037-5041, 1:95										
ВІ	RP	Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals with Low Doses of Heparins", J. Clin. Invest., 83: 752-756, 1989											
BJ	RP	Gitay-Goren et al, "The Binding of Vascular Endothelial Growth Factor to its Receptors is Dependent on Cell Surface-associated Heparin-like Molecules", J. Biol. Chem., 267(9): 6093-6038, 1992											
ВК	CC	Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparin Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.											
BL	RP	Spivak-Kroizman et al, "Heparin-Induced Oligomerization of FGF Molecules is F.esponsible for FGF Receptor Dimerization, Activation, and Cell Proliferation", Cell, 79: 1015-1024, 994											
ВМ	CS	Yayon Factor	et al, "Cell Sur to its High Aff	rface, He inity Rec	parin- ceptor'	Like ', Cei	Molecules 11, 64: 841-	are required fo 848, 1991	r Binding of E	Basic Fibro	blast Growth		
BN	-												
EXA	AMINI	ER Ra	esecca.	Prow	tri		DAT	E CONSIDER	ED 7-3	11-18			
EXA	EXAMINER Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation is in conformance with matter or not citation is in conformance with matter or not citation.												

					<u> </u>		<u> </u>					
Form PTO-1449 (Modified)							y. Docket No. 0/1		Application 08/922	Applicat of No. 08/922, 1705 CE/VED FEB 9 1998  Group / st Unit: 1800		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)							plicant: s PECKER e	t al	$G_{R}$	FEB y	1998	
							ing Date: eptember 2, 1	997	Group /	est Unit: 7	800	
					U.S. PA	TEN	IT DOCUM	ENTS				
		EXAMINER DOCUMENT INITIAL NUMBER						NAME	CLASS	SUB- CLASS	FILING DATE	
CA											<u> </u>	
				FC	REIGN	PAT	TENT DOC	JMENTS				
		DOCUM			ATE	COUNTRY		CLASS	SUB-CLASS	TRAN	SLATION	
l								YES	NO			
СВ									·			
	- <del></del>		OTHER AR	RT (In	cluding	Autl	hor, Title, Da	ate, Pertinent P	ages, Etc.)			
Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasn a Proteins", Basic Membranes: Cellular and Molecular Aspects (eds. Rohrbach & Timpl) pp 327-343, Academic Press,  Orlasndo, Fla., 1993												
CD	RP	Vlodavsky et al, "Extracellular Sequestration and release of Fibroblast Growth Fac or: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991										
CE	RP	Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells releases Active Fibroblast Growth Factor from ExtraCellular Matrix", Cell Regulation, 1: 833-842, 1990										
CF	R	Ishai-Michaeli et al, "Importance of Size and Sulfatiuon of Heparin in Release of Easic Fibroblast Growth Factor from the Vascular Endothelium and ExtraCellular Matrix", <i>Biochen istry</i> , 31(7): 2080-2088, 1992										
CG	R	Folkman et al, "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 1988										
СН	R	Vlodavsky et al, "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synth sis and Deposition into Subendothelial ExtraCellular Matrix", <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2292-2:96, 1987										
CI	RS	Folkman et al, "Angiogenic Factors", Science, 235: 442-447, 1987										
Cl	RP	Burgess et al, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins", Annu. Rev. Biochem., 58:575-606, 1989										
СК	R	Vlodavsky et al, "Involvement of the ExtraCellular Matrix, Heparin Sulfate Protec glycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: <i>Tumor Angeogene:is</i> , Eds. Lewis et al, Oxford Univ. Press, pp 125-140, 1997										
Cl	R	Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastis by B ocking Tumor-Cell- Derived Heparanases", Int. J. Cancer, 40: 511-518, 1987										
CM	RP	Bashkir Release	n et al, "Basic l ed by Heparitar	Fibrot nase a	olast Gro nd Hepai	wth rin-L	Factor Bind ike Molecu	s to Subendoth les", <i>Biochemi</i>	lial ExtraCell stry,28:1737-	u ar Matrix 1743, 1989	and is	
CV												
EXA	MINE	? Re	beca	Po	y.		DATE	E CONSIDEREI	7-2	1-98		
EXA if no	AMINE of in con	R Initial if	reference consider	dered. red In	whether o	or no y of	t citation is in this form with	conformance w	ith MPEP 609; cation to applic	Fraw line that.	hrough citation	

4 of 4 Sheet Atty. Docket No. Form PTO-1449 (Modified) 910/1 Applicant: INFORMATION DISCLOSURE CITATION Iris PECKER et al IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY) Filing Date: September 2, 1997 U.S. PATENT DOCUMENTS **FILING** CLASS SUB-NAME DATE DOCUMENT EXAMINER DATE NUMBER CLASS INITIAL DA FOREIGN PATENT DOCUMENTS SUB-CLASS: TRANSLATION COUNTRY CLASS DOCUMENT DATE NUMBER NO YES DB OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Gospodarowicz et al, "Permissive effect of the ExtraCellular Matrix on Cell Proliferation in vitro", Proc. DC Natl. Acad. Sci. USA, 77(7): 4094-4098, 1980 Vlodavsky et al, "Morphological Appearance, Growth Bhavior and Migratory Activity of Human Tumor DD Cells Maintained on ExtraCellular Matrix Versus Plastic", Cell, 19: 607-616, 1980 Vlodavsky et al, "Involvement of Heparanase in Tumor Metastis and Angiogenesi;", Israel J. Med. Sci., DE 24: 464-470, 1988 Vlodavsky et al, "Lymphoma Cell-nediated Degradation of Sulfated Proteoglycan; in the Subendothelial DF ExtraCellular Matrix: Relationship to Tumor Cell Metastis", Cancer Research, 43 2704-2711, 1983 Liotta et al, "Tumor Invasion and the ExtraCellular Matrix", Lab. Inv., 49(6): 636-649, 1983 DG Nicolson, G.L., "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion, invasion and DH growth of Malignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143 188, 1988 Nakajima et al, "Heparanases and Tumor Metastis", J. Cell. Biochem., 36: 157-167, 1988 DI Vlodavsky et al, "Inhibition of Tumor Metastis Inhibiting Species of Heparin", Inv. Metast., 14: 290-D.J 302, 1994 Vlodavsky et al, "Expression of Heparanases by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", Inv. Metast, 12: 112-127 1992 Ruoslahti et al. "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991 Kjellen et al, "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 50: 443-475, 1991 Wight, T.N., "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9: 1-20, 1989 Jackson, et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Rev., 71(2): 481-539, 1991

EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applic int.

Biol., 4: 793-801, 1992

EXAMINER

Wight et al, "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", Curr. Opin. Cell

**DATE CONSIDERED** 

n P'i O	1449 (Mod	dified)	<u> </u>	Atty Dockett	No.	09/071,	Application No. 09/071,739  RECEIVED  JUL 1 5 1998  GROUPII: 1800				
	ואז א	N DISCLOSUI AN APPLICATI AL SHEETS IF	ICKAJ.	Applicant: Iris PEC':		JUL					
					98						
			TRADE!	ATENT DOCL	IMENIS	CLASS	SUB-	FILING			
E	XAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	DATE			
<b>A</b>					O CLID (TENTE)		<u> </u>				
			FOREI	GN PATENT D	CLASS	SUB-CLASS	TRANS	SLATION			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	NO			
				+							
AB			D ADT (Include	ding Author, Tick	e, Date, Pertiner	nt Pages, Etc.)					
π.	—т	OTHE	R ART (Include	teoglycans in Cel	l Adhesion, mi	gration and Prolif	feration", C	Current			
AC				gleans: Molecular							
AD	an	ni -lagioni	Processes FIL	V21010E1CH1 ICC. IC							
AE	MO	Wight, T.N.,	CellBiology of	f Arterial Proteog	lycans , Arterio	nnu Rev Biochei	n., 60: 443	-475, 1991			
AF	WD	Kjellen et al, '	'Proteoglycans	: Structures and I	nteractions , A	tor Activities" C	 !ell. 64:867	-869, 1991			
AG	MO	Ruoslahti et a	l, "Proteoglyca	ins as Modulate rs	of Growin rac	Engines and	Plasma Pro	tein", in			
АН	MD	Basement Me	mbranes: Celli	lar Matrix-Bou 10	, a. ,						
Al	mo	Vlodavsky et System: Poss	al, "Expression in the state of	n of Heparanas : ent in Diapedes s			· <del>-</del>				
AJ	127, 1992 Learning Metastasis by Heparanase Inhibiting Species of Heparin",										
ļ	1. The state of th										
AK	NU		uror Invaci	on and the Extric	ellular Matrix'	, Lab. Invest., 49.	050 05,				
AL	Subendothelial Extracellular Matrix. Relationship to										
AN Parish et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by B cell-Derived Heparanase", Int. J. Cancer, 40: 511-518, 1987  Vlodavsky et al, "Morphological Appear: nce, Growth behavior and Migratory Activity Vlodavsky et al, "Morphological Appear: nce, Growth behavior, Cell, 19: 607-616, 1980											
AO	WE	Vlodavsky Tumor Cel	et al, "Morpho ls Maintained o	logical Appear non Extracellular N	ce, Growth beh Matrix vs. Plasti	c", Cell, 19: 607-	616, 1980				
AF	>			<u> </u>	DATE CONSI	DEDED 17	112.199				
		(	1		A SAME AND A SAME AND	CICKILL ""					

A					She	eet	2 01	_3_					
Form F TO-1449 (Mod fied)							ty. Doci	cet N	<b>o</b> .	Application No. 09/071,739			
INFORMATION DISCLOSURE CITATION E Applican: IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)  Filipp Da e: Group Art Unit:													
	( )111 7 6 14									Group Art Unit:			
RECEIVED											-0		
	EXAMINER DOCUMENT NUMBER				DAT						CLASUL GRO	કુ <sub>ં</sub> કુ_199 કુંકુકું	FILING DATE
BA	<u> </u>												
		<del>-  </del>		FC	DREIGN	PAT	ENT I	OCI	JMENTS				
		DOCUM			DATE		COUNTRY		CLASS	SUB-CLASS		TRANSLATION	
										ļ		YES	NO
<u> </u>	<u> </u>												
OTHER ART (Including Author, Tit e, Date, Pertinent Pages, Etc.)													
	Gospodarowicz et al, "Permissive Effect of the Extracellular Matrix on Cell Proliferation in-vitro", Proc. Natl. Acad. Sci. USA, 77:4094-4098, 1980												
- BD	D. 6045												
BE	m	Polkman et al, "Angiogenic Factors", Science, 23:: 442-447, 1987											
BF	M	Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Factor: a Regulatory Mechanism?", Trends Biochem. Sci, 16: 832-849, 1990 \ QQ \											
BG	M	Ichai Michaeli et el "Hennesses Astisita Francis III Di el la Nicola III de la Nicola III d											
ВН	W	Completed "Heaving Colors Day 11 To the Late of the Colors											
/	M	(1572)									11,249 -		
3J √	W	Hoogewer peptide -2	f et al, "CXC ( are Heparin/H	Chem-	okines C n Sulfate	Conne e-Des	ctive T	issue Enz	Activating per	ptide- Chen		utrophil A	Activiating
(BK)	7												
BL	W												
3M	W										Cultured		
(N)	ND	Nakajima ( Cancer, 45	et al, Immuno 5: 1088-1095,	hemi 1990	cal Loca	lizati	on of l	Iepa	ranase in Mous	e and	Human M	[elanorna	s", Int. J.
B,O √	M	Mollinend and Gelatin	o et al, "Major n ase in Tertia	Colo	calizatio	n of f Hun	the Extra	racel utrop	lular-Mairix Do	egrad . J., 3.	lative Enzy 27: 917-92	mes Hep 93, 1997	aranase
:AN	IINEI	/ X/ \n	main	-2	July -	_	$\overline{}$		CONSIDERED	7	1/12/90		
AM	INER:	Initial if refe	rence considere	d, wh	ether or n	ot cit	ation is	in co	nformance with I	MPEP	609; Draw	line throu	gh citation

. •					Shee	t 3	o1	_3_					<del></del> 1	
Form F ΓΟ-1449 (Modified)							y. Doc :et 0/5	No.			Application No. 09/071739			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)						The Mills of the M					JUL 1 5 1998  GROUP 1800  Group Art Unit:			
				- W	STRAP	FEN	T DOCU	ΙМΕ	NTS					
	EXAMINER DOCUMENT NUMBER				DAT	E	NAME				CLASS	SUB- CLASS	FILING DATE	
CA													<u> </u>	
·				FO	REIGN	PAT	CENT OC	CU	MENTS	Γ		T		
		DOCUM		DA	ATE	COUNT		₹Y	CLASS	SU	B-CLASS	TRANSLATION		
		NUMBER										YES	NO	
Н														
	1		OTHER AR	RT (Inc	cluding	Auth	or, Ti:le,	, Da	te, Pertinent P	ages,	Etc.)			
CO	m m m	De Vouge et al, "Immunoselection of GRP94/Er doplasmin From a KNRK Cell-Specific \(\lambda\)gt11 Library Using Antibodies Directed Against a Putative Hoparanase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994  Graham et al, "Comparison of the Heparanase E 1zymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996  Kosir et al, "Human Prostrate Carcinoma Cells Froduce Extracellular Heparanase", J. Surg. Res., 67: 98 105, 1997									e			
ĆP_	140			Abstract 3378, Cancer Res., 37: 495 1996										
ca	MO	Ernst et al, "Enzymatic Degradation of Glycosaininoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995												
	NE	Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25-15-89, 1977												
	NO	O IV								rs", <i>Blood</i>				
Ö	WC	Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981												
0	M	Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996												
(	/ W	Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 <sup>1</sup> ", Cancer Res., 50: 6075-6)86, 1990												
6	M	J 85: 172	et al. "Xenogra 25-132, 1993											
	M	Nakajii Mouse	ma et al, Hepar B16 melanom	an Sul a Subli	fate De nes", S	grada cienc	tion: I.el e, 220 6	latio	n to Tumor In 513, 1983	vasio	n and Met	atastic Pro	operties of	
CR	<del>-   ` - `</del>		•								- <del></del> -			
	MINE	P /	M M M d a	<del>_</del>	An'C	22	D <sub>V</sub>	АТЕ	CONSIDEREI	)	7/13/	99		

C III I Impulse.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

▼ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox